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Abstract 
Rab27 is a member of the Rab family of Ras-like GTPases and is expressed in two isoforms, 
Rab27a and Rab27b that share 72% amino acid identity. Previous studies have suggested 
Rab27a and Rab27b to regulate inflammation through exocytosis in a variety of leukocytes 
including T lymphocytes, NK cells, mast cells and neutrophils. A key process in inflammation 
is mast cell secretion, a process in which Rab27b has been established as a positive 
regulator but the role of Rab27a remains unclear. In this study we confirm that in response 
to IgE crosslinking, Rab27a appears to play a negative role in secretion, however Rab27a was 
observed to promote secretion in absence of Rab27b, so this effect is likely due to 
abnormally distributed cortical F-actin and enhanced granule docking in absence of Rab27a. 
Furthermore Rab27a may exert this regulation through effector Melanophilin. We also 
confirm that the effector Munc13-4 is important for promoting mast cell secretion, likely 
through interaction with both Rab27a and Rab27b.  
Rab27 has also been suggested to regulate inflammation by promoting granule secretion in 
neutrophils. Here we find that Rab27a was localised to structures at the uropod and that 
Rab27a deficient neutrophils display defective chemotaxis due to impaired uropod release. 
Inhibition of extracellular serine proteases inhibited wild-type but not Rab27a deficient 
neutrophil chemotaxis suggesting that defective protease secretion may underlie Rab27a 
deficient neutrophil chemotaxis defect. Analysis of αMβ2 integrin subunit CD11b after 
chemokine stimulation revealed that CD11b surface expression was sustained on Rab27a 
deficient neutrophils compared to wild-type, suggesting that cleavage of CD11b may be 
impaired. Inhibition of other proteins known to promote primary granule secretion, Rab27b 
and Rab27 effectors Slp1 and Munc13-4 also impaired neutrophil chemotaxis. Together 
these data suggest that Rab27a promotes uropod detachment through release of proteases 
contained in primary granules to promote neutrophil chemotaxis. 
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Chapter 1 - Introduction 
1.1 – The Mast Cell 
1.1.1 – Mast cells in inflammation 
The mast cell has long been recognised to be a potent store of histamine, chemoattractants 
and other pre-formed mediators that are released upon activation to promote inflammation 
and contribute to asthma and allergic disease (186). Activation of mast cells induces influx of 
other classes of leukocytes such as neutrophils and eosinophils directly through binding of 
chemoattractants to leukocyte chemoattractant receptors to stimulate chemotaxis and 
indirectly by stimulating vasodilation. When this response is activated appropriately, mast 
cells may initiate inflammation and allow pathogens to be cleared quickly.  As such mast 
cells form a critical part of the host’s defence against pathogens but regulated and 
appropriate mast cell secretion is critical. When mast cells are inappropriately activated 
through antigens derived from peanuts, pollen, house dust mite or other allergens as in type 
I hypersensitivity reactions, the result may be anaphylaxis, allergic rhinitis (hay fever) or 
allergic asthma. Therefore the understanding of processes regulating mast cell secretion are 
vital in understanding what causes inappropriate responses in these diseases. Recent 
studies have implicated a variety of proteins to regulate mast cell secretion, one of them 
being Rab27 which will be discussed later. 
 
1.1.2 - Brief history 
Paul Ehrlich first described “mastzellen” as a 24-year-old medical student in 1878 through 
innovative use of basic and acidic aniline dyes. What Ehrlich saw were plump (well-fed) cells 
(“mast” deriving from the German word for food) full of metachromatic granules. 
Metachromasia refers to the ability of mast cell granule contents to react with aniline dyes 
and change their colour, a distinguishing feature of mast cells. Ehrlich supposed that the 
mast cell nourished the surrounding tissue as they were “well-fed”. While mast cells are 
critical for their role in connective tissue remodelling and repair, they also contain proteases, 
cytokines and chemoattractants that confer survival, growth and chemotactic effects on 
several cell types, such as fibroblasts, myofibroblasts, smooth muscle cells, neurons and 
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endothelial cells (43). Ehrlich also suggested that the origin of mast cells was from the bone 
marrow, an idea proved true years later.  
 
1.1.3 - Development of the mast cell 
Kitamura and colleagues proved the bone-marrow source of mast cells back in 1978. 
Haematopoetic stem cell deficient mice are also mast cell deficient and transplantation of 
normal bone marrow into these mice restores mast cells (90). It is now accepted that mast 
cells derive from Lyn
-
 c-kit
+ 
Sca-1
- 
Ly6C
- 
FcεRIα
- 
CD27
- 
β7
+ 
T1/ST2
+ 
in adult murine bone 
marrow (33) and also from CD34
+ 
c-kit
+ 
haematopoietic stem cells in human bone marrow 
(89). Unlike other cells that differentiate from haematopoietic stem cells, mast cells are 
released as committed progenitors.  These committed progenitors were identified in blood 
and were defined as c-kit
high
, Th-1
low
, contained cytoplasmic granules and encoded RNAs for 
various mast cell proteases but lacked FcεRI expression (156). Committed progenitors then 
migrate into tissues where they differentiate according to local environmental cues. It is 
because of this that mast cells are heterogeneous in nature, though it is accepted that they 
fall into two broad types, connective tissue type and mucosal type that differ in their 
protease repertoire (Figure 1). It was recently suggested that this difference is in mast cell 
phenotype is due to the tissue environment (193). 
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Figure 1. Mast cell differentiation. Tissue mast cells are derived from haematopoietic stem cells (HSC) in the 
bone marrow. Mast cell progenitors (MCp) are released into the blood which migrate into tissues and undergo 
differentiation and maturation to become mature connective type mast cells (CTMC) or mucosal mast cells 
(MMC). SCF stem cell factor, T tryptase, C chymase, FcεRI high affinity IgE receptor, Bsp-1 basophil-specific 
antibody-1. Figure adapted from (106).  
Pre-formed Mediators Newly synthesised mediators 
Histamine Leukotrienes (LTB4, LTC4) 
Serotonin Prostoglandins (PGD2, PGE2) 
Proteoglycans (Heparin, Chondroitin E) TNF- α 
Tryptase IL-8/ENA-78 
Carboxypeptidase A MCP-1/RANTES 
Chymase MIP-1 α 
β-hexosaminidase TGF- α 
β-glucuronidase IL-1 
β-D-galactosidase IL-3 
Cathepsin G IL-4 
Renin IL-6 
Platelet activating factor (PAF) GM-CSF 
TNF-α  
Table 1. Stored and newly-synthesised mediators released by mast cells. 
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Figure 2. Ultrastructure of bone marrow-derived mast cell.  Multivesicular granules filled with small 
membrane vesicles ranging from 60 to 80 nm in diameter (type I), granules with an electron-dense core 
surrounded by small vesicles (type II) and electron-dense granules devoid of membranous content (type III). 
Image courtesy of Silene T. Wavre-Shapton.  
1.1.4 - Biogenesis of granule types 
Mast cells store many pre-formed mediators in cytoplasmic granules. Table 1 summarises 
the major mediators stored in and newly-synthesised in response to activation by mast cells.  
Ultrastructurally 3 different types of granules have been identified in mast cells 
(Figure 2). Type I and II granules were also found to express Lysosome Associated 
Membrane Protein 1 (LAMP-1) and the dense core of type II and type III granules to contain 
serotonin (150). It is not known what the significance of having 3 types of granules is (or if 
they are indeed different types or just different maturation states of the same granule type), 
or how the biogenesis of each type is regulated though several proteins are known to 
influence the biogenesis of mast cell granules. 
In primary mast cells, correct storage of cargo in granules is dependent on serglycin 
proteoglycan which acts as a matrix to correctly package and store material in granules (71). 
Polyamine content was found to affect histamine synthesis early during mast cell 
maturation (59). The lysosomal regulator Lyst also regulates granule size as suggested by 
abnormally enlarged granule size in Lyst mutant (Beige) mice (35).  
Because of the difficulty in genetic manipulation of primary mast cells, many studies 
have used rat basophilic leukemia (RBL-2H3) cells as a model to study mast cell secretion 
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and granule maturation. Overexpression of Secretogranin III was found to promote granule 
biogenesis (149). Synaptotagmin III was implicated in granule maturation and regulation of 
granule size through regulation of recycling of cargo from immature granules to the 
endocytic recycling compartment (64). Synaptotagmin IX was also found to be involved in 
protein sorting to secretory granules in a similar mechanism (68).  
 
1.1.5 - Consequences of mast cell secretion 
Mast cells are known to be critical effectors of asthma and allergy, and the effects of mast 
cell release of pre-formed mediators and of de novo mediators affect many processes and 
cell types. Figure 3 summarises the important mediators released by mast cells and their 
various effects on other processes.  
 
Figure 3. Summary of effects of mast cell mediators proteases and cytokines in vivo.  TNF-α, Tumor necrosis 
factor-α; bFGF, basic fibroblast growth factor; PAF, platelet activating factor; SCF, stem cell factor. From (37). 
Copyright permission obtained from appropriate publisher. 
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Figure 4. FcεRI mediated signalling pathways leading to secretion from mast cells. Two distinct signals 
converge to stimulate mast cell degranulation and cytokine production. Activity of the PI3-K/Gab2/SHP-2 axis 
activate protein kinase C (PKC) and the PI3-K/Rac/Vav/SLP-76 axis stimulate calcium influx through activation 
of PLCγ1 and PLCγ2 to stimulate cleavage of PIP2 to IP3 and DAG. From (14). Copyright permission obtained 
from appropriate publisher. 
1.1.6 – Mechanism of IgE-dependent secretion 
Mast cells are activated by the binding of antigen-specific Immunoglobulin E (IgE) to 
receptors on the cell surface and subsequent antigen exposure (14), therefore the process 
of IgE production is of great importance to mast cell function. Local cues and stimulation by 
T lymphocytes cause B lymphocytes to differentiate into plasma cells (140). These produce 
and secrete antibodies into the extracellular environment. Local cues drive the 
differentiation of naïve CD4
+
 T lymphocytes to a T helper 1 (Th1) or T helper 2 (Th2) effector 
cells.  Stimulation of B lymphocytes  by Th1 producing cytokines Interferon-γ (IFN-γ) and 
Tumor Necrosis Factor-α (TNF-α) causes class switching and drive plasma cells to secrete 
IgM and IgG whereas stimulation by Th2 producing cytokines Interleukin-4 (IL-4) and 
Interleukin-5 (IL-5) promote production of IgE (40).  
IgE molecules then bind to mast cells FcεRI via their Fc region and subsequent 
exposure to their specific antigen recognised by the Fab region allows multiple IgE 
molecules bound to different Fcε receptors to bind the same antigen molecule in a process 
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called “crosslinking” (14). Crosslinking allows FcεRI to come into close proximity or “cluster” 
and triggers a signalling cascade leading to degranulation of mast cells. This is the main 
physiological method by which mast cells become activated. Figure 4 details the various 
signalling mediators involved in degranulation of mast cells  (14). IgE binds to the α-subunit 
of the multimeric FcεRI receptor. Upon antigen exposure, FcεRI aggregates, causing 
immuno-receptor tyrosine-based activation motifs (ITAMs) on the β and γ subunits to 
become phosphorylated by Lyn and Syk protein tyrosine kinase (181).  Syk goes on to 
activate linker of activation (LAT) which further activates the association of several proteins 
to LAT to form a multiprotein complex consisting of LAT, Grb2, Sos, Ras, Vav, Rac, PI-3 kinase, 
SLP-76 and Gads. The formation of this complex results in the activation of phospholipase C 
γ1 and γ2 that cleaves PIP2 into IP3 and DAG (146). IP3 activates release of calcium from 
intracellular calcium stores in the endoplasmic reticulum and this increase in free cytosolic 
calcium stimulates calcium release activated calcium (CRAC) channels in the plasma 
membrane to open and allow calcium to enter the cell from the extracellular environment 
(53). DAG stimulates PKC activation which in turn activates mast cell degranulation by 
various methods described later.  Receptor crosslinking also causes Fyn tyrosine kinase to be 
activated, important to the activation of adaptor protein Gab2 and subsequent PI-3 kinase 
activation (66, 141). While the activity of PI3 kinase is known to be required for secretion 
and required for the activation of Gab2 and Rac, its exact function remains to be 
determined. The Fyn-Gab2-PI3K axis stimulates PKC activation. It is the synergy of the two 
signals (PKC activation and calcium influx) that effectively causes mast cell degranulation of 
pre-formed mediators and de novo synthesis of cytokines and other mediators. 
 
1.1.7 – Exocytic machinery in mast cells 
The exocytic proteins involved in mast cell secretion have recently been the subject of great 
interest.  The Soluble NSF attachment protein receptor (SNARE) proteins in particular have 
been found to play an important role in membrane fusion. The proteins vesicle associated 
membrane protein-8 (VAMP-8), Syntaxin3, Mammalian uncoordinated 18-2 (Munc18-2), 
Synaptosomal-associated protein 23 (SNAP-23) and Syntaxin 4 have been proposed to form 
the SNARE complex that promotes membrane fusion in mast cells (Figure 5). SNAP-23 is a t-
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SNARE, localised to the plasma membrane (PM) and introduction of blocking antibodies 
reduce degranulation of rat peritoneal and human mast cells (67, 157). Similar treatment of 
blocking antibodies to Syntaxin4 also reduced histamine release from human mast cells 
(157). The positive role of VAMP-8 has been confirmed using RBL-2H3 cells and murine 
BMMCs deficient in VAMP-8 and human mast cells with anti-VAMP-8 blocking antibodies 
(105, 157, 178). Studies using RBL-2H3 cells have shown that Munc18-2 and Syntaxin 3 
immunoprecipitate together, expression of Munc18-2 containing an interfering effector 
loop inhibits secretion and disruption of microtubules by Nocodazole redistributed Munc18-
2 suggesting that Munc18-2/Syntaxin 3 complex may regulate granule secretion and this 
function may be linked to the microtubule network (117, 148, 175). Synaptotagmin proteins 
act as a calcium sensor to promote secretion and Synaptotagmin II knockout was found to 
severely impair murine BMMC secretion (120). Synaptotagmin II is thought to interact with 
the SNARE complex upon formation and confer calcium sensitivity to exocytosis. Another 
calcium sensor found to be involved in mast cell secretion is Complexin II (176). Rab3d and 
its kinase Rak3d (Rab3d associated kinase) have been implicated in secretion in Rat 
basophilic leukemia-2H3 (RBL-2H3) (147, 154) though Rab3d was found not to play a role in 
primary murine peritoneal mast cells (153). Finally several studies have implicated Rab27b, 
Munc13-4 and Doc2α to have a positive role in secretion. Rab27b is thought to promote 
microtubule to actin based transport (124) and Munc13-4 thought to promote vesicle 
tethering/priming prior to exocytosis (129). Doc2α is a calcium sensor and interaction of 
Rab27b/Munc13-4 with Doc2α confers calcium sensitivity to Rab27 function (73).  
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Figure 5. Exocytic machinery involved in membrane fusion in mast cells. The activation of FcεRI stimulates 
exocytosis of mast cell granules through influx of calcium that binds calcium sensors such as Synaptotagmin II 
(Syt II) and Doc2α that causes conformational changes that promote granule fusion with the plasma 
membrane and through activation of IκB kinase (IKK), protein kinase C (PKC) and phospholipase D (PLD) that 
stimulate exocytosis through phosphorylation of exocytic machinery proteins to promote granule fusion with 
the plasma membrane. Secretory carrier membrane proteins (SCAMPs). From (11). Copyright permission 
obtained from appropriate publisher. 
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1.2 – The neutrophil 
1.2.1 – Brief history and introduction 
During his doctoral thesis of 1878, Paul Ehrlich described three different types of 
granulocytes based on his use of acidic and basic analine dyes that allowed the staining and 
visualisation of multi-lobed nuclei and facilitated their classification into basophilic (base 
loving), eosinophilic (acid loving) and neutrophilic (neutral loving) leukocytes (50). 
Neutrophils are the most abundant class of granulocyte, differentiating from stem cells in 
the bone marrow (16).  Neutrophils are a crucial element of the innate immune system, 
providing the first line of defence against invading pathogens (128). They perform vital 
functions such as phagocytosis and killing of pathogens through release of granular anti-
microbial products and production of reactive oxygen species (70). Neutrophils go through 
different stages of differentiation, characterised by patterns of transcriptional activity 
(C/EBP various isoforms, Gfi-1 and PU.1 are particularly important in maturation) and 
changes in nuclear morphology as a consequence. In the early stages of differentiation 
(myeloblast, promyelocyte) the nucleus appears round however in later stages of 
differentiation, the nucleus becomes increasingly segmented (Figure 6). During this process 
neutrophil granules are also made.  
 
1.2.2 –Chemotaxis and extravasation 
To perform their function, neutrophils must be mobilised from the bone marrow to the 
circulation where their transendothelial extravasation from the blood to tissues is directed 
by a chemoattractant such as macrophage inflammatory protein 2 (MIP-2), interleukin-8 (IL-
8), formyl-met-leu-phe (fMLP) leukotriene B4 (LTB4) or complement 5a (C5a).  Extravasation 
is a complex process involving the expression of many adhesion proteins that promote the 
slowing of activated neutrophils in circulation, their rolling and subsequent firm adhesion 
and then their directed migration across endothelial barriers (Figure 7). Neutrophil 
recruitment begins with the interaction of endothelium selectins such as E, L and P selectins 
with their carbohydrate ligands such as P-selectin glycoprotein ligand 1 (PSGL-1) on the 
neutrophil (119). These transient interactions slow neutrophils enough to allow more firm 
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adhesion to take place. Neutrophil adhesion to endothelium is mediated by VLA-4 (α4β1), 
Mac-1 (αMβ2) and LFA-1 (αLβ2) on neutrophils and members of the immunoglobulin 
superfamily such as Inter-cellular adhesion molecule 1 and 2(ICAM-1 and ICAM-2), Inter-
vascular adhesion molecule 2 (VCAM-2) or receptor for the activation of glycation 
endproducts (RAGE) on the endothelium (196). The importance of adhesion molecules in 
extravasation was highlighted in mice deficient in one or more leukocyte integrins where 
the adhesion and recruitment of lymphocytes or neutrophils was reduced in absence of LFA-
1 and/or Mac-1 (13, 48, 111, 123). Inside out signalling of integrins mediated by chemokines 
causes activation and involves several pathways including Rap, Rac and Rho GTPases (189) 
leading to cytoskeletal rearrangements and subsequent transendothelial migration. The 
process of actin polymerisation is essential to the migration process because it promotes 
formation of pseudopodia and filopodia by pushing membrane forward at the leading edge 
of the cell. This is essential for movement and is driven by Cdc42, Rac1, Rac2 and the Rac 
and Cdc42 GEFs p-Rex1 and Vav1 that activate Rac and Cdc42 (101, 155, 174). Cdc42 and 
Rac activate neuronal Wiscott-Aldrich syndrome protein (N-WASP)/WASP interacting 
protein (WIP) or suppressor of cAMP receptor (SCAR)/WASP-family verprolin homologous 
protein (WAVE) complexes that in turn activate the actin related protein 2/3 (Arp2/3) 
complex. Arp2/3 then binds to existing actin filaments and creates a new nucleation site to 
which actin monomers may be added to form a new branch of filamentous actin (F-actin). At 
the trailing edge, Rho activation and myosin II contraction are critical for uropod 
detachment and continued migration (174).  
During the chemotaxis process, neutrophils are thought to release proteases to 
degrade cell-cell junctions in order to squeeze between the endothelial layer (125). 
Neutrophils migrate towards tissue sites of injury or infection in a process termed 
chemotaxis (57). At the site of injury, a chemokine is produced that diffuses out and creates 
a chemokine gradient.  This gradient allows the progressive migration of neutrophils by 
maintaining cell polarity. Chemotaxis requires initial chemokine/receptor engagement that 
triggers signalling events leading to polarisation of the cell towards the source of the 
chemokine and actin polymerisation to drive the leading edge forward and formation of a 
primary lamella (100). Directional migration requires successive rounds of adhesion at the 
leading edge and detachment of the uropod. Uropod detachment is thought to be as a  
33 
 
 
 
Figure 6. Differentiation of neutrophils from progenitor cells. The early stages of neutrophil differentiation 
(myeloblast and promyelocyte) are characterised by transcriptional activity of C/EBPα and Gfi-1, which drive 
early processes such as azurophil granule (red) production. Specfic granule (green) production is driven in the 
intermediate phase of differentiation by transcription of C/EBPε. The late stages of differentiation including 
production of tertiary granules (yellow) are driven by transcriptional activity of C/EBPβ, δ and ζ and PU.1. From 
(16). Copyright permission obtained from appropriate publisher. 
 
 
Figure 7. Molecular interactions important for neutrophil extravasation in vivo. Neutrophils in circulation are 
slowed by transient interactions of sialyl-Lexis
x
 moiety containing carbohydrates (such as PSGL-1) on 
neutrophils with endothelium E, L or P selectins. This slows neutrophils down and allow them to roll along the 
endothelium surface. This interaction also increases expression of neutrophil LFA-1 which then engages with 
endothelium ICAM-1 to initiate tight binding. The chemokine gradient directs neutrophils to squeeze through 
the endothelial barrier, degrading cell-cell junctions by release of neutrophil proteases to pass through. 
Neutrophils can then continue to migrate through tissues to the site of injury or infection. From (78). Copyright 
permission obtained from appropriate publisher. 
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result of actinomyosin-based contraction at the trailing edge that breaks adhesions at the 
rear of the cell (34, 167). Recent evidence where inhibition of granule secretion through 
chelation of extracellular calcium has suggested that granule secretion may promote 
neutrophil chemotaxis (39).  
 
1.2.3 –Neutrophil granules 
Neutrophils were discovered to contain different classes of granules based on their affinity 
for the azure A dye (those with a higher affinity for azure A termed azurophilic granules and 
those with a lower affinity termed specific granules) (168) and the enhanced staining of 
myeloperoxidase (MPO) during electron microscopy helped highlight these differences as it 
is only present in azurophilic granules (6, 7). Tertiary granules were later identified by 
electron microscopy (168). The different granule types are made at different stages in 
neutrophil differentiation. In the early stages of differentiation (myeloblast and 
promyelocyte), primary/azurophilic granules are synthesised. During the myelocyte and 
metamyelocyte stage, secondary/specific granules are produced.  At the later stages (band 
cell and polymorphonuclear granulocyte) tertiary/gelatinase granules are created (Figure 6).  
The presence of different classes of granules were confirmed by use of subcellular 
fractionation techniques (91, 134) and later studies found the existence of a distinct subset 
of organelles that were more readily secreted than the previous classes of granules, the 
secretory vesicle (17, 20). 
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Figure 8. Chemoattractant signalling pathways leading to downstream activation of neutrophils. Activation 
of Rho family proteins allows cytoskeletal rearrangements to be made to allow cell motility. The activation of 
phospholipase C stimulates an influx of calcium and activation of PKC to stimulate secretory processes 
required for chemotaxis. The activation of PI3-kinase allows the production for PIP3 important for directional 
sensing. The activation of MAP kinases and tyrosine kinases also help to mediate phosphorylation events 
important for efficient chemotaxis. From (131). Copyright permission obtained from appropriate publisher. 
 
Azurophilic granules Specific granules Tertiary granules Secretory vesicles 
Acid β-glycerophosphatase  β2-Micoglobulin  Acetyltransferase  Plasma proteins 
(e.g. tetranectin) 
Acid glucopolysaccharide  Collagenase  β2-Microglobulin   
α1-Antitrypsin Gelatinase 
  
Gelatinase  
  
 
α-Mannosidase hCAP-18  Lysozyme  
Azurocidin/CAP37Heparin 
binding protein   
Histaminase   
Bactericidal permeability 
increasing protein  
Heparanase    
β-Glycerophosphatase Lactoferrin    
β-Glucuronidase  Lysozyme    
Cathepsin G  NGAL    
Defensins  Urokinase-type 
plasminogen 
activator   
  
Elastase Sialidase    
Lysozyme  SGP28 
  
  
Myeloperoxidase Vitamin B12-binding 
protein 
  
N-Acetyl-β-glucosaminidase
  
   
Proteinase-3
  
   
Sialidase    
Ubiquitin-protein    
Table 2. Contents of human neutrophil granules and secretory vesicles.  From (18). 
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1.2.4 – Neutrophil secretion 
Different classes of neutrophil granules are known to be differentially mobilisable 
depending on the strength of the stimulus, with secretory vesicles being the fastest (most 
sensitive to stimulation) to mobilise, followed by tertiary granules, then specific and lastly 
azurophilic granules (19, 191). These different classes of granules were found to store 
various proteins with antibacterial properties by a combination of subcellular fractionation 
and cryoelectron microscopy techniques. 
Azurophilic granules – The main functions of azurophilic granules are to aid the production 
of hypochlorous acid (HOCl), other toxic chlorine products, tyrosine radicals and reactive 
nitrogen intermediates which all can attack the surface membranes of pathogens (92) by 
releasing MPO (which reacts with H2O2 produced by NADPH oxidase) into the phagosome 
and the extracellular space.  Azurophilic granules contribute to bacterial, fungal, viral and 
protozoan killing through release of defensins (small cationic antimicrobial and cytotoxic 
peptides (29-30 aa) (5, 58, 152)) which form multimeric pores in the pathogen membrane 
(45, 58, 103, 188). Azurophilic granules are also important in extracellular matrix 
degradation and cleavage of cell-substrate adhesions through release of serprocidins (serine 
proteases with microbicidal activity) neutrophil elastase (NE), cathepsin G and proteinase-3 
that degrade elastin, fibronectin, laminin, type IV collagen and vitronectin to promote 
neutrophil transmigration and tissue infiltration. 
Specific granules – Specific granules are known to be an abundant source of antimicrobial 
products (listed in table 2) so the main function of specific granules is pathogen killing 
through proteins such as Lactoferrin, hCAP-18, NGAL and lysozyme (29, 62, 109, 136, 161)  
Tertiary granules – In contrast to specific granules, the main role of tertiary granules is to 
mediate extracellular matrix degradation through release of matrix metalloproteases 
(MMPs), neutrophil collagenase (MMP-8), gelatinase (MMP-9) and leukolysin (MT6-
MMP/MMP-25). The release of MMPs is thought to be critical for degradation of all major 
components of extracellular matrix and is important for neutrophil extravasation and 
transmigration (18, 84, 138). The expression of tissue inhibitors of metalloproteases (TIMPs) 
is thought to be important in regulating MMP activity and the balance of MMP to TIMP 
activity is critical for acute respiratory distress syndrome (ARDS), asthma and pulmonary 
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fibrosis (27). In addition tertiary granules have some antimicrobial properties and contain 
natural resistance-associated macrophage protein 1 (nRAMP1) that translocates to the 
phagosome upon activation and is important in starving phagocytosed pathogens of metal 
ions such as Fe
2+
, Mn
2+
 and Zn
2+
 (26, 77).  
Secretory vesicles – The release of secretory vesicles potentiates the neutrophil response as 
they contain a supply of chemoattractant receptors that are translocated to the plasma 
membrane upon activation of neutrophils (163, 164). Secretory vesicle membranes contain 
CD11b/CD18 (Mac-1, CR3), fMLP receptors, LPS receptor CD14, FcγRIII CD16, and leukolysin 
all of which translocate to the plasma membrane upon activation (46, 84, 162, 164, 165). 
The result of these changes is that neutrophils are more responsive to stimuli and are able 
to adhere firmly to vascular membranes prior to transmigration in vivo. 
 
1.2.5 – Exocytic machinery 
The exocytosis of neutrophil granules occurs in several stages The first stage is translocation 
of granules from the cytosol to the plasma membrane in a process regulated by actin 
cytoskeleton remodelling and microtubule assembly (25). The next is vesicle 
tethering/docking that restrains vesicles close to the plasma membrane, followed by vesicle 
priming which involves phosphorylation events to allow SNARE protein complexes to 
associate followed by vesicle fusion with the plasma membrane and release of vesicle 
contents into the extracellular space (Figure 9).  
Several proteins have been shown to form part of the exocytic machinery regulating the 
release of neutrophil granules. Recent studies have shed light on the exocytic machinery 
regulating release of neutrophil granules and highlighted subtle differences in the 
machinery involved in the release of different granule populations which may explain 
differences in their ease of mobilisation. Figure 10 shows the exocytic machinery involved in 
azurophilic granule secretion.  
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Figure 9. The steps in vesicle trafficking leading to fusion with plasma membrane. Vesicles are translocated 
from the cytosol to the plasma membrane (1), and are held there by tethering/docking proteins (2). Vesicles 
are primed for release by SNARE protein phosphorylation events (3) and this results in the opening of a fusion 
pore and subsequent vesicle fusion (4). This promotes granule mediator release and also incorporates granule 
membrane proteins into the plasma membrane. From (98). Copyright permission obtained from appropriate 
publisher. 
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Azurophilic granules – Several SNARE proteins have been implicated to play a role in the 
secretion of neutrophil granules. Using blocking antibodies in human neutrophils, (108, 126) 
the syntaxin4/VAMP-1/7 complex was implicated specifically in the secretion of azurophilic 
granules. The involvement of syntaxin6 but not SNAP-23 had previously been suggested 
from similar experiments (116). Recent evidence has highlighted a role for Munc18-2 in this 
process and also implicated a role for its binding partner syntaxin 3 (23). Actin remodelling 
mediated by the RhoGTPase Rac2 is known to regulate primary granule exocytosis, probably 
by allowing depolymerisation at the cortex and increasing granule access to the plasma 
membrane (1, 122). Finally studies using primary knockout murine neutrophils and 
differentiated HL-60 cells has suggested a role for Rab27a, Rab27b, Slp1 and Munc13-4 in 
granule-plasma membrane recruitment and subsequent exocytosis of azurophilic granules 
(24, 80, 127). This is likely to be due to Rab27 promoting the transition from microtubule to 
actin based transport and allowing secretory organelles to be retained close to the plasma 
membrane as suggested in mast cells (51, 124), NK cells (107), CTLs (170), CD4
+
 T 
lymphocytes (69) and  melanocytes (76). The binding of Rab27 to effectors Slp1 and 
Munc13-4 and through their C2 domains interaction with membrane phospholipids may 
retain granules at the membrane prior to secretion though this remains to be proven.  
Specific granules – The main differences between specific and azurophilic granule secretion 
machinery are that in permeabilised human neutrophils, anti-SNAP-23 and VAMP-2 (but not 
VAMP-7) antibodies were found to block secretion of specific granule contents. Munc18-3 
(but not Munc18-2) is known to colocalise with specific granules and is redistributed to the 
plasma membrane upon stimulation, thus implicating it in this process (23, 108, 126). Finally 
a role for Rab27a has been suggested in this process by experiments in human neutrophils 
using blocking antibodies however this finding has been questioned by data from murine 
neutrophils where specific granule secretion proceeds independently of Rab27a (72, 80). 
Tertiary granules – The main differences in tertiary granule exocytic machinery compared to 
azurophil or specific granule secretion are that a confirmed role for Munc18-3/syntaxin3 has 
been suggested from localisation studies (23) and that a role for Rab27a and Munc13-4 has 
been suggested from studies using blocking antibodies on human neutrophils (24).  
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Figure 10. Exocytic machinery involved in azurophil, specific and tertiary granule secretion. Rab27 is thought 
to promote microtubule to actin transition and Rac2 promotes disassembly of F-actin to promote granule 
docking at the plasma membrane. Rab27 interaction with effectors Slp1 and/or Munc13-4 may also promote 
granule docking. The interactions of various SNARE proteins SNAP-23, Syntaxins, VAMPs and Munc18 then 
promote granule fusion with the plasma membrane. All SNARE components implicated in neutrophil secretion  
to date have been depicted though complexes formed by these components are yet to be revolved. Modified 
from (14). 
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1.3 – Rab GTPases 
1.3.1 - Introduction 
In mammalian cells, over 60 members of the Rab family of Ras-like GTPases have been 
identified (143). Rab GTPases are essential regulators of intracellular trafficking, regulating 
specific steps in trafficking due to their localisation to specific organelle membranes  (Figure 
11) (169). The mechanism of selective membrane localisation is poorly understood though 
there are several theories. The presence of Rab specific regions (F) and sub-family (SF) 
regions have been suggested to be involved in targeting Rab GTPases  as substitution of part 
of the SF2 and SF3 regions of Rab27a with that of Rab5a resulted in loss of secretory granule 
targeting in melanocytes and redistributed Rab27a to the Golgi and/or ER (2) . The function 
of Rab guanine exchange factors (GEFs) has also been linked to targeting activity (177, 192). 
Rab targeting was also previously hypothesised to involve effector binding and the C-
terminal hypervariable domain of Rab GTPases (32) but this was recently questioned as Rab 
mutants that  bind effectors poorly were targeting appropriately and swapping C-terminal 
hypervariable regions of various Rabs did not affect their localisations (2, 177).  
 
1.3.2 – Regulation of RabGTPases  
Rab GTPases are key regulators of intracellular traffic, providing specificity due to their 
differential localisation on distinct organelles (169). Rab GTPases must first be able to 
associate with membrane and this occurs through the chaperone protein Rab escort protein 
(REP) and the post-translational addition of prenyl groups by Rab geranylgeranyl transferase 
(RabGGTase) (Figure 12) (142). REP then escorts the Rab to the membrane where it is 
inserted. Rab GTPases are then activated by Rab guanine exchange factors (RabGEFs) that 
exchange Rab bound GDP for GTP. Changes in GDP/GTP binding mediates changes in Rab27 
conformation mediated by so called “switch” regions (145). In the GTP bound conformation 
Rab GTPases can interact with a diverse set of effectors to elicit specific functions within the 
cell (65). Once their function is fulfilled, Rab guanine nucleotide activating proteins 
(RabGAPs) then stimulate GTP to GDP hydrolysis activity of Rab GTPases to inactivate the 
Rab. It is then extracted from the membrane by guanine dissociation inhibitor (GDI) to be 
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recycled to another membrane. In this way Rab GTPases act as molecular switches, cycling 
between the GDP-bound inactive state and GTP-bound active state (8).  
 
1.3.3 – Rab27 
The importance of Rab27a is highlighted by the fact that mutations that impair Rab27a 
expression or function lead to disease in humans. Deficiency of Rab27a leads to Griscelli 
syndrome type II, a disease characterised by partial albinism and variable immunodeficiency 
(9, 93). Partial albinism is caused by the defective transfer of pigment containing 
melanosomes from melanocytes to keratinocytes in a process regulated by Rab27a (75). 
Variable immunodeficiency is caused by the defective secretion of secretory lysosomes from 
a variety of different leukocytes, though is thought to be largely due to impaired secretion 
from cytotoxic T lymphocytes (9). 
 
.  
 
 
 
 
 
 
 
 
 
43 
 
 
Figure 11. Specific localisation and function of Rab GTPases within the cell. Rab GTPases exhibit distinct 
localisations within the cell to confer specificity to individual trafficking steps. From (169). Copyright 
permission obtained from appropriate publisher. 
 
Figure 12. Rab GTPase prenylation, membrane association, activation and membrane extraction. GDP bound 
Rab in the cytosol associates with REP and this complex serves as a substrate for RabGGTase which adds prenyl 
groups to Rab-GDP. The Rab can then associate with the membrane and RabGEF stimulates the exchange of 
GDP for GTP. Rab-GTP can then bind with effectors to perform its functions. After it has performed its function, 
RabGAP then stimulates the hydrolytic activity of RabGTPase to hydrolyse GTP to GDP. Rab can then be 
extracted from the membrane by GDI to be recycled to a different membrane. From (61). Copyright permission 
obtained from appropriate publisher. 
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1.3.4 – Effector binding 
Rab27 is known to bind a diverse set of effector proteins (Figure 13). As the tissue 
distribution of effectors is different, the interaction of Rab27 with effectors changes 
depending on which cell type is being studied (55). The best studied example of Rab27 
effector interaction is in melanocytes that produce pigment containing organelles called 
melanosomes. Rab27a forms a tripartite complex with melanophilin and myosin Va to allow 
peripheral retention and their subsequent release (75, 76). The crystal structures of Rab27b 
bound to the Rab binding domain of melanophilin was recently reported (Figure 14) (95) 
and highlighted residues 6, 84, 88 and 91 of Rab27b as being critical for the interaction as 
they form hydrogen bonds (6, 91) and hydrophobic interactions (84, 88) with melanophilin. 
Residues 84, 88 and 91 are contained in switch region 2 highlighting the importance of GTP-
binding and conformational change of Rab27b in effector binding. Residue 6 is contained in 
the Rab complementarity determining region (CDR), an area conserved in Rab isoforms of 
the same sub-family. Substitution of residue 6 alone resulted in almost complete loss of 
melanophilin binding. The addition of tyrosine, leucine, phenylalanine and aspartic acid at 
equivalent points in Rab3a sequence conferred melanophilin binding, demonstrating 
specificity of binding provided by these interactions.  The crystal structure of Rab27a bound 
to the Rab binding domain of Slp2 was also recently reported (31) 
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Figure 13. Distinct families of effector proteins that bind Rab27. (A) Rab27 effectors that bind via their SHD 
domain and contain phospholipid binding C2A and C2B domains. (B) Rab3 effectors that bind via their SHD 
domains. (C) Rab27 effectors that lack C2A and C2B domains that may also bind myosin Va/VIIa and actin. (D) 
Unconventional Rab27 effector Munc13-4 that lack a conventional Rab binding domain but have C2 domains. 
From (55). Copyright permission obtained from appropriate publisher. 
 
Figure 14. Schematic of crystal structure of Rab27b interaction with the Rab binding domain of melanophilin. 
From (95). Copyright permission obtained from appropriate publisher. 
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1.3.5 – Rab27 and effectors in the immune system 
Rab27 exists in two isoforms (Rab27a and Rab27b) and has been recently been described to 
be critical for the regulated secretion from a variety of different leukocytes including 
platelets (179), CD4+ and CD8+ T lymphocytes (69, 170), mast cells (63, 124, 129), 
neutrophils (24, 72, 127), NK cells (69, 107, 190) and eosinophils (42). Studies in leukocytes 
have yet to determine whether Rab27 forms a tripartite complex like in melanocytes though 
some recent studies have shed light on Rab27 function in the immune system. A study in NK 
cells recently found that Rab27a deficiency results in fewer mobile lytic granules at the 
plasma membrane and more mobile lytic granules in the cytosol (107). This supports a 
model where Rab27 aids granule localisation at the plasma membrane to facilitate docking 
and tethering. Similar observations were made in neutrophils where the number of primary 
granules docked at the plasma membrane as measured by TIRF microscopy was reduced in 
absence of Rab27a and/or Rab27b (80). In mast cells Rab27 deficiency was shown to 
increase the number and average displacement of granules that was inhibited by 
nocodazole, demonstrating that Rab27 may aid the transition of microtubule to actin based 
movement (124). The exact mechanism by which this occurs is not known but in recent 
times Munc13-4 has emerged as the most important Rab27 effector in the immune system. 
Recently Munc13-4 was shown to aid priming of secretion of Rab27a-expressing vesicles in 
LPS treated neutrophils (83). Interestingly the same study found that LPS priming of 
exocytosis was dependent on both Rab27a and Munc13-4, LPS induced exocytosis of small 
vesicles was dependent on Munc13-4 but independent of Rab27a. Studies on Rab27 and 
Munc13-4 have debated whether Munc13-4 is able to play a role in exocytosis independent 
of Rab27a. A recent study using mutants of Munc13-4 between residues 280 and 285 that 
bind Rab27 poorly (FQL > AAA and IHK > AAA) found that the Rab27/Munc13-4 complex is 
specifically required for secretion from RBL-2H3 cells (51). In addition to this they found that 
cells expressing point mutant Munc13-4 lost the propensity to stall secretory lysosomes at 
the plasma membrane upon stimulation, suggesting again that Rab27 is required for the 
plasma membrane localisation and docking/tethering of granules prior to membrane fusion. 
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1.4 - Aims of this study 
The critical role of Rab27 in exocytosis of secretory lysosomes in the immune system has 
been extensively studied. However it has recently emerged in cell types expressing both 
Rab27a and Rab27b that it is the interplay between the two isoforms that is critical for 
regulation of secretion (80, 124, 137, 179). Two such examples are the regulation of mast 
cell and neutrophil secretion which are important for allergic and inflammatory diseases, 
and for pathogen killing and wound healing respectively.  
While there is near consensus on the positive role of Rab27 in secretion in 
leukocytes, current evidence on the role of Rab27a in mast cells is contrary to that. Two 
previous studies have suggested that Rab27a may play a negative role in secretion (63, 124). 
Rab27 isoforms have been reported to play independent roles in the same cell type 
previously as knockout or knockdown of Rab27a and Rab27b cause inhibition of secretion in 
neutrophils and HeLa cells seemingly independently of the other isoform (80, 137) but have 
not previously been demonstrated to play opposing roles in the same cell type. However to 
date the role of Rab27a and the interplay between the two isoforms has not been 
investigated in mast cells. Therefore the first aim of this study was to better define the role 
of Rab27a in mast cells and to understand if the interplay between the two isoforms is 
responsible for the apparently negative role of Rab27a in exocytosis. One of the only studies 
to define a negative role in secretion was in HUVEC cells where Rab27a expression ensured 
only mature Weibel-Palade bodies were released. Therefore the leading hypothesis in mast 
cells would be that in absence of Rab27a both mature and immature secretory granules are 
released from mast cells. 
In neutrophils, Rab27a and Rab27b have been implicated to be positive regulators of 
azurophil granule secretion implicated to regulate different steps of the same pathway of 
exocytosis (72, 80, 127). Interestingly in absence of both isoforms, a compensatory 
mechanism was suggested to exist to restore detectable secretion of primary granules (80). 
Recently a link between regulated secretion and chemotaxis was made, with many proteins 
promoting regulated secretion including members of the synaptotagmin family, Rab3a and 
Rab27a were found to regulate chemotaxis of the SupT1 T cell line in vitro (39). Reports of 
impaired in vitro chemotaxis of neutrophils from Griscelli syndrome patients (93, 97) have 
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suggested that in addition to a role in granule exocytosis, Rab27a may also play a role in 
neutrophil chemotaxis and that the two processes may be linked. However as both Rab27a 
and Rab27b are expressed in neutrophils, it is likely to be the interplay between the two 
isoforms that regulates such a process. Therefore the second aim of this study was to 
determine if Rab27a/b play a role in neutrophil chemotaxis and if so, to determine the 
mechanism by which they regulate it. The importance of the interplay between the Rab27 
isoforms is likely to be key in understanding this so will be again be investigated. The leading 
hypothesis would be that Rab27 promoted secretion may promote chemotaxis, possibly 
through release of granules at the leading edge of the cell to aid polarisation required for 
the initiation of migration. 
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Chapter 2 – Materials and Methods 
2.1 – General methods 
2.1.1 - Mouse Strains 
Wild-type C57BL/6 (BL/6), Rab27a
+/+
, Rab27a
ash/ash
 (ashen), Rab27b
-/- 
(Rab27b KO), 
Rab27a
ash/ash
 Rab27b
-/- 
(Rab27DKO), Mlph
ln/+ 
and Mlph
ln/ln
 (leaden) mice were bred in house 
and generated as described previously (179). Generation of Unc13d
Jinx/jinx
 (jinx) mice was 
described previously (85). All strains share the parental C57BL/6 (BL/6) strain. Rab27 mutant 
mice were bred and maintained under United Kingdom project license PPL 70/7078 at the 
Central Biomedical Services of Imperial College, London, United Kingdom. 
 
2.1.2 - Antibodies and Reagents 
Mouse monoclonal anti-Rab27a (4B12) antibody, rabbit polyclonal anti-Rab27a and anti-
Rab27b antibodies were as described previously (10). Mouse monoclonal anti-serotonin and 
rat anti-mouse LAMP-1 antibodies were purchased from Abcam (Cambridge, UK). Goat anti-
Munc13-4 antibody was purchased from Everest Biotech (Oxford, UK). Rabbit anti-calnexin 
was purchased from Stressgen (Ann Arbor, MI). Secondary antibodies conjugated to 
horseradish peroxidase (HRP) were purchased from DAKO (Glostrup, Denmark). Alexa-488 
and -568 conjugated secondary antibodies were purchased from Molecular Probes (Eugene, 
OR, USA). SPE-7 mouse IgE was purchased from Sigma- Aldrich (Poole, UK). Dinitrophenyl-
human serum albumin (DNP-HSA), phorbol-myristate-acetate (PMA), ionomycin and 4-
Nitrophenyl N-acetyl-β-D-glucosaminide were purchased from Sigma- Aldrich (Poole, UK).  
 
2.1.3 - Flow Cytometry 
Bone marrow derived mast cells (BMMCs) were analysed for c-kit and FcεRI surface 
expression as follows. An aliquot of 0.2 x 10
6 
cells was taken and cells washed twice in FACS 
buffer (1x phosphate buffered saline (PBS), 0.5% BSA, 0.05% sodium azide) and resuspended 
in FACS buffer containing anti-CD16/CD32 antibody (BD Biosciences, San Diego, CA) to block 
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Fcγ receptors at 1:100 dilution for 15 min on ice. Cells were resuspended in SPE-7 IgE at 1 
µg/mL concentration for 1 hour followed by two washes and subsequent suspension in FITC-
anti-IgE and PE-anti-c-kit antibodies (BD Biosciences) at 1:100 dilution for 30 min on ice. 
Cells were subsequently washed twice and analysed with the FACScalibur system (BD 
Biosciences). After 4 weeks of culture, >95% of cells were double positive for c-kit/CD117 
and FcεRI.  
For flow cytometry of bone marrow derived neutrophils (BMDN), PE-conjugated 
anti-Ly6G (BD biosciences), APC-conjugated CXCR2 (R & D systems), alexa647-conguated 
anti-CD11b (BD biosciences) antibodies were used at 1:100 dilution and alexa-conjugated 
Phalloidin (Molecular Probes) used at 1:1000 dilution. For surface staining, 2 x 10
5
 BMDN 
were washed twice and resuspended in rat anti-FcγRII/RIII antibody (BD biosciences) then 
with primary antibodies for 30 min and subsequently with alexa-conjugated secondary 
antibodies for 30 min on ice. 
 
2.1.4 - Immunoblotting 
BMMCs or BMDN were washed twice in phosphate buffered saline (PBS) and resuspended 
in lysis buffer (50 mM Tris-HCl (pH 7.4), 1 x protease inhibitors, 2% (w/v) SDS). Lysis was 
confirmed by brief sonication. Total cell lysate was loaded onto polyacrylamide SDS-PAGE 
gels and proteins were separated by electrophoresis at 40 mV in 1 x SDS-PAGE running 
buffer (30 mM Tris pH 6.8, 192 mM glycine, 0.1% (w/v) SDS). Wet-transfer of proteins to 
PVDF membranes was performed at 500 mAmp for 105 min in 1 x transfer buffer (40 mM 
glycine, 48 mM Tris, 1.25 mM SDS, 20% methanol). Membranes were blocked by incubation 
in 10% (w/v) non-fat milk powder in PBS/0.1% Tween-20 at room-temp for 30 min or 
overnight at 4°C with 100 rpm shaking. All subsequent steps were performed in 10% (w/v) 
non-fat milk powder in PBS/0.1% Tween-20. After blocking, membranes were incubated 
with primary antibodies followed by incubation with HRP-conjugated species specific 
secondary antibodies. Detection was performed using chemiluminescent film and ECL plus 
reagent (Amersham Biosciences, Piscataway, NJ, USA).  
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2.1.5 - Confocal fluorescence microscopy and Pearson’s correlation analysis 
Confocal microscopy was performed essentially as described previously (124) with the 
following modifications. 1 x 10
5
 BMMCs were resuspended in 100 µL of complete medium 
and placed onto poly-lysine coated coverslips for 20 min and immediately fixed using 4% 
(w/v) PFA. 1 x 10
5
 BMDN were allowed to adhere to uncoated coverslips for 20 min prior to 
fixation. Cells were blocked and permeabilised with 0.05% (w/v) saponin, 0.5% (w/v) BSA in 
PBS for 15 min at room temp. The same buffer was used for all subsequent antibody 
incubation and washing steps. For serotonin staining, anti-serotonin antibody (Abcam) was 
diluted 1:1000 in buffer prior to cell staining for 30 minutes at room temperature. Coverslips 
were washed with PBS three times and species specific alexa-488 conjugated secondary 
antibody (Molecular probes) was diluted 1:400 in buffer prior to cell staining for 30 minutes 
at room temperature. Coverslips were again washed three times in PBS and coverslips were 
mounted onto glass slides using immuneOfluor mounting solution (MP biomedicals, Solon, 
Ohio) and confocal analysis was performed using a Zeiss inverted LSM-510 microscope. 
Pearson’s correlation analysis was performed using ImageJ (NIH) software using the 
Colocalisation plugin (Kouichi Nakamura, Kyoto Univ, 2006).  
 
2.1.6 - Electron microscopy 
Between 3 and 5 x 10
6
 BMMCs were fixed for 10 min by adding 2 x fixative (4% (w/v) PFA, 
4% (w/v) Glutaraldehyde in 0.2 M sodium cacodylate buffer pH 7.4) to cells in suspension to 
retain morphology as much as possible. Cells were pelleted by centrifugation and 
resuspended in 1 x fixative for 30 min. Between 3 and 5 x 10
6
 BMDN were resuspended in 1 
x fixative for 30 min. Cells were pelleted, osmicated, incubated in tannic acid, dehydrated in 
ethanol and embedded in Epon as described previously (171).  Ultrathin sections were 
stained with lead citrate, analysed with a Jeol 1010 transmission electron microscope and 
images gathered with a Gatan OriusSC100B charge-coupled device camera. Granule size and 
number were measured from high magnification electron microscopy images. Homotypic 
fusions were those displaying a typical hourglass profile. Granule-plasma membrane 
distance was measured by ImageJ software (NIH).  
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2.2 – Mast cell methods 
2.2.1 - Primary Mast Cell Culture 
Mast cells were cultured as described previously (124). Briefly, bone marrow was flushed 
from femurs and tibias of mice using a 25-gauge needle and resuspended in complete 
medium (RPMI 1640 (Invitrogen Life Technologies, Paisley, UK), 10% heat-inactivated fetal 
bovine serum (FBS), 10 U/mL penicillin/streptomycin, 55 µM β-mercaptoethanol, 20 ng/mL 
recombinant murine interleukin 3 (IL-3) and 20 ng/mL stem-cell factor (SCF) (Peprotech, 
London, UK)) at a density of  0.5 x 10
6 
/mL. Non-adherent cells were transferred to new 
flasks and resuspended in fresh medium at a density of 0.5 x 10
6 
/mL every 3-4 days.  
 
2.2.2 - Measurement of ß-hexosaminidase release 
Measurement of ß-hexosaminidase release was performed essentially as described 
previously (124) using a colourmetric assay based on the cleavage of 4-Nitrophenyl N-acetyl-
b-D-glucosaminide by ß-hexosaminidase to a coloured product. BMMCs were pelleted by 
centrifugation at 300 g for 5 min and resuspended in complete medium containing 0.125 
μg/mL SPE-7 mouse anti-DNP IgE (Sigma-Aldrich) and cultured for 24 hours to sensitise cells. 
After this time, BMMCs were pelleted by centrifugation at 300 g for 5 minutes, washed once 
with HEPES buffer (140 mM NaCl, 5 mM KCl, 0.6 mM MgCl2, 1 mM CaCl2, 10 mM HEPES (pH 
7.4), 5.5 mM glucose, 0.5 mg/mL BSA) to remove any unbound IgE and resuspended at a 
density of 1 x 10
6
/mL in HEPES buffer. 1 x 10
5
 BMMCs were added DNP-HSA to a final 
concentration of 0, 10 and 30 ng/mL in a 96 well round bottom plate to crosslink IgE and 
activate BMMCs. For IgE-independent stimulations, 1 x 10
5
 BMMCs were added to 
ionomycin or PMA/ionomycin at 1 µM and 200 nM/1 µM final concentrations respectively 
to activate BMMCs independently of the IgE signalling pathway. Stimulations were allowed 
to proceed at 37°C for 30 minutes. After stimulation, BMMCs were pelleted by 
centrifugation at 300 g for 5 minutes in a pre-cooled centrifuge and then placed on ice. 
Supernatants were collected and pellets were lysed by resuspension in 100 µL of 1 % Triton-
X100 diluted in water. 20 µL of supernatant or pellet lysate were added to 60 µL of 1.3 
mg/mL 4-Nitrophenyl N-acetyl-b-D-glucosaminide in 0.1 M sodium citrate (pH 4.2) and 
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incubated at 37°C for 90 minutes to allow the reaction to proceed between secreted 
(supernatant) or non-secreted (pellet) β-hexosaminidase and its substrate. The reaction was 
stopped by addition of 150 µL of 0.2 M glycine (pH 10.5). Absorbances were read at 405 nm 
using a microplate reader to measure reactions and therefore the amount of β-
hexosaminidase secreted. Percentage of β-hexosaminidase release was determined as 
enzymatic activity of supernatant/total enzymatic activity.  
 
2.2.3 – Plasmid amplification and purification 
pEGFP-Rab27a and pEGFP-Rab27b plasmids were as described previously (9, 75). 1-10 ng of 
plasmid was used to transform E.coli DH5-α (Invitrogen). 50 µL of DH5-α was incubated on 
ice with plasmid DNA for 15 minutes. DH5-α were then incubated at 42°C for 30 seconds, 
then immediately placed on ice for 2 minutes. 1 mL of LB broth was added and DH5-α 
incubated at 37°C for 1 hour with 200 rpm shaking. After this time, E.coli were plated onto 
LB agar containing 50 µg/mL ampicillin to select cells containing the plasmid DNA and 
incubated at 37°C overnight. Colonies were picked and used to inoculate 50 mL of LB broth 
containing ampicillin and cultured at 37°C for 4 hours with 200 rpm shaking. After 4 hours, 
the culture was added to 2 litres of LB broth containing ampicillin and incubated overnight 
at 37°C with 200 rpm shaking. After this time, E.coli were pelleted, washed with PBS and 
then plasmid extracted using the Plasmid Maxiprep kit (Qiagen) using manufacturer’s 
instructions. Plasmid concentration and purity was measured using the Nanodrop system 
(Wilmington USA).  Typical plasmid concentrations obtained were 1-2 µg/µL. 
 
2.2.4 - Plasmid and siRNA transfection of BMMCs 
pEGFP-Rab27a or pEGFP-Rab27b plasmids were transfected into BMMCs by nucleofection 
using the Amaxa nucleofector apparatus and the mouse macrophage kit (Lonza, Cologne). 1 
x 10
6 
BMMCs were pelleted by centrifugation at 300 g for 5 minutes and resuspended in 100 
µL of transfection solution supplied with the kit. 1 µg of plasmid DNA or 2 nmoles siRNA 
(Dharmacon) was added to cells and the suspension added to cuvettes. Nucleofection in the 
apparatus was performed using settings T-017 and Y-010. Cells were taken out of cuvettes 
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and gently added to 2 mL of pre-warmed complete medium. Cells were incubated overnight 
at 37°C and 5% CO2 prior to confocal analysis. Typical plasmid transfection rates were below 
10%.  
 
2.2.5- RNA isolation and cDNA synthesis 
RNA was extracted from BMMCs using the RNeasy® kit (Qiagen) according to 
manufacturer’s protocol. Briefly cells were disrupted with 350 µL of Buffer RTL and vortexed. 
Lysate was transferred to a QIAshredder spin column placed in a 2 mL spin collection tube 
and subjected to centrifugation at 16,000 g for 2 minutes for homogenisation. 0.5 mL of 
70% ethanol was added to the lysate collected and mixed before transferring 700 µL of the 
sample to RNeasy columns to bind RNA. Columns were washed using RW1 and RPE buffers 
to wash away impurities. Finally RNA was eluted using 50 µL RNase free water. The 
concentration of RNA was measured using the Nanodrop spectrophotometer (Wilmington 
USA). cDNA was generated from RNA using the Superscript III first strand synthesis system 
(Invitrogen) according to manufacture’s recommendations. 150 ng of extracted RNA diluted 
with 11 µL of DEPC treated water was added to RNase free tubes and heated to 65°C to 
denature secondary structures. Tubes were placed on ice for 2 minutes before 5 x MgCl2. 10 
mM dNTP mix and random hexamers were added. +RT tubes contained Superscript III and –
RT tubes contained DEPC treated water, Samples were incubated at 42°C for 2 hours and 
180 µL DEPC treated water was added before cDNA was stored at 20°C. 
 
2.2.6 - RT-PCR 
Primers for Slp2 were designed using invtrogen software (OligoPerfect™ Designer) and 
supplied by Invitrogen. Target specificity, GC content and melting points were taken into 
consideration. Slp2 oligo sequences were (forward 5’ – GCTGTAGGGAAAACCACCAA – 3’, 
reverse 5’ – TCACTTGGAAAGCTTGGCAA – 3’). GAPDH primers (forward 5’-
GGCAAATTCAACGGCACAGT – 3’, reverse 5’ – AGATGGTGATGGGCTTCCC – 3’) were used as a 
control. PCR mix comprised DEPC treated water, -Mg 10x PCR buffer, 25 MgCl2 , 10 mM 
dNTP mix, GAPDH primers and Slp2 primers. 44.5 µL of mix was added to RNase free tubes 
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and 0.5 µL (2.5 units) of Taq polymerase (Invitrogen) was added to tubes. To +RT tubes, 5 µL 
of cDNA was added, to –RT tubes, 5 µL of –RT reaction was added. Samples were inserted 
into the Robocycler® Gradient 96 PCR machine (Stratagene, CA, USA). Gradients of 56-67°C 
were used to optimise annealing temperatures of primers. The PCR program used was as 
follows. Denaturation: 94°C for 2 minutes (1 cycle); annealing: 94°C for 15 seconds, 60°C for 
1 minute, 72°C for 1 minute (40 cycles); elongation: 72°C for 10 minutes (1 cycle). 1.5 % 
agarose gel was produced to measure amplified samples via electrophoresis. A Bio Rad 
ChemiDoc XRS+ gel imager was then used to view amplified products from cDNA. 
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2.3 – Neutrophil methods 
2.3.1 – Neutrophil purification 
Bone marrow derived neutrophils (BMDN) were isolated and purified as described 
previously (185). Bone marrow was flushed from femurs and tibias of mice. Erythrocyte lysis 
was performed by resuspending cells in a solution consisting of 168 mM NH4Cl, 10 mM 
Tris/HCl, pH 7.4. Cells were washed in PBS, resuspended in 1 mL of PBS and layered onto a 
Histopaque gradient (Histopaque 1119 and Histopaque 1077)
 
and separated by 
centrifugation for 45 minutes at 700 g without braking. The neutrophil-containing
 
lower cell 
layer at the interface of the two layers was collected and washed twice with HBSS buffer. 
Typical neutrophil purity was between 80-90% neutrophils by flow cytometry staining for 
the neutrophil specific marker Ly6G. 
 
2.3.2 – In vivo neutrophil recruitment assay 
The recruitment of neutrophils to the bronchoalveolar space was performed as described 
previously (56). Mice were briefly anaesthetised with isofluorane and 0.8 µg of recombinant 
murine MIP-2 (Peprotech) or vehicle PBS was administered intranasally. After 6 hours of 
treatment, mice were sacrificed by terminal anaesthesia followed by exsanguination and the 
bronchoalveolar lavage collected in 3 x 0.4 mL washes using 1 mL syringes and a canula 
inserted into the trachea. Cell counts were obtained using a haemocytometer and 
neutrophil percentages obtained by flow cytometry staining with anti-Ly6G antibody. 
Neutrophils
 
were identified as Ly6G
high
 cells and the characteristic
 
high side-scatter profile. 
 
2.3.3 – In vitro transwell chemotaxis assay 
Purified neutrophils or differentiated HL-60 cells were resuspended at 5 x 10
6
/mL in RPMI 
1640 supplemented with 0.1% BSA and their chemotaxis assessed as previously described 
(30, 184). 20 µL of the neutrophil suspension
 
was placed on top of a Neuroprobe ChemoTx 
chemotaxis plate (Receptor
 
Technologies, Adderbury, United Kingdom) with a 3 µm pore 
size. The bottom wells contained
 
29 µL RPMI 1640/0.1% BSA with indicated concentrations 
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of recombinant murine MIP-2 (Peprotech) and LTB4 and fMLP (Sigma-Aldrich). After 30 
minutes (or 1 hour for HL-60), migrated cells were collected, resuspended in 200uL of FACS 
buffer (PBS, 0.5% BSA, 0.01% sodium azide) and counted for 30 seconds on high setting 
using a FACScalibur machine (BD biosciences). 
 
2.3.4 – HL-60 cell culture and differentiation 
The human promyelocytic leukemia cell line HL-60 (American Type Culture Collection 
A.T.C.C.) were cultured in DMEM + 20% fetal bovine serum + 10 units/mL 
penicillin/streptomycin at 37ºC in 5% CO2 and maintained in suspension at a density of 
between 1 x 10
5 
and 1 x 10
6 
/mL. To stimulate differentiation, HL-60 were resuspended in 
medium containing 1.3% DMSO or ATRA (1 µM) for 72 hours.  
 
2.3.5 – HL-60 siRNA transfection 
HL-60 cells were transfected as described previously (127). 5 x 10
6 
cells were pelleted by 
centrifugation at 300 g for 5 minutes, resuspended in 100 µL transfection solution in the 
presence of 20 µM non-targeting siRNA (Dharmacon) or two Rab27a specific siRNA oligos 
and nucleofected using the Amaxa nucleoporator apparatus (Lonza). The sequences used 
were: 5´-ggagagguuucguagcuua, Rab27a(1) and 5´-ccaguguacuuuaccaaua, Rab27a(2). Cell 
line kit V and electrical setting T-01 were used. Nucleofected cells were then differentiated 
to mature neutrophils by suspension in medium containing 1.3% DMSO for 72 hours. 
 
2.3.6 – Assessment of actin polymerisation  
For quantification of total F-actin, 2 x 10
5
 neutrophils per tube were added and pelleted by 
centrifugation to remove medium. 100 µL of medium containing either 1 nM MIP-2 or 10 
nM LTB4 was added and cells were resuspended by vortexing and incubated at 37°C for 
indicated times. Cells were then fixed immediately by addition of 1 mL of ice-cold 4% PFA. 
Cells were fixed at room temperature for 30 minutes and subsequently pelleted by 
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centrifugation at 400 g for 10 minutes and fixative removed. Cells were washed 3 times with 
PBS and then permeabilised by addition of 0.5 % saponin in FACS buffer for 15 minutes at 
room temperature. Alexa-647-phaloidin was added at a dilution of 1:1000 and cells were 
stained for 30 minutes at room temperature. Cells were washed 3 times in FACS buffer and 
analysed using the FACScalibur machine (BD Biosciences). Fluorescence in unstimulated cells 
was classed as 100% total F-actin and fluorescence from stimulated cells worked out 
accordingly. 
 
2.3.7 – Zigmond chamber live cell neutrophil chemotaxis assay 
Isolated murine neutrophils (1 x 10
5 
were resuspended in 50 µL of RPMI 1640 + 1 % BSA and 
allowed to adhere to coverglass for 30 min at 37ºC at 5% CO2. Non-adherent cells were 
removed by washing and coverglass inverted into a Zigmond chemotaxis chamber 
(Neuroprobe). In the left well RPMI 1640 + 1% BSA was added and in the right 10 nM MIP-2 
(in RPMI 1640 + 1% BSA). The Zigmond chamber was placed on a heat-controlled stage 
(37ºC) and a gradient of chemokine was allowed to develop for 5 min before the start of 
recording. Brightfield images were taken every 30 sec for 30 min using a 10x objective on a 
Zeiss widefield microscope. Stacks of images were analysed using ImageJ software (National 
Institutes of Health) with the chemotaxis plug-in (Ibidi) to analyse track, velocity and 
direction of each moving cell. 
 
2.3.8 – EGFP-Rab27a localisation 
EGFP-Rab27a neutrophils (1 x 10
5
) were purified from transgenic EGFP-Rab27a expressing 
mice (180), resuspended in 100 µL RPMI 1640 + 1% BSA and plated onto coverslips for 20 
min at 37ºC, and placed into a MIP-2 chemokine gradient in a Zigmond chamber for 5 min 
and then fixed using 4% PFA at room temperature for 30 minutes. Coverslips were washed 
and then mounted as previously described in 2.1.5. 
 
2.3.9 – Surface CD11b and LAMP-1 measurements 
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For CD11b and LAMP-1 surface measurements, 2 x 10
5
 BMDN were resuspended in RPMI 
1640 + 1% BSA and stimulated with 1 nM MIP-2 at 37ºC for indicated times and placed on 
ice prior to CD11b/LAMP-1 staining. Cells were stained for 30 minutes using CD11b and 
LAMP-1 antibodies at a dilution of 1:100. CD11b was alexa-647 conjugated so those samples 
were washed 3 times in FACS buffer and analysed. For LAMP-1 staining, cells were washed 3 
times in FACS buffer and resuspended in FACS buffer containing alexa-488 conjugated anti-
rat secondary antibody at a dilution of 1:400 for 30 minutes on ice. Cells were washed 3 
times with FACS buffer and then analysed using the FACScalibur machine.  
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Chapter 3 - Rab27 and effectors in mast cell secretion 
3.1 – Introduction 
Studies of passive cutaneous anaphylaxis (an in vivo model of mast cell induced 
inflammation) from Rab27b knockout mice and beta-hexosaminidase secretion from 
Rab27b knockout BMMCs have suggested that Rab27b plays a positive role in secretion 
(124). From studies of beta-hexosaminidase secretion from Rab27a knockdown RBL-2H3 
cells and ashen
 
BMMCs, and from passive cutaneous anaphylaxis (PCA) from ashen mice, 
Rab27a is thought to play a negative role in mast cell secretion (63, 124). From beta-
hexosaminidase secretion assays from knockdown RBL-2H3 cells, the only Rab27 effector 
implicated to play a positive role in mast cell secretion is Munc13-4 (129). This raises the 
possibility that Rab27a and another effector or effectors may regulate secretion via an 
independent mechanism. While single knockdown or knockout of Rab27a or Rab27b impairs 
secretion of HeLa B6H4 cells neutrophils seemingly independently of the other isoform (80, 
137), only in knockdown HeLa cells has independent functions been linked to different 
effectors (137) and no study to date has demonstrated Rab27a and Rab27b to have 
opposing roles in the same cell type. While not impossible, the idea that Rab27a and Rab27b 
may play opposing roles in the same cell type is counterintuitive given that Rab27a and 
Rab27b share 70% amino acid sequence identity and are thought to bind the same family of 
effector proteins. To attempt to resolve this paradox, bone marrow derived mast cells 
(BMMCs) were cultured from wild-type (Rab27a
+/+
), Rab27a deficient (ashen), Rab27b 
knockout (Rab27b KO) and Rab27a/b double deficient (Rab27DKO) mice and subjected to 
extensive phenotypic analysis in order to better understand the function and functional 
interplay of Rab27 isoforms in mast cell secretion. 
 
 
 
 
 
61 
 
3.2 - Results 
3.2.1 – Expression of c-kit and IgεRI on Rab27 deficient BMMCs 
Mast cells are cultured from a mixed population of bone marrow leukocytes that contain 
CD34
+ 
haematopoietic stem cells. Culture of a mixed population of leukocytes from bone 
marrow in medium containing interleukin 3 (IL-3) and stem cell factor (SCF) has been shown 
to yield cultures of functionally mature mast cells with over 90% purity after 4 weeks in 
culture without the need of a purification method (124). After this time, the purity of mast 
cell cultures may be determined by analysing the surface expression of c-kit and IgεRI. C-kit 
is the receptor for SCF and is required for appropriate growth and maturation of mast cells 
(89). IL-3 binds to the IL-3 receptor and also stimulates growth and differentiation of mast 
cells from haematopoietic stem cells (151). IgεRI is the receptor for IgE through which mast 
cells become activated to secrete upon exposure to a particular antigen (14). While c-kit is 
expressed on haematopoietic stem cells, IgεRI surface expression is upregulated upon 
differentiation of mast cells. However basophils also express IgεRI, therefore double staining 
for IgεRI and c-kit is required to distinguish mast cells. Staining for c-kit and IgεRI 
demonstrates the purity of mast cell cultures through analysis of percentage of double 
positive cells and also indicates appropriate maturation as surface levels of c-kit and IgεRI 
increase with mast cell maturation. BMMCs from Rab27 deficient mice were analysed by 
flow cytometry for c-kit and IgεRI. Consistent with an earlier report of appropriate 
maturation of BMMCs from Rab27 deficient BMMCs (124), after 4 weeks, cultures from all 
Rab27 deficient mice displayed above 90% double-positive cells (wild-type 97.22 ± 0.27 %, 
ashen 97.13 ± 0.77%, Rab27b KO 92.25 ± 0.38% and Rab27DKO 95.55 ± 0.37%) (Fig 3.2.1 A 
and B). As a trend higher c-kit surface expression was observed on ashen BMMCs and lower 
surface expression on Rab27b KO BMMCs but due to high variability these differences were 
not significant (wild-type 323.44 ± 25.04 MFI, ashen 422.14 ± 37.94 MFI, Rab27b KO 199.95 
±  26.35 MFI, Rab27DKO 304.64 ± 26.65 MFI) (Fig 3.2.1 C). Interestingly Rab27b KO but not 
ashen or Rab27DKO BMMCs consistently expressed lower levels of IgεRI compared to wild-
type (wild-type 82.77 ± 13.36 MFI, ashen 61.72 ± 13.33 MFI, Rab27b KO 35.28 ± 5.22 MFI, 
Rab27DKO 63.73 ±  10.55 MFI) (Fig 3.2.1 D) suggesting that Rab27b KO BMMCs may be 
impaired or delayed in their maturation in culture. 
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3.2.2 – Expression of Rab27a and Rab27b in Rab27 deficient BMMCs 
The expression of Rab27a and Rab27b protein in BMMCs has been observed previously 
(124) however to confirm BMMCs were from the appropriate wild-type or Rab27a deficient 
mice, western blot analysis was used to detect Rab27a and Rab27b protein. By western blot, 
expression of appropriate Rab27 isoforms in various Rab27 deficient BMMCs was 
demonstrated (Fig 3.2.2). While antibodies were more specific for the isoform they were 
purified to detect, some cross-reactivity was detected in other cell types such as neutrophils 
(Fig 4.2.1). However cross-reactivity was not observed in BMMCs. Isoforms could be 
distinguished by western blot because Rab27a and Rab27b appear at slightly different sizes 
(Rab27a is detected above the 28kDa marker and Rab27b is detected below it).  
Interestingly overexpression of Rab27b was not observed in absence of Rab27a which is in 
contrast to western blot analysis of neutrophils from ashen mice (80).  
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Figure 3.2.1 – Expression of c-kit and IgεRI on Rab27KO BMMCs. (A) Flow cytometry analysis of 
surface expression of IgεRI and c-kit and (B) percentages of double positive cells of WT (Rab27a
+/+
), 
Ashen (Rab27a
ash/ash
), Rab27b KO (Rab27b
-/-
) and Rab27DKO (Rab27a
ash/ash
, Rab27b
-/-
) BMMCs.  
Quantification of (C) c-kit and (D) IgεRI surface receptor expression using mean fluorescence 
intensity. Data compiled from 3 independent experiments. Error bars s.e.m. * P  < 0.05 Student’s t 
test. N.s. not significant. 
 
Figure 3.2.2 – Expression of Rab27a and Rab27b in wild-type and Rab27 deficient BMMCs. (A) 
Western blot using 50 µg of WT (Rab27a
+/+
), ashen (Rab27a
ash/ash
), Rab27b KO (Rab27b
-/-
) and 
Rab27DKO (Rab27a
ash/ash
, Rab27b
-/-
) BMMC lysates from various Rab27 mutant mice. Data 
representative of 3 independent experiments. 
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Functional characterisation of Rab27 deficient BMMCs 
3.2.3 – Rab27a and Rab27b can promote BMMC secretion in response to IgεRI crosslinking 
but Rab27a can also negatively regulate BMMC secretion 
The role of Rab27b in mast cell secretion has previously been studied (124). To understand 
the role of Rab27a in BMMC granule secretion, beta-hexosaminidase secretion from Rab27 
deficient BMMCs in response to IgεRI crosslinking was measured. Beta-hexosaminidase is 
known to be released in parallel to histamine and other mediators contained in all granule 
types in mast cells and is a convenient method to measure secretion (99). This is because 
upon addition of a substrate to beta-hexosaminidase containing supernatants, a 
colourmetric reaction occurs and can be used to calculate the percentage of total cell beta-
hexosaminidase that is secreted. Unstimulated BMMCs displayed very low levels of 
spontaneous secretion and no significant differences were observed between wild-type and 
Rab27 deficient BMMCs (at 0 ng/mL DNP-HSA wild-type 2.13 ± 0.19%, ashen 2.22 ± 0.42, 
Rab27b KO 3.26 ± 1.09% and Rab27DKO 3.95 ± 0.70%) (Fig 3.2.3). In response to IgεRI 
crosslinking with DNP-HSA, ashen BMMCs displayed a small but significant increase in 
secretion compared to wild-type at both 10 and 30 ng/mL DNP-HSA while Rab27b KO 
BMMCs displayed a significant decrease in secretion at both concentrations.  (at 10 ng/mL 
DNP-HSA wild-type 32.75 ± 1.90%, ashen 37.87 ± 2.22, Rab27b KO 7.53 ± 1.19%, Rab27DKO 
3.92 ± 0.18% and at 30 ng/mL DNP-HSA wild-type 20.28 ±  1.23%, ashen 23.70 ± 1.25%, 
Rab27b KO 7.29 ± 1.19 and Rab27DKO 3.78 ±  0.19% beta-hexosamindase secretion). 
Rab27DKO BMMCs did not display detectable secretion at either 10 or 30 ng/mL DNP-HSA 
and displayed significantly less secretion than Rab27b KO BMMCs at 10 ng/mL DNP-HSA (Fig 
3.2.3). These results suggest that Rab27a is a negative regulator of secretion as has been 
suggested previously in studies of BMMCs and RBL-2H3 cells where absence or knockdown 
of Rab27a increased beta-hexosaminidase secretion in vitro (63, 124). Comparison of 
Rab27b KO and Rab27DKO BMMCs (Fig 3.2.3) at 10 ng/mL DNP-HSA shows that in absence 
of Rab27b, Rab27a can promote secretion. The trend is the same at 30 ng/mL DNP-HSA but 
differences between Rab27b KO and Rab27DKO BMMCs at this sub-optimal concentration 
of DNP-HSA were not significant. Taken together these data suggests that both isoforms can 
promote IgεRI dependent secretion of BMMCs, but that another factor is involved that 
explains why Rab27a acts as a negative regulator of secretion in wild-type BMMCs. As 
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Rab27DKO BMMCs display no detectable secretion using IgεRI crosslinking, these data 
suggest that mast cell secretion under physiological conditions is critically dependent on the 
balance of Rab27a/b function.  
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Figure 3.2.3 – IgE-R dependent beta-hexosaminidase secretion of Rab27 KO BMMCs. BMMCs from 
WT (Rab27a
+/+
), ashen (Rab27a
ash/ash
), Rab27b KO (Rab27b
-/-
) and Rab27DKO (Rab27a
ash/ash
, Rab27b
-/-
) mice were sensitised overnight with IgE-DNP and subsequently stimulated with DNP-BSA to cause 
IgE crosslinking . Beta-hexosaminidase release was measured after 30 mins stimulation by reaction 
with p-nitrophenyl-N-acetyl-β-D-glucosamine. * P < 0.05, *** P < 0.001 by student’s t test. N.s. 
denotes differences not statistically significant. Data representative of 4 independent experiments. 
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3.2.4 – Rab27a and Rab27b promote BMMC secretion in response to IgεRI independent 
stimulation 
The signalling pathway activated upon clustering of IgεRI leading to downstream activation 
of PKC and calcium influx have previously been defined (14). Activation of PKC and influx of 
calcium occur late in this pathway and precede mast cell secretion. Many processes occur 
upon influx of calcium and activation of PKC including cortical F-actin disassembly (possibly 
through myosin II phosphorylation) and phosphorylation of SNARE proteins that promote 
granule fusion with the plasma membrane (14, 173). To bypass the IgεRI  signalling pathway 
and to assess the secretory capability of Rab27 deficient BMMCs in a more direct manner, 
secretion of beta hexosamindase in response to calcium ionophore (ionomycin) or 
simultaneous treatment of ionomycin and protein kinase C activator PMA was measured. 
The pathways involved were described in section 1.1.6 Figure 5.  
In response to ionomycin stimulation in the presence of extracellular Ca
2+
, ashen BMMCs 
displayed similar secretion to wild-type (Fig 3.2.4 A). Rab27b KO BMMCs displayed impaired 
secretion and Rab27DKO BMMCs showed further reduced secretion (wild-type 70.80 ± 
1.87%, ashen 69.06 ± 0.49%, Rab27b KO 26.03 ± 2.32%, Rab27DKO 9.37 ± 0.77%) (Fig 3.2.4 
A). Ionomycin is a lipid soluble molecule that creates pores in the cell membrane to allow 
the influx of extracellular calcium into the cell. This influx is much greater than that caused 
as a result of physiological activation of mast cells through IgεRI and so are likely to elicit a 
more robust secretory response. This is why the percentages of beta-hexosaminidase 
secreted in response to ionomycin are much greater than those observed using IgE 
crosslinking. These results suggest that late secretory events are impaired in Rab27b KO 
BMMCs whereas ashen BMMC secretion is affected by early events or those prior to 
stimulation. Activation via ionomycin bypasses upstream events leading to calcium influx 
and stimulate late secretory events whereas activation via IgE crosslinking stimulates both 
early signalling events in secretion and late events such as calcium influx as a result of 
upstream signalling. Rab27b KO BMMCs display impaired secretion to both IgE crosslinking 
and ionomycin and so bypassing early secretory events does not rescue secretion suggesting 
that late events in secretion are responsible for defective secretion. However the level of 
impairment of Rab27b KO BMMCs using ionomycin was less than that using IgE crosslinking 
(22.98% of wild-type secretion using IgE and 36.77% using ionomycin) suggesting that using 
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a more direct method of secretion can partially restore Rab27b KO secretion. By contrast, 
ashen BMMCs do not display altered secretion in response to ionomycin suggesting late 
events are not affected, however display increased secretion compared to wild-type using 
IgE crosslinking therefore suggesting that early secretory events may be responsible for 
altered secretion.  
Simultaneous treatment of BMMCs with ionomycin and PMA significantly enhanced beta-
hexosaminidase secretion from all BMMCs (wild-type 78.33 ± 0.36%, ashen
 
77.71 ± 2.24%, 
Rab27b KO 51.42 ± 1.88%, Rab27DKO 18.08 ± 0.79%) however Rab27b deficient BMMCs 
displayed significantly greater enhancement (Fig 3.2.4 B). This result suggested that robust 
calcium influx and PKC activation can restore function of Rab27b KO BMMCs. As Rab27a has 
been suggested to both promote secretion in absence of Rab27b, robust calcium influx and 
PKC activation in Rab27b KO BMMCs may enhance the positive secretory capability of 
Rab27a or reverse Rab27a negative regulation of secretion. Rab27a was suggested to 
regulate early secretory events from beta hexosaminidase secretion from IgE crosslinking 
(Fig 3.2.3) so the activity of PMA in phosphorylation of signalling molecules prior to calcium 
influx may explain this result. Rab27DKO displayed defective secretion to ionomycin and 
PMA stimulation suggesting that the secretory capability of BMMCs is significantly impaired 
in absence of Rab27a and Rab27b. This may be due to defective docking of granules to the 
plasma membrane through effectors as is thought to be the main role for Rab27 in secretion 
in RBL-2H3 cells (51).  
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Figure 3.2.4 – IgE-R independent beta-hexosaminidase secretion of Rab27 KO BMMCs. (A) BMMCs 
from WT (Rab27a
+/+
), ashen (Rab27a
ash/ash
), Rab27b KO (Rab27b
-/-
) and Rab27DKO (Rab27a
ash/ash
, 
Rab27b
-/-
) mice were washed and stimulated with 1 µM ionomycin or a combination of 200 nM PMA 
and 1 µM ionomycin for 30 mins. (B) Differences between ionomycin and ionomycin/PMA 
stimulation of beta-hexosaminidase secretion from Rab27 deficient BMMCs. *P < 0.05, ** P < 0.01, 
*** P < 0.001 by student’s t test. Data representative of 3 independent experiments (A) or compiled 
from 3 independent experiments (B). 
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Morphological characterisation of Rab27 deficient BMMCs 
3.2.5 – Granule density is increased in absence of Rab27a but not Rab27b 
Given the finding that Rab27b KO BMMCs may display defects in maturation by flow 
cytometry as suggested by reduced c-kit and IgεRI surface expression compared to wild-type 
(Fig 3.2.1), BMMCs were analysed by electron microscopy to determine whether the 
morphology of BMMCs was altered as a consequence of defective or delayed maturation. 
Ashen and Rab27DKO BMMCs displayed increased density of granule contents by electron 
microscopy compared with wild-type BMMCs whereas Rab27b KO BMMCs did not (Fig 3.2.5 
A and B). As mentioned previously mast cells have 3 types of granules. Type I are those 
containing small intragranullar vesicles, type II are those with intragranullar vesicles and a 
dense core and type III are those containing only a dense core. Ashen and Rab27DKO 
BMMCs clearly displayed denser type I and type II granules compared to wild-type. Changes 
in density of type III granules were difficult to assess as they already contained dense 
contents. A recent study suggested that knockdown of Rab27a may lead to an increase of 
secretory organelle contents as observed by cryo-electron microscopy staining of CD63 in 
HeLa B6H4 cells (137) and these results are consistent with that finding. These data suggest 
that Rab27a may specifically influence granule biogenesis processes whereas Rab27b may 
not perform this function. Further differences by electron microscopy were observed and 
were characterised in the hope of understanding better the functions of Rab27a and Rab27b 
in mast cells. 
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Figure 3.2.5 – Granule contents are denser in absence of Rab27a but not Rab27b. Electron 
micrograph images showing morphology of WT (Rab27a
+/+
), ashen (Rab27a
ash/ash
), Rab27b KO 
(Rab27b
-/-
) and Rab27DKO (Rab27a
ash/ash
, Rab27b
-/-
) BMMCs (A) and density of granules from wild-
type and Rab27 deficient BMMCs. Scale bars 2 µm.  (B). F denotes granule-granule fusion events. 
Scale bars 1 or 0.5 µm. EM performed by Dr. Silene T. Wavre-Shapton. 
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3.2.6 – Granule size is reduced in absence of Rab27a but not Rab27b 
During electron microscopy analysis, differences in granule size between Rab27 deficient 
BMMCs were observed. Granule size was measured in wild-type and Rab27 deficient 
BMMCs from randomly selected granules of all types using images taken from comparable 
sections within the cells. Granule diameter was found to be significantly reduced in ashen 
and Rab27DKO BMMCs but not in Rab27b KO BMMCs compared to wild-type BMMCs (wild-
type 0.81 ±  0.03 µm, ashen 0.64 ± 0.03 µm, Rab27b KO 0.78 ±  0.02 µm and Rab27DKO 0.58 
± 0.02 µm) (Fig 3.2.6). Interestingly granule diameter was slightly smaller in Rab27DKO 
BMMCs than ashen BMMCs though this was not significant. While this result suggested that 
Rab27a regulates granule size, it did not entirely exclude a role for Rab27b in this process. 
When increases in secretory organelle contents were observed in Rab27a knockdown HeLa 
cells, this was accompanied by an increase in organelle size by electron microscopy (137). 
This result is not consistent with findings presented here and suggest that Rab27a may play 
a slightly different role In organelle biogenesis in mast cells.  
 
3.2.7 – Granule-granule fusion events are observed less frequently in ashen BMMCs 
During EM studies, the presence of apparent granule-granule fusion profiles were observed 
(Fig 3.2.5). While there is no direct evidence that intergranular fusion plays a role in granule 
biogenesis, this was previously suggested based on the fact that by electron microscopy 
type II granules are thought to arise by fusion of type I and type III granules (150). We 
observed differences in the number of fusion profiles in Rab27 deficient BMMCs compared 
to wild-type. Fusion profiles were defined as those having a typical hourglass profile and 
those where no barrier membrane between granules was observed. We observed that in 
ashen and Rab27DKO but not Rab27b KO BMMCs there was a significant decrease in 
granule-granule fusion events observed compared to wild-type BMMCs (wild-type 3.08 ±  
0.75, ashen 0.75 ±  0.35, Rab27b KO 3 ±  0.64, Rab27DKO 1 ±  0.25 events/section) (Fig 3.2.7). 
These observations support the idea that Rab27a may be involved in the biogenesis of 
granules in resting cells perhaps by regulating intergranule fusion. Given that ashen and 
Rab27DKO BMMCs appeared to be similar by EM (Fig 3.2.5, 3.2.6) and that their secretion 
73 
 
profiles are very different (Fig 3.2.3), it is not immediately obvious whether granule 
maturation affects the amount of beta-hexosaminidase secreted. 
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Figure 3.2.6 – Granule size is reduced in absence of Rab27a. Granule diameter was measured from 
EM images from WT (Rab27a
+/+
) (n = 95), ashen (Rab27a
ash/ash
) (n = 102), Rab27b KO (Rab27b
-/-
) (n = 
135) and Rab27DKO (Rab27a
ash/ash
, Rab27b
-/-
) (n=113) BMMCs. *** P < 0.001 by student’s t test, 
error bars s.e.m. Data compiled from 3 independent experiments. 
 
Figure 3.2.7 – Rab27a but not Rab27b regulates homotypic fusion in resting cells. Homotypic 
granule-granule fusions were counted and averaged from 12 BMMCs from WT (Rab27a
+/+
), ashen 
(Rab27a
ash/ash
), Rab27b KO (Rab27b
-/-
) and Rab27DKO (Rab27a
ash/ash
, Rab27b
-/-
) mice. Only fusions 
resulting in a continuous granule were counted. Data compiled from 3 independent experiments. 
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3.2.8 - Granule number and type are not affected in Rab27 deficient BMMCs 
While there seemed to be differences in granule contents density and granule size between 
ashen and Rab27DKO compared to wild-type (Fig 3.2.5, 3.2.6) the impact of these 
observations on granule types and number were still not known. To analyse this in more 
detail EM images from wild-type and Rab27 deficient BMMCs were counted for different 
granule type and overall number of granules per section using images from comparable 
parts of the cell. Surprisingly no significant differences were observed in granule types and 
in the number of granules in Rab27 deficient BMMCs compared to wild-type (Fig 3.2.8). This 
result is counterintuitive considering that in absence of Rab27a granule-granule fusion 
events are observed less frequently (Fig 3.2.7) so one might expect to see more granules in 
absence of Rab27a. This result suggests that in absence of Rab27a (and Rab27b) that 
granule type and number are still adequately regulated. 
  
3.2.9 – Rab27a knockout reduces granule-plasma membrane distance while Rab27b 
knockout increases granule-plasma membrane distance 
A previous study on Rab27 in mast cells using live cell microscopy had suggested that Rab27 
may promote granule docking by promoting the transition of granules from microtubule 
based transport to actin based transport at the cell periphery. To test this hypothesis, 
granule-plasma membrane distance was measured in wild-type, ashen
 
and Rab27b KO 
BMMCs using EM images obtained previously and Image J software. Granule-plasma 
membrane distance was significantly reduced in ashen and significantly increased in Rab27b 
KO BMMCs compared to wild-type (wild-type 0.81 ±  0.07 µm, ashen 0.63 ±  0.06 µm and 
Rab27b KO 1.03 ±  0.07 µm) (Fig 3.2.9). While these results suggest that Rab27 isoforms may 
play opposing roles in mast cell secretion, they may relate to previous findings that Rab27a 
may be a negative regulator and Rab27b a positive regulator of secretion as measured by 
beta-hexosaminidase secretion (Fig 3.2.3) and PCA assays (124). 
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Figure 3.2.8 – Granule type and number are comparable to wild-type in Rab27 deficient BMMCs.  
Granule types and number were counted from high magnification images of BMMCs from WT 
(Rab27a
+/+
) (n=27), ashen (Rab27a
ash/ash
) (n=22), Rab27b KO (Rab27b
-/-
) (n=27) and Rab27DKO 
(Rab27a
ash/ash
, Rab27b
-/-
) (n=22) mice. Error bars s.e.m. 
 
 
Figure 3.2.9 – Granule-plasma membrane distance is differentially affected in Rab27a or Rab27b 
knockout BMMCs. Granule-plasma membrane distance was measured from high magnification EM 
images using ImageJ software from wild-type (WT) (n=113), ashen (n=107) and Rab27b KO (n=110) 
granules.* P < 0.05, ** P < 0.01 by student’s t test. Data representative of 3 independent 
experiments.  
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3.2.10 – Intracellular localisation of Rab27a and Rab27b in BMMCs 
So far EM studies suggested differences in the role of different Rab27 isoforms in granule 
maturation. We hypothesised that differences in Rab27a and Rab27b function may arise 
from different localisations within the cell as previously described in HeLa cells and 
neutrophils where Rab27a and Rab27b play independent roles (80, 137). To test this, the 
intracellular localisation of Rab27a and Rab27b was analysed. Consistent with previous 
observations of granule localisation of Rab27a and Rab27b (124), Rab27a and Rab27b 
partially colocalised with type II and type III granule marker serotonin (Fig 3.2.10 A, B). 
However both isoforms colocalised more strongly with type I and type II granule marker 
LAMP-1 (Fig. 3.2.10 C, D). This was confirmed using colocalisation analysis software to 
measure Pearson’s correlation coefficient in Image J. Interestingly both isoforms colocalised 
equally well with both markers indicating no significant differences in their intracellular 
localisation (Fig 3.2.10 E). So far the only way Rab27 isoforms have been demonstrated to 
play different roles is through different localisations in the same cell (80) and this raises the 
possibility that another mechanism of functional distinction between the two Rab27 
isoforms exists in mast cells. 
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Figure 3.2.10 – Intracellular localisation of Rab27a and Rab27b in resting cells. Wild-type BMMCs 
were nucleofected by Amaxa using EGFP-Rab27a (A,C) or EGFP-Rab27b (B,D) constructs, stained for 
markers Serotonin (A,B) and Lamp-1 (C,D) and analysed by confocal microscopy. (E) Pearson’s 
correlation analysis of colocalisation performed on 20 cells. Scale bars 2 µm. Immunofluorescence 
performed by Dr Christina Wasmeier. 
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3.2.11 – Rab27a knockout perturbs F-actin distribution while Rab27b knockout increases 
F-actin thickness and total content. 
While Rab27b is thought to promote granule docking at the plasma membrane through 
transition of granules from microtubule to actin based transport (124), the same function 
for Rab27a does not explain IgE-dependent secretion of ashen BMMCs observed in Fig 3.2.3 
as secretion is enhanced (the opposite phenotype to Rab27b KO BMMCs). One finding that 
should be considered is by EM that the granule-plasma membrane distance was reduced in 
ashen
 
BMMCs (Fig 3.2.9), suggesting that Rab27a may inhibit granule docking at the plasma 
membrane. One factor thought to be critical for the docking of granules at the plasma 
membrane is the presence of F-actin beneath the plasma membrane at the cell cortex. This 
F-actin helps the cell to retain its shape and integrity and is also thought to act as a barrier 
to secretion. Rab27a is known to be linked to actin through effectors melanophilin and 
MYRIP (76, 110). Furthermore Rab27a was recently implicated in the regulation of actin 
distribution and dynamics during phagocytosis in macrophage-like differentiated HL-60 cells 
(195). To test whether Rab27a can modulate BMMC secretion by altering cortical actin, 
wild-type, ashen and Rab27b KO BMMCs were stained using fluorescent phalloidin that 
specifically stains F-actin and analysed by immunofluorescence. Wild-type BMMCs displayed 
a uniformly distributed cortical shell of F-actin while a significantly higher proportion of 
ashen
 
BMMCs displayed uneven irregular patchy distribution (wild-type 9.72 ± 1.68%, ashen 
33.88 ± 4.40% and Rab27b KO 6.23 ± 1.20% BMMCs with irregular F-actin) (Fig 3.2.11 A, B, 
C). While Rab27b KO BMMCs displayed a regular even distribution of cortical F-actin (Fig 
3.2.11 C), surprisingly they displayed more intense staining of cortical F-actin (Fig 3.2.11 B), 
accompanied by a significantly increased amount of total cellular F-actin by phalloidin 
staining and flow cytometry analysis (wild-type 46.68 ± 1.49 MFI, ashen 46.55 ± 0.89 MFI, 
Rab27b KO 53.14 ±  0.64 MFI) (Fig 3.2.11 D). These results suggest that Rab27a regulates the 
normal distribution of F-actin and that Rab27b regulates the amount of F-actin at the cortex. 
Irregular distribution of F-actin might allow granules to dock closer to the plasma membrane 
and more cortical actin might result in granules docking further from the plasma membrane 
so these findings may relate to differences in granule-plasma membrane distance observed 
in ashen
 
and Rab27b KO BMMCs compared to wild-type by EM (Fig 3.2.9). It is also possible 
that granule docking itself may destabilise cortical actin. 
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Figure 3.2.11 – Rab27a and Rab27b differentially regulate F-actin distribution and content.  (A) 
Confocal microscopy of F-actin and serotonin distribution in WT (Rab27a
+/+
) and ashen 
(Rab27a
ash/ash
) BMMCs. Scale bars 5 µm.(B) F-actin distribution and content of WT (Rab27a
+/+
), ashen 
(Rab27a
ash/ash
) and Rab27b KO (Rab27b
-/-
) BMMCs by alexa-568 phalloidin staining. . Scale bars 20 
µm. (C) Quantification of F-actin regular and irregular distribution in Rab27 deficient BMMCs. (D) 
Flow cytometry quantification of total F-actin content in Rab27 deficient BMMCs. * P < 0.05, ** P < 
0.01 by student’s t test. Data representative of 3 independent experiments. 
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Rab27 effectors Slp2 and Melanophilin in BMMC secretion 
3.2.12 – Slp2 is expressed in primary BMMCs 
Melanophilin was suggested to be an effector involved in F-actin regulation that influences 
secretion. Interestingly knockdown of Slp2 was suggested to alter cell shape through 
phospholipid binding activity of Slp2 in melanocytes (96). In CTLs, Slp2 has been linked to 
the regulation of secretion through linkage of granules to the plasma membrane to promote 
secretion at the immune synapse (74). The effector or effectors involved in linkage of 
granules to the plasma membrane in BMMCs are yet to be determined. As a first step to 
identifying them, effector expression was analysed in BMMCs starting with Slp2. RNA was 
extracted from wild-type BMMCs using the RNeasy kit (Qiagen) and cDNA created using 
random hexamers. This cDNA was used to try to detect Slp2 transcripts which were 
detected by RT-PCR (Fig 3.2.12 A). Slp2 protein was also detected from wild-type BMMC 
lysates by western blot (Fig 3.2.12 B).  
 
3.2.13 – Slp2 protein levels could not be reduced by siRNA transfection of wild-type 
BMMCs 
Studies have previously employed knockout mice to analyse the role of proteins in primary 
BMMCs due to difficulties in transfection of BMMCs with siRNA. However siRNA is a 
convenient method of studying the role of a protein family such as the Rab27 effectors. To 
test whether siRNA could be successfully applied, transfection using the amaxa system was 
tested. This approach was successful to transfect plasmid into BMMCs (Fig 3.2.10) however 
the transfection efficiency was very low. Consistent with this, we did not observe 
knockdown of Slp2 using specific oligonucleotide sequences for Slp2 (Fig 3.2.13). Several 
other targets were tested (Rab27a, Rab27b and Melanophilin) and also could not be 
silenced in BMMCs using siRNA. This proved to limit the progress of this study significantly 
as individual effector knockout mice or bone marrow would be needed for each effector. Dr 
C. Wasmeier also tested knockdown using transduction of BMMCs with lentiviruses 
expressing effector specific shRNA. However this also proved unsuccessful.  
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Figure 3.2.12 – Slp2 is expressed in BMMCs by RT-PCR and western blot.  (A) RT-PCR detection of 
Slp2 mRNA in wild-type BMMCs. (B) Detection of Slp-2 protein in wild-type BMMCs by western blot. 
Slp2 antibody a kind gift of M. Fukuda. Experiment performed during supervision of Mr Mohammed 
Kamal. 
 
 
Figure 3.2.13 – Slp2 cannot be silenced using siRNA in BMMCs. BMMCs were nucleofected using 
amaxa program T-020 with 20 µM non-targeting (NT) or Slp2 siRNA, cultured for 72 hours and 50 µg 
of lysate subjected to western blot analysis. Experiment performed during supervision of Mr 
Mohammed Kamal. 
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3.2.14 – Melanophilin is expressed in BMMCs and knockout increases BMMC secretion 
Another way in which Rab27 is thought to perform different functions in different cell types 
is through interaction with different effectors. The results presented so far suggested that 
Rab27 may influence secretion through regulating F-actin distribution and content. To 
investigate a potential link to the actin cytoskeleton through Rab27 effectors, the expression 
of Melanophilin was tested in BMMCs. Melanophilin was found to be expressed in BMMCs 
by western blot and was absent in BMMCs cultured from the melanophilin deficient leaden 
mouse characterised previously (118) (Fig 3.2.14 A). Secretion of beta-hexosaminidase was 
tested from wild-type Mlph
ln/+
 (ln/+) mice and leaden Mlph
ln/ln
 (ln/ln) BMMCs. Knockout of 
melanophilin enhanced secretion from BMMCs in response to DNP-HSA stimulation in a 
fashion similar to that observed in ashen
 
BMMCs (at 10 ng/mL DNP-HSA wild-type (ln/+) 
20.95 ± 0.31% and leaden 40.71 ± 0.73) (Fig 3.2.14 B). An increase in beta-hexosaminidase 
secretion was also observed in leaden BMMCs compared to wild-type using ionomycin 
stimulation (wild-type (ln/+) 61.75 ± 2.51% and leaden 72.17 ± 0.83%) (Fig 3.2.14 B). Loss of 
melanophilin might destabilise actin structure in BMMCs. While knockdown of melanophilin 
in melanocytes has not been suggested to alter cell shape (96), melanocytes are adherent 
cells so their shape is supported by attachment to a substrate. BMMCs grow in suspension 
and so do not have a substrate to support their shape and therefore may be more reliant on 
actin stabilising proteins such as melanophilin to regulate cell shape and function. These 
results support the idea that Rab27 regulated F-actin distribution influences secretion. 
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Figure 3.2.14 – Melanophilin (Mlph) is expressed in BMMCs and leaden BMMCs display enhanced 
secretion compared to wild-type. (A) Western blot analysis of melanophilin protein expression using 
100 µg of heterozygous control Mlph
ln/+
 (ln/+) and melanophilin deficient Mlph
ln/ln
 (ln/ln) BMMC 
lysates. Calnexin was used as a loading control. (B) Beta-hexosaminidase secretion after 30 min of 
ln/+ and ln/ln lysates in response to medium alone (0), 10 ng/mL DNP-HSA (DNP) and 1 µM 
ionomycin. * P ≤ 0.05, *** P ≤ 0.001 Student’s t test. Error bars s.e.m. B performed with Dr. Christina 
Wasmeier. 
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Rab27 effector Munc13-4 in secretion using jinx BMMCs 
3.2.15 – Expression of c-kit and IgεRI on jinx BMMCs is similar to wild-type  
Overexpression studies indicated that Munc13-4 promotes secretion in the RBL-2H3 
basophilic leukemia cell line (129) often used as a model for mast cells so seemed another 
good effector candidate to test in our more physiological model. Based on this we 
hypothesised a role for Munc13-4 in BMMC secretion and to test this we obtained bone 
marrow from a knockout mouse that was created by a random mutagenesis approach (44). 
The Munc13-4 knockout mouse jinx (Unc13d
jinx/jinx
) is a model of type 3 familial 
haemophagocytic lymphohistiocytosis that do not display clinical features until they are 
infected with lymphocytic choriomeningitis virus. They are also susceptible to mouse 
cytomegalovirus, a read-out of defective NK cell function. Jinx NK cells and CTLs were found 
to show defective secretion in the same study. As a first step to characterise the role of 
Munc13-4 in BMMCs, bone marrow was obtained via a collaborator from jinx mice and 
BMMCs were cultured. The purity of BMMCs was tested using flow cytometry staining of c-
kit and IgεRI as previously described (Fig 3.2.1). Over 90% double positive cells were 
consistently observed in culture after 4 weeks (Fig 3.2.15 A and B) and no significant 
differences in surface expression of c-kit (Fig 3.2.15 C) and IgεRI (Fig 3.2.15 D) were 
observed between wild-type (BL/6) and jinx BMMCs. 
 
3.2.16 – Expression of Munc13-4 in primary BMMCs and knockout in jinx BMMC  
The next step was to confirm that Munc13-4 protein could be detected in primary BMMCs 
(as it has only ever been demonstrated to be expressed in the RBL-2H3 cell line), and that 
jinx BMMCs do not contain Munc13-4. Munc13-4 protein was detected in wild-type (BL/6) 
at the 117 kDa marker, close to its predicted molecular weight of roughly 120 kDa. This band 
was absent in jinx BMMCs and so was suggested to be the band corresponding to full length 
Munc13-4 protein (Fig 3.2.16). 
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Figure 3.2.15 – Expression of c-kit and IgεRI on BL/6 and jinx BMMCs. (A) Flow cytometry analysis 
of surface expression of IgεRI and c-kit and (B) percentages of double positive cells of C57BL/6 (BL/6) 
and Unc13d
jinx/jinx 
(jinx) BMMCs . Quantification of c-kit (C) and IgεRI (D) surface receptor expression 
using mean fluorescence intensity. 
 
 
Figure 3.2.16 – Expression of Munc13-4 in wild-type and jinx BMMCs. Western blot using 100 µg of 
lysate of C57BL/6 (BL/6) and Unc13d
jinx/jinx 
(jinx) BMMCs and blotted with anti-Munc13-4 or anti-
Rab27b antibodies. Experiment performed with Dr. Chiara Recchi. Data representative of 2 
experiments. 
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3.2.17 – Ultrastructural analysis of wild-type and jinx BMMCs 
To further investigate the maturation of jinx BMMC granules, ultrastructural analysis was 
performed. Jinx BMMCs consistently displayed all of the appropriate granule types and 
appeared similar to wild-type in terms of size and granule density (Fig 3.2.17). While this 
study has hypothesised that Rab27a may play a role in granule maturation through granule-
granule fusion, Munc13-4 acts late in granule secretion with the plasma membrane in mast 
cells and so is unlikely to participate in the same process (51, 73, 129). Furthermore a 
previous study reported that knockdown of Munc13-4 in RBL-2H3 cells did not perturb 
granule maturation or biogenesis (129) which is consistent with findings presented here. 
 
3.2.18 – Munc13-4 promotes BMMC secretion in response to IgεRI crosslinking 
To assess the function of Munc13-4 in mast cells and to compare it to Rab27 function, beta-
hexosaminidase secretion assays were performed on C57BL/6 wild-type, jinx and Rab27DKO 
BMMCs in parallel. Low basal secretion was observed in unstimulated BMMCs from all 
genotypes (wild-type 2.45 ± 0.75%, jinx 1.87 ± 0.4% and Rab27DKO 3.95 ± 0.70%).  Beta-
hexosaminidase secretion from jinx BMMCs in response to IgεRI crosslinking was severely 
impaired using 10 and 30 ng/mL DNP-HSA and strongly resembled Rab27DKO secretion (at 
10 ng/mL DNP-HSA wild-type (BL/6) 22.20 ±  1.59%, jinx 2.97 ± 0.36% and Rab27DKO 3.92 ± 
0.18% and at 30 ng/mL DNP-HSA wild-type (BL/6) 12.73 ± 1.60%, jinx 2.83 ± 0.36 and 
Rab27DKO 3.78 ± 0.19% beta-hexosaminidase secretion) (Fig 3.2.18). A recent study in RBL-
2H3 cells utilising point mutations of Munc13-4 that poorly bind Rab27a suggested that the 
Rab27/Munc13-4 complex is specifically required for docking and subsequent release of 
secretory granules at the plasma membrane (51) . The finding that jinx and Rab27DKO 
BMMCs display very similar levels of secretion is consistent with a model where Rab27a/b 
and Munc13-4 promote docking and subsequent release of secretory granules in the same 
pathway. It was suggested in a previous study that Rab27b may promote the transition of 
granules from microtubules to actin and facilitate docking of granules at the plasma 
membrane (124), so this hypothesis is consistent with those findings. This data also argues 
against a model of different effectors for Rab27a and Rab27b in promoting mast cell 
secretion. It also suggests that Rab27a and Rab27b may both use Munc13-4 to promote 
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docking and secretion of granules in primary murine BMMCs as jinx BMMCs display similar 
levels of secretion to Rab27DKO and not Rab27b KO BMMCs. 
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Figure 3.2.17 – Jinx BMMCs display normal morphology by EM. Representative electron microscopy 
images of C57BL/6 (BL/6) and Unc13d
jinx/jinx 
(jinx). EM performed by Dr. Silene T. Wavre-Shapton. 
 
 
Figure 3.2.18 – IgE dependent secretion of BL/6, jinx and Rab27DKO BMMCs. Beta-hexosaminidase 
secretion from C57BL/6 (BL/6) and Unc13d
jinx/jinx 
(jinx) and Rab27a
ash/ash
, Rab27b
-/- 
(Rab27DKO) 
BMMCs was measured in response to 0 or 10 or 30 ng/mL DNP-HSA after 30 mins. *** P < 0.001 by 
student’s t test. Data representative of 3 independent experiments. Error bars s.e.m. 
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3.2.19 – Munc13-4 promotes BMMC secretion in response to IgεRI independent 
stimulation 
Next to determine whether Munc13-4 was regulating secretion specifically in response to 
the IgεRI signalling pathway or if late secretory events responding to calcium influx were 
impaired, the IgεRI signalling pathway was bypassed by using ionomycin and simultaneous 
treatment of ionomycin and PMA as previously described. Unstimulated BMMCs displayed 
low basal secretion that was not significantly different between genotypes. Using calcium 
influx alone, significantly impaired secretion was observed to a very similar extent from jinx 
BMMCs and Rab27DKO BMMCs compared to wild-type (1 µM ionomycin wild-type 68.81 ± 
1.40%, jinx 8.64 ± 0.84% and Rab27DKO 9.37 ± 0.77% beta-hexosaminidase secretion) (Fig 
3.2.19), further suggesting that Rab27a and Rab27b may promote secretion in BMMCs 
through effector Munc13-4. Using simultaneous treatment of PMA and ionomycin, similar 
results were observed (wild-type 76.54 ± 1.54%, jinx 14.35 ± 0.62% and Rab27DKO 18.08 ± 
0.79% beta-hexosaminidase secretion) (Fig 3.2.19). Interestingly, ionomycin and PMA 
treatment together were able to stimulate significantly more secretion than ionomycin 
alone from jinx BMMCs as for Rab27DKO BMMCs which may reflect a Rab27/Munc13-4 
independent pathway of exocytosis.  
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Figure 3.2.19 – IgE independent secretion of BL/6, jinx and Rab27DKO BMMCs. Beta-
hexosaminidase secretion from C57BL/6 (BL/6) and Unc13d
jinx/jinx 
(jinx) and Rab27a
ash/ash
, Rab27b
-/- 
(Rab27DKO) BMMCs was measured in response to 0, 1 µM ionomycin or a combination of 200 nM 
PMA and 1 µM ionomycin for 30 mins . *** P < 0.001 by student’s t test. Data representative of 3 
independent experiments. Error bars s.e.m. 
 
 
 
 
 
 
 
 
 
 
 
92 
 
3.3 – Discussion 
3.3.1 - Summary 
This part of the study utilised an in vitro culture system of differentiating mast cells from 
CD34
+ 
haematopoietic stem cells using IL-3 and SCF. Using this system, mast cells from wild 
type Rab27a
+/+
, ashen, Rab27b KO and Rab27DKO were generated and their functionality 
analysed. Rab27b KO BMMCs displayed diminished levels of IgεRI by flow cytometry but 
ashen and Rab27DKO displayed wild-type levels of maturation markers c-kit and IgεRI (Fig 
3.2.1). Functional analysis highlighted differences in Rab27a and Rab27b function in IgεRI 
dependent exocytosis, as ashen and Rab27b KO BMMCs displayed significantly increased 
and reduced secretion respectively. Further impairment of secretion in Rab27DKO BMMCs 
suggested that in absence of Rab27b that Rab27a can promote secretion (Fig 3.2.3, 3.2.4). 
Rab27 deficient BMMCs were tested for their ability to secrete upon stimulation by 
ionomycin or combined PMA/ionomycin treatment. Ionomycin treatment negated 
differences between wild-type and ashen
 
BMMCs and combined treatment of ionomycin 
and PMA significantly rescued secretion from Rab27b KO BMMCs suggesting that direct 
stimulation by PKC activation is critical in rescue of Rab27b KO BMMC secretion (Fig 3.2.4). 
However calcium influx and PKC activation did not fully rescue Rab27b KO BMMC secretion 
suggesting a more important role for Rab27b in mast cell secretion than Rab27a. Rab27DKO 
BMMC secretion also was not rescued by PKC activation and calcium influx suggesting a role 
for Rab27 in late secretory events.  
While Rab27b KO displayed reduced IgεRI surface expression, morphological analysis 
did not reveal defects in granule contents or size (Fig 3.2.5, 3.2.6). By contrast ashen and 
Rab27DKO BMMCs displayed increased granule content density was observed by electron 
microscopy. This was accompanied by reduced granule size (Fig 3.2.6) and less frequent 
granule-granule fusion events (Fig 3.2.7) suggesting that Rab27a may play a role in granule 
biogenesis though granule type and number were not affected in any Rab27 deficient 
BMMCs (Fig 3.2.8). Ashen BMMC granules displayed a significantly reduced distance to the 
plasma membrane while Rab27b KO granules were significantly further away from the 
plasma membrane (Fig 3.2.9), suggesting that Rab27b may promote granule docking and 
Rab27a may inhibit docking at the plasma membrane.  
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To account for these differences, the subcellular localisation of Rab27a and Rab27b 
were analysed, however no major differences were found (Fig 3.2.10). Analysis of F-actin 
distribution and content revealed that Rab27a regulates appropriate F-actin distribution 
while Rab27b regulates the amount of F-actin present (Fig 3.2.11). These observations 
correlated with granule proximity to the plasma membrane (Fig 3.2.9) suggesting that 
differential regulation of F-actin might underlie differences in secretion in response to IgE 
crosslinking.  
A potential link to the actin cytoskeleton through Rab27 effector melanophilin was 
investigated and melanophilin deficient leaden BMMCs also displayed increased secretion 
compared to wild-type (Fig 3.2.14) suggesting that Rab27 may regulate F-actin distribution 
through melanophilin. The Rab27 effector Munc13-4 was analysed using Munc13-4 deficient 
jinx mice. Jinx BMMCs appeared as wild-type by electron microscopy (Fig 3.2.17) and 
displayed wild-type levels of surface c-kit and IgεRI (Fig 3.2.15), however exhibited severe 
impairment similar to Rab27DKO BMMCs in response to IgE dependent and independent 
secretion (Fig 3.2.18, 3.2.19) suggesting a late secretory role for Munc13-4. Together these 
results suggest that Rab27 may play a dual role in mast cells, regulating F-actin distribution 
and content early in secretion, possibly through effector melanophilin, that may affect 
granule proximity (and subsequent fusion) to the plasma membrane and late in secretion to 
promote docking and plasma membrane fusion through Munc13-4.  
 
3.3.2 – What is the function of Rab27a in mast cells? 
• A role for Rab27a in granule biogenesis? 
Electron microscopy data presented point to a role for Rab27a in granule biogenesis (Fig 
3.2.5) possibly by promoting granule-granule fusion. This would not be the first report of 
Rab27a regulated secretory organelle size and content (137), however an altered 
appearance by EM does not necessarily prove a role in granule biogenesis. Furthermore the 
impact of such a role on BMMC secretion remains questionable considering that the 
secretory capacity of Rab27a
ash/ash 
BMMCs appears similar to wild-type using ionomycin (Fig 
3.2.4). Nonetheless a recent study suggested that Rab27a regulates the release of mature 
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secretory organelles and knockdown of Rab27a in HUVEC cells promotes the release of 
immature Weibel-Palade bodies and has the net effect of increasing total secretion of Von 
Willebrand factor (132). Granule contents in ashen BMMCs appear denser than wild-type 
and therefore may be unsorted material in immature granules, therefore a similar model 
may be proposed. In wild-type cells, only mature granules would be released and the 
presence of Rab27a on immature granules would stop them being released. In ashen 
BMMCs, absence of Rab27a results in an increase in secretion due to the release of 
immature granules as well as mature granules (Figure 15). Such a model is based solely on 
electron microscopy and beta-hexosaminidase secretion data from ashen BMMCs, and it is 
difficult to see how the positive role of Rab27a in secretion in absence of Rab27b would fit 
with such a model. As little is currently known about the biogenesis of mast cell granules, 
this model would be difficult to prove, however experiments measuring release of immature 
products such as pro forms of proteases and cathepsins might give more information on the 
nature of released products from ashen BMMCs.  
 
Figure 15. Immature granule inhibition model of Rab27a function in mast cell secretion. Rab27a 
inhibits release of immature granules. In wild-type BMMCs only mature granules are released 
whereas in ashen BMMCs both mature and immature granules are released. 
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• A role for Rab27a in stabilising cortical F-actin? 
Analysis of F-actin distribution and content suggested that Rab27a and Rab27b may 
differentially regulate F-actin distribution and content (Fig 3.2.11). Rab27a seems to 
regulate the even distribution of F-actin and this may limit the access of granules to the 
plasma membrane (Fig 3.2.9, 3.2.11). This function can be seen as a regulatory one to 
discourage inadvertent secretion and therefore in this sense Rab27a is playing a negative 
role in secretion. These data lead to a model whereby in wild-type cells Rab27a ensures that 
the F-actin cortex is evenly distributed that this ensures granules do not dock too close to 
the plasma membrane. In ashen BMMCs, F-actin distribution is not regulated correctly and 
thin areas in the cortex allow granules to dock closer to the plasma membrane and this aids 
granule release upon activation (Figure 16). This model incorporates data from 
immunofluorescence, electron microscopy, secretion experiments and therefore is a 
feasible explanation for increased secretion in ashen BMMCs.  
 
Figure 16. F-actin stabilisation model of Rab27a function in mast cell secretion. Presence of Rab27a 
in wild-type BMMCs stabilises F-actin and regulates the distribution appropriately so that granules 
are not held too close to the plasma membrane. In ashen BMMCs, F-actin is not regularly distributed 
such that thin areas of F-actin allow granules to be closer to the plasma membrane. This allows 
granules to be more easily released upon activation. 
96 
 
A role for Rab27a in promoting granule docking and plasma membrane fusion through 
Munc13-4? 
Beta-hexosaminidase secretion assays using Rab27b KO BMMCs using both DNP-HSA (Fig 
3.2.3) and ionomycin and PMA (Fig 3.2.4) have suggested that the presence of Rab27a alone 
can promote secretion that is abolished in Rab27DKO BMMCs. Because this occurs with 
both stimulants, Rab27a is probably acting at a late stage to promote secretion. Beta-
hexosaminidase secretion assays using jinx BMMCs have suggested that this late step might 
be the docking and fusion of granules with the plasma membrane via Munc13-4. Rab27a 
and Rab27b have both previously been shown to interact with Munc13-4 (73) and the 
Rab27/Munc13-4 pathway was recently shown to be specifically required for granule 
docking at the plasma membrane using Munc13-4 mutants that bind Rab27 poorly in RBL-
2H3 cells. Interestingly the propensity to stall granules at the plasma membrane upon 
activation was lost when mutant Munc13-4 was overexpressed suggesting that 
Rab27/Munc13-4 interaction aids granule docking at the plasma membrane upon activation 
(51). All of these observations implicate the Rab27a/Munc13-4 pathway to be involved in 
promoting granule docking and fusion to promote mast cell secretion (Figure 17) though the 
reasons that this is not observed in the presence of Rab27b in BMMCs remain unclear. 
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Figure 17. Rab27a promotion of granule secretion through Munc13-4. In resting cells, granules are 
present in the cytosol, however upon priming with molecules such as PMA or LPS, or upon activation 
via the IgE pathway, granules become docked close to the plasma membrane through association of 
Rab27a on granules with Munc13-4 at the plasma membrane. Upon calcium influx and SNARE 
complex formation, granules subsequently fuse with the plasma membrane and release their 
contents into the extracellular space. 
 
3.3.3 – What is the role of Rab27b in mast cells?  
• Why does PKC activation rescue Rab27b KO BMMC secretion? 
The differences between Rab27a and Rab27b function are most clearly observed using 
ionomycin and PMA treatment (Fig 3.2.4). PMA stimulates the activation of PKC in mast cells 
and this leads us to ask the question why does PKC activation rescue secretion from Rab27b 
KO . PKC activation may; 
• Activate phospholipase D (to produce phosphatidic acid, a second messenger of PIP2 
important for actin reorganisation) (36) 
• Phosphorylate myosin II heavy chain (and myosin light chain kinase) widely 
implicated in actinomyosin rearrangement,  and phosphorylation coincides closely 
with secretion in RBL-2H3 (112) 
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• PKCα and PKCβI colocalise with actin filaments at membrane ruffle sites (ruffles are a 
sign of actin arrangements required for secretion and are blocked by PKC inhibitors) 
(194) 
• PKC phosphorylates SNAP-23 and syntaxin 4 and Munc18-2, possibly promoting 
SNARE protein assembly and granule docking at the plasma membrane (14) 
The first 3 points suggest that the role of PKC activation may be to destabilise F-actin and 
promote docking of granules at the plasma membrane. This idea is supported by the fact 
that Rab27b KO BMMCs display thicker cortical F-actin and granules are further away from 
the plasma membrane in resting cells (Fig 3.2.11, Fig 3.2.9) and would therefore require 
extra assistance to destabilise actin to allow secretion to occur. The last point may indicate a 
role for PKC activation in promoting granule docking and plasma membrane fusion more 
directly by phosphorylating SNARE proteins. In either case, the result of PKC activation is 
likely to result in an increase in granules docked at the plasma membrane as is seen in RBL-
2H3 cells where granule docking at the plasma membrane activation of cells with calcium 
ionophore and PMA treatment is dependent on Munc13-4 interaction with Rab27 (51). In 
this case where Rab27b is absent, Rab27a may be able to promote a late step in secretion 
possibly by interacting with Munc13-4.  
 
• How might Rab27b promote granule docking? 
A previous study suggested that Rab27b promotes docking by promoting peripheral 
retention of granules by promoting microtubule to actin transition in mast cells (124). 
Evidence from Rab27b KO BMMCs that granules are further away from the plasma 
membrane by EM (Fig 3.2.9) agrees with this function of Rab27b in granule docking. 
However this study also finds that the F-actin cortex is thicker (Fig 3.2.11) in Rab27b KO 
BMMCs which may also be responsible for granules being further from the plasma 
membrane. The activation of PKC can compensate for lack of Rab27b and may be due to the 
destabilisation of F-actin or due to enhanced docking (through phosphorylation of SNARE 
proteins). The current evidence cannot distinguish whether defective microtubule to actin 
transfer of granules or thicker F-actin cortex is responsible for the impaired secretion of 
Rab27b KO BMMCs and future experiments should assess which of these factors is most 
important using actin depolymerising agents (such as Latrunculin B) coupled with secretion 
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assays. It is likely that a combination of the two factors is important for granule docking in 
mast cells. 
 
• A role for Rab27b in promoting granule docking and plasma membrane fusion 
through Munc13-4? 
What is suggested from secretion assays (Fig 3.2.3, 3.2.4) is that both Rab27a and Rab27b 
can play a positive role in secretion. Furthermore they may do this through interaction with 
Munc13-4 to promote granule docking to the plasma membrane and subsequent fusion (Fig 
3.2.18, 3.2.19). In this regard Rab27a and Rab27b play similar roles in mast cell secretion 
and a similar model of Rab27b promoting secretion through Munc13-4 can be proposed 
(Figure 17). Rab27b seems more important in this process as Rab27b KO BMMCs do not 
secrete at wild-type levels whereas ashen
 
BMMCs can (Fig 3.2.4). Interestingly these 
observations are very similar to those from Rab27 deficient platelets (179). 
All of these factors could bias Rab27b to be better at promoting secretion than Rab27a in 
mast cells. An alternative explanation to the increased secretion of ashen
 
BMMCs (Fig 3.2.3) 
is that Rab27a specifically regulates factors in the IgεRI signalling pathway. Rab27a has not 
previously been demonstrated to inhibit any proteins involved in the IgεRI signalling 
pathway and while not impossible, there is no precedent for this function so makes this 
explanation unlikely. 
 
3.3.4 - A model of Rab27a/b, Mlph and Munc13-4 function in mast cell secretion 
Absence of Rab27 effector melanophilin increases secretion compared to wild-type and 
mimics Rab27a deficiency (Fig 3.2.14). Melanophilin binds to actin through Myosin Va (76) 
and absence of melanophilin may cause abnormal actin structure as observed in ashen
 
BMMCs (Fig 3.2.11). This was not directly tested due to time constraints but a previous 
study that inhibited unconventional myosins suggested they may play a role in secretion in 
mast cells (172). This data allows us to understand how Rab27 might influence the actin 
cytoskeleton in resting BMMCs. The fact that leaden BMMCs secretion resembles ashen
 
BMMC secretion is also interesting and raises the possibility that Rab27a and Melanophilin 
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may specifically regulate actin dynamics and Rab27b cannot. Rab27b KO BMMCs display 
thicker cortical F-actin (Fig 3.2.11 D) but this may not necessarily be because of lack of 
Rab27b function. Absence of Rab27b may enhance Rab27a function which in this case is to 
ensure the even distribution of F-actin, possibly through stabilising actin through 
melanophilin. An enhancement of this function would lead to a thicker F-actin cortex as 
observed (Fig 3.2.11). As BMMCs cannot be easily manipulated, this question cannot be 
easily answered in this system, however use of actin depolymerising agents such as 
Latrunculin B prior to secretion assays would confirm the role that F-actin plays in secretion 
of Rab27 deficient mast cells. Rab27a was recently implicated in regulating actin dynamics 
during phagocytosis through effector Coronin 1A that can bind actin. Absence of Rab27a 
increased the rate of phagocytosis by speeding up actin remodelling (195). Interestingly 
knockout of Coronin 1A in BMMCs results in an increased amount of total F-actin but 
unaltered secretion (4) suggesting that Rab27a may regulate F-actin distribution and 
content through other effectors. 
The data presented here suggest a model where Rab27a/b through interaction with 
Melanophilin may differentially regulate F-actin distribution and content in resting BMMCs 
to modulate granule docking (Figure 18). This may also involve Myosin Va and additional 
effectors.  Upon activation Rab27a and Rab27b may both regulate granule docking and 
fusion with the plasma membrane through interaction with Munc13-4, however Rab27b is 
more important in this process than Rab27a in mast cells. Together these data point to 
partially redundant roles for Rab27a and Rab27 in mast cell secretion through effectors 
melanophilin and Munc13-4.  
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Figure 18. Model of Rab27a/b, Mlph and Munc13-4 function in mast cells. Presence of Rab27a, 
Mlph and possibly MyoVa in wild-type BMMCs stabilises F-actin and regulates the distribution 
appropriately so that granules are not held too close to the plasma membrane. In ashen BMMCs, F-
actin is not regularly distributed such that thin areas of F-actin allow granules to be closer to the 
plasma membrane. This allows granules to be more easily released upon activation. In activated cells, 
Munc13-4 promotes the docking and subsequent release of granules through interaction with 
Rab27a and Rab27b.    
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Chapter 4 – Rab27 and related proteins in neutrophil 
chemotaxis 
4.1 - Introduction 
As outlined in chapter 3, the main outcome of mast cell degranulation in tissues is the 
release of many cytokines, proinflammatory factors and chemoattractants (such as LTB4) 
that directly bind to surface receptors on leukocytes at stimulate their activation and 
migration to sites of inflammation or injury. They can also indirectly stimulate the migration 
of other leukocytes to the site of inflammation by promoting vasodilation and by activating 
endothelium to express adhesion molecules such as selectins that promote leukocyte 
adhesion and extravasation. The major advantage of this is that if a pathogen has stimulated 
the response, an influx of leukocytes would help to clear the pathogen before the infection 
can spread. One of the first leukocytes to respond are neutrophils. Neutrophils are present 
in large numbers in the blood (typically about 30-40% of circulating leukocytes) and 
represent the first line of defence in the body against invading pathogens. Neutrophils 
phagocytose and kill invading pathogens and participate in wound healing, but first must be 
stimulated to migrate to sites of inflammation through a gradient of chemoattractant in a 
process of chemotaxis (16). Neutrophils also secrete a wide variety of antimicrobial factors 
from secretory granule including lactoferrin, azurocidin, defensins and serine proteases (19).  
Recently the role of Rab27a in neutrophil secretion has been characterised (24, 72, 
80, 127). Analysis of granulocytes from Rab27a deficient Griscelli syndrome patients yielded 
the first reports that Rab27a may also be involved in neutrophil chemotaxis (93, 97). These 
reports focussed on primary defects in leukocyte secretion and therefore did not 
characterise the defective chemotaxis observed. A link between granule secretion and 
chemotaxis has long been suspected due to findings that neutrophil chemotaxis is 
dependent on extracellular calcium and that an increase in intracellular free calcium 
stimulates rear-end retraction, a process that also involves myosin II (49, 102, 115). This link 
was recently strengthened with the finding that calcium sensing proteins of the 
Synaptotagmin family, Rab27a and other exocytic Rab GTPases promote chemotaxis of T 
lymphocytes in vitro (39). In neutrophils both Rab27a and Rab27b are known to regulate the 
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release of primary granules that contain a variety of mediators including serine proteases 
along with their effectors Slp1 and Munc13-4 (24, 80, 127). 
The secretion of neutrophil serine proteases is known to be important for cleavage 
of adhesion proteins ICAM-1 and VCAM-1 (28, 104) and to be important for E-cadherin 
cleavage during neutrophil transmigration (60). A significant recent study suggested 
neutrophil secretion of serine proteases during chemotaxis is important for cleavage of cell 
surface αMβ2 integrin subunit CD11b and aids uropod release and rear end detachment 
(199). These findings together suggest that proteins that promote the release of primary 
granules such as Rab27a/b, Slp1 and Munc13-4 may be important for neutrophil chemotaxis 
by regulating adhesion via cleavage of adhesion molecules important for uropod 
detachment. To investigate a possible role for Rab27a/b and related proteins in the 
chemotaxis of neutrophils, the ashen mouse naturally deficient in Rab27a, Rab27b
 
KO mice 
and Rab27a/b double deficient mice generated previously (179) were assessed using in vitro 
and in vivo assays of neutrophil recruitment and chemotaxis. Rab27a knockdown human 
promyelocytic leukemia cell line HL-60 were also used to study Rab27a in the context of 
human cells and other proteins were assessed using knockout mice or antibody blocking 
assays.  
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4.2 - Results 
4.2.1 – Rab27 regulates neutrophil migration to the lungs in vivo using a lung specific 
model 
To test the role of Rab27 in migration and recruitment of neutrophils in vivo, a MIP-2 driven 
model of lung recruitment was used. Rab27a/Rab27b double knockout (Rab27DKO) mice 
were stimulated intranasally with 0.8 µg MIP-2 to assess neutrophil migration in vivo. In 
unstimulated or PBS stimulated mice, one observes a majority of cells that are alveolar 
macrophages (Fig 4.2.1 A), however in MIP-2 stimulated mice one would expect to see a 
majority of neutrophils and possibly monocytes as a result of secondary inflammation. After 
2 hours of treatment, the mice were sacrificed and the BAL collected as previously described. 
Total cells were counted using a haemocytometer and percentages of neutrophils were 
obtained by Ly6G staining and confirmed using cytospins. Cell isolates are often spun by 
centrifugation onto glass slides and stained using analine dyes that differentially stain cells 
based on the presence of acidic or basic compartments and their nuclei so that cells may be 
differentiated based on morphology and staining. This is one method to obtain percentages 
of specific cells but relies on judgement to distinguish cells which can lead to inaccuracies, 
especially as some cells such as monocytes often have nuclei resembling that of neutrophils. 
For this reason it was used only as a confirmation for results obtained by Ly6G staining 
which is a more reliable method that does not rely on subjective judgement based on 
physical appearance. Both wild-type and Rab27DKO mice displayed low number of 
neutrophils recruited using vehicle (PBS) alone. Wild-type mice showed a robust 
recruitment of neutrophils to the lungs using MIP-2 treatment, however Rab27DKO mice 
displayed significantly impaired neutrophil recruitment (wild type 10.01 ± 2.90 x 10
5
, 
Rab27DKO 0.41 ± 0.19 x 10
5
 neutrophils) (Fig 4.2.1 B). This was accompanied by impaired 
total number of leukocytes in Rab27DKO (wild-type 14.48 ± 3.65 x 10
5
, Rab27DKO 2.76 ± 
0.32 x 10
5
 total leukocytes). This result confirmed that Rab27 is important in the in vivo 
migration of neutrophils.  
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Figure 4.2.1 – Neutrophil recruitment to the lungs of wild-type and Rab27DKO mice using a MIP-2 
lung specific model. (a) Cytospins of cells recruited to the brochalveolar space of wild-type and 
Rab27DKO
 
mice treated intranasally with 0.8 µg MIP-2 for 2 hours. (b) Total cells and neutrophils 
recruited to the bronchalveloar space of wild type (C57BL/6) mice (n=6) and Rab27DKO mice (n=6) 
treated with MIP-2 and wild-type mice (n=5) and Rab27DKO mice (n=5) treated with PBS. Percentage 
of BAL cells that were neutrophils determined by cytospin counts. P values Student’s t-test. Error 
bars s.e.m. 
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4.2.2 – Expression of Rab27a in murine bone marrow derived neutrophils (BMDN) 
Rab27a was previously shown to be expressed in neutrophils purified from murine blood 
(24). Rab27a was also found to be expressed in HL-60 cells and found to be upregulated 
during differentiation to mature neutrophils using DMSO (127). Bone marrow contains a 
large number of mature neutrophils and can be purified relatively easily (22, 185) and so 
was chosen as a source of neutrophils. To study Rab27a in the context of neutrophil 
chemotaxis, it was first necessary to confirm that Rab27a expression could be detected in 
BMDN. By western blot, neutrophils protein lysates from wild-type and ashen bone marrow 
purified by histopaque gradient were separated based on size by SDS-PAGE and then 
transferred to PVDF membrane. Membranes were blotted by mouse monoclonal (4B12) 
antibody specific for Rab27a and subsequently with anti-mouse HRP conjugated secondary 
antibody. Detection was performed using ECL reagent and chemiluminescent film. 
Expression of Rab27a protein in wild-type neutrophils and its absence in ashen neutrophils 
was demonstrated (Fig 4.2.2).  
 
4.2.3 – Rab27a promotes neutrophil recruitment in vivo 
As a first step to test the role of Rab27a in neutrophil migration, we took advantage of a 
model developed by a collaborator. The model specifically stimulates neutrophil migration 
to the lungs using the relatively selective CXC chemokine macrophage inflammatory protein 
2 (MIP-2) which binds the chemokine receptor CXCR2 on neutrophils. We utilised this model 
to study the role of Rab27a in neutrophil migration in vivo. Age and sex-matched C57BL/6 
wild-type and Rab27a deficient ashen mice were treated intranasally with MIP-2 or with 
vehicle alone (PBS). After a period of 6 h the bronchoalveolar lavage (BAL) was collected 
from all mice using a cannula inserted into the trachea and 3 washes of the lungs with PBS. 
Total cells were counted using a haemocytometer and dead cells were stained by diluting 
cells in trypan blue dye. Trypan blue dye is able to enter dead cells as the plasma membrane 
is permeable but live cells remain unstained so dead cells appear blue and live cells appear 
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white. To obtain percentages of BAL cells that were neutrophils, BAL cells were stained 
using anti-Ly6G antibody and analysed by flow cytometry. Ly6G is a subunit of the Gr-1 
complex, a myeloid differentiation marker. While Gr-1 is expressed by all granulocytes, Ly6G 
is only expressed by neutrophils and so is a good marker to use. Significant MIP-2 stimulated 
recruitment of neutrophils was observed in both wild-type and ashen mice, however 
absence of Rab27a significantly reduced the percentage of bronchoalveolar lavage (BAL) 
leukocytes that were neutrophils (wild-type 76.43 ± 4.09% versus ashen 61.10 ± 4.61%, Fig 
4.2.3 A) and the total number of neutrophils recruited to the BAL (wild-type 29.43 ± 4.5 x 
10
4
 cells versus ashen 16.99 ± 3.92 x 10
4
 cells, Fig 4.2.3 C). The total number of leukocytes 
was also reduced but this was not significant (Fig 4.2.3 B), possibly due to the secondary 
influx monocytes that would affect total leukocyte numbers. This result suggested that 
Rab27a promotes neutrophil migration in vivo. 
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Figure 4.2.2 – Expression of Rab27a in purified murine BMDN. Western blot of 50 µg lysates from 
wild-type (C57BL/6) and ashen
 
neutrophils using mouse monoclonal (4B12) anti-Rab27a antibody. 
 
Figure 4.2.3 – Rab27a promotes neutrophil chemotaxis in vivo using a lung specific model of 
recruitment.  (a) Flow cytometry of cells recruited to the brochalveolar space of wild-type (C57BL/6) 
and ashen
 
mice treated intranasally with MIP-2; cells were stained with anti-Ly6g. Numbers indicate 
percentage Ly6G positive cells. Total cells (b) and neutrophils (c) recruited to the bronchalveloar 
space of wild type mice (n=5) and ashen
 
mice (n=7) treated with MIP-2 and wild-type mice (n=6) and 
ashen
 
mice (n=7) treated with PBS. * P ≤ 0.05, Student’s t-test. Error bars s.e.m. 
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4.2.4 – Rab27a promotes neutrophil chemotaxis in vitro 
While the results from Fig 4.2.3 suggested that migration of ashen neutrophils
 
was impaired, 
other interpretations are possible. For instance if there were a reduced number of 
neutrophils in the blood (neutropenia) in ashen mice to begin with, that might explain the 
reduction in MIP-2 stimulated neutrophil numbers. Ashen mice were suggested to exhibit 
neutropenia when stimulated with lymphocytic choriomeningitis virus (139), however under 
resting conditions Rab27a deficient mice were previously reported to contain comparable 
numbers of neutrophils in the blood (24) so this is unlikely to explain the results from Fig 
4.2.3. Nevertheless migration and recruitment of neutrophils in vivo can be affected by 
changes in endothelial and epithelial permeability. A recent study found Rab27a to be 
expressed in the lung epithelium and that loss of Rab27 leads to abnormal lung epithelium 
structure in mice of 12 weeks old, the same age as ashen mice used in Fig 4.2.3 (15). 
Another recent study suggested that knockdown of Rab27a in human umbilical vein 
endothelial cells (HUVECs) affects Weibel-Palade body secretion and reduces the length of 
multimers of von willebrand factor (VWF) released (132). VWF plays an important role in 
neutrophil recruitment and extravasation in vivo (144). These factors could not be excluded, 
so to rule out changes in lung epithelium or endothelium being responsible for impaired 
neutrophil recruitment observed in ashen mice.  Neutrophils were purified from wild-type 
and ashen bone marrow and their transwell chemotaxis assessed in vitro using leukotriene 
B4 (LTB4) and recombinant murine MIP-2 to stimulate transwell chemotaxis. 
Chemoattractant signalling in neutrophils involves different G-protein coupled receptors 
(GPCRs) depending on the ligand used but all elicit the same activation of phospholipase C 
that cleaves PIP2 to IP3 and DAG to increase intracellular calcium and activates PKC to 
stimulate secretion of granules during chemotaxis (131) so produce similar end results. Both 
LTB4 and MIP-2 are physiological stimuli that stimulate neutrophil chemotaxis in vivo, 
however LTB4 represents a chemoattractant deriving from mast cell origin while MIP-2 is 
produced by a variety of leukocytes including macrophages, monocytes and mast cells. 
Epithelial cells that have been activated by proinflammatory factors have also been 
suggested to produce MIP-2 and LTB4 to stimulate neutrophil recruitment (3, 135). Using 
different receptors rules out the possibility of defective chemoattractant receptor 
expression or function underlying the chemotactic defect.   
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To test the function of Rab27a in chemotaxis of neutrophils directly, wild-type and 
ashen BMDN transwell migration was assessed in vitro towards MIP-2 and LTB4 and random 
migration (chemokinesis) was measured by allowing cells to migrate towards medium alone. 
Ashen BMDN displayed significantly impaired chemotaxis compared to wild-type neutrophil 
towards a range of concentrations of MIP-2 (Fig 4.2.4 A) and LTB4 (Fig 4.2.4 B) through a 
semi-permeable polycarbonate transwell filter containing 3 µm pores over a period of 30 
minutes. For this assay, neutrophils are resuspended in medium containing 1% BSA and are 
placed on top of a semi-permeable filter with 3 µm pores and below the filter is placed 
either medium alone to assess random migration (chemokinesis) or various concentrations 
of chemoattractants diluted in medium to stimulated neutrophil migration through the 
pores in the filter to the bottom of the transwell. The 3 µm pore size is preferable for 
neutrophil chemotaxis studies as it is slightly smaller than the diameter of the average 
neutrophil and thus neutrophils are required to change shape in order to pass, making the 
assay more stringent than if using a larger pore size. Using increasing concentrations of MIP-
2 and LTB4, an increase in the number of neutrophils migrated across the semi-permeable 
filter was observed for both wild-type and ashen neutrophils, however ashen displayed 
significantly impaired migration numbers compared to wild-type (Fig 4.2.4).  This result 
suggests that Rab27a specifically promotes chemotaxis of primary murine neutrophils and 
this occurs regardless of the chemotactic agent used. This result confirms the finding that 
Rab27a promotes chemotaxis of neutrophils in vivo from Fig 4.2.3. 
 
4.2.5 – Dimethyl sulphoxide treatment more efficiently induces HL-60 cell differentiation 
than does all–trans retinoic acid. 
To complement studies on primary murine neutrophils and to test the relevance of data 
obtained in mice to a human cell type, HL-60 were also utilised to study the role of Rab27a 
in neutrophil chemotaxis. HL-60 is a promyelocytic leukemia cell line that does not 
chemotax efficiently unless induced to differentiate to mature neutrophils in vitro. Two 
different reagents were tested for their ability to induce maturation of HL-60 cells into 
neutrophil like cells, all-trans retinoic acid (ATRA) and dimethyl sulphoxide (DMSO). After 3 
days in culture both ATRA and DMSO treated cells showed signs of differentiation as 
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observed by the elongation and segmentation of cell nuclei, however DMSO treatment 
induced a greater percentage of cells to mature to neutrophil-like cells over a 7 day period  
(Fig 4.2.5 A). This was confirmed by western blot by analysing Rab27a expression. It has 
previously been reported that Rab27a is upregulated during HL-60 cell differentiation to 
neutrophil-like cells (127) and while both ATRA and DMSO treatment increased Rab27a 
expression compared to undifferentiated cells, treatment with DMSO upregulated Rab27a 
to a greater extent than ATRA treatment (Fig 4.2.5 B). For these reasons DMSO was chosen 
for future experiments to differentiate HL-60 cells. The precise mechanism by which DMSO 
and ATRA cause differentiation of HL-60 is not known, though it is thought that DMSO may 
allow parts of the genome containing genes critical in promoting differentiation to become 
more accessible for transcription machinery. ATRA most likely causes differentiation 
through interaction with the retinoic acid receptor at the cell surface. Both treatments 
result in transcription of several genes important for myeloid differentiation to mature 
neutrophils (38).  
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Figure 4.2.4 – Rab27a promotes transwell migration of neutrophils in vitro. Transwell migration of 
wild-type (C57BL/6) and ashen
 
neutrophils over a range of (a) MIP-2 and (b) LTB4 concentrations 
after 30 mins. Data is representative of three independent experiments. P values, two-way ANOVA. 
Error bars  s.e.m. 
 
Figure 4.2.5 – DMSO treatment is more efficient at inducing maturation of HL-60 cells than ATRA. 
HL-60 cells were cultured for 3 days in standard medium alone or supplemented with ATRA (1 µM) 
or DMSO (1.3%) were cytopun onto slides and stained with Kwik-diff and x40 magnification images 
taken on a light microscope . Arrows indicate cells with segmented nuclei characteristic of mature 
neutrophils. (b)  50 µg of cell lystates were loaded onto 12.5% SDS-PAGE gels and Rab27a expression 
was analysed by western blot. Data representative of 3 independent experiments. Experiment 
performed during supervision of Mr. Wenjia Liao. 
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4.2.6 – Rab27a can be effectively silenced in HL-60 cells using two specific siRNA 
sequences 
As a first step to testing the role of Rab27a in HL-60 chemotaxis, knockdown of Rab27a using 
siRNA was performed. A previous study had optimised Rab27a specific siRNA transfection of 
undifferentiated HL-60 cells using the amaxa system (Lonza) (127). The previously optimised 
conditions used program T-001 and cell line kit V (containing an optimised transfection 
buffer) and 20 µM of Rab27a specific siRNA. HL-60 cells were transfected with either 20 µM 
Rab27a specific siRNA sequences or 20 µM non-targeting siRNA which is a scrambled oligo 
sequence of the same length and acts as a control for the effects of siRNA transfection. 
Transfected HL-60 cells were then resuspended in medium containing 1.3% DMSO and 
allowed to differentiate for 3 days in culture. This protocol  effectively silenced Rab27a over 
a 3 day period of differentiation in culture (127). This protocol was reproduced exactly and 
consistently yielded over 90% knockdown of Rab27a protein using two specific siRNA 
sequences as assessed by western blot using mouse monoclonal (4B12) Rab27a specific 
antibody (Fig 4.2.6 A and B). The fact that siRNA for Rab27a was present before Rab27a 
upregulation during differentiation occurred undoubtedly aided Rab27a knockdown. This 
provided an ideal system for further investigation of Rab27a function in HL-60 cells. 
 
4.2.7 – Rab27a promotes HL-60 cell transwell chemotaxis in vitro  
Having established that Rab27a was efficiently silenced in HL-60 cells, the role of Rab27a in 
chemotaxis was tested. To do this, the transwell chemotaxis assay was used as previously. 
The best characterised chemoattractant for HL-60 cells is the bacterial peptide formyl-Met-
Leu-Phe (fMLP) (155) so this was chosen to be preferable over human MIP-2 (GROβ/CXCL2). 
It was desirable as mentioned previously to test that Rab27a promotion of chemotaxis was 
not specific to a particularly signalling pathway but to the chemotaxis process itself and so 
chemoattractants stimulating different signalling pathways were employed throughout this 
study. MIP-2 and receptor CXCR2, LTB4 and receptor BLT1/2 were used for primary BMDN 
and fMLP and formyl peptide receptor (FPR) for HL-60 cells. DMSO differentiated HL-60 cells 
depleted of Rab27a displayed significantly reduced chemotaxis towards indicated 
concentrations of fMLP over a 60 minute period compared to DMSO differentiated HL-60 
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cells transfected with non-targeting siRNA (Fig 4.2.7). This finding confirmed our results 
from primary murine BMDN and suggested that Rab27a can also promote neutrophil 
chemotaxis in human cells. If Rab27a regulated secretion was promoting chemotaxis, this 
data also provided the first clues to what subset of granules might be involved. HL-60 only 
contain primary granules (127) therefore release of this granule type may be involved in 
neutrophil chemotaxis.  
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Figure 4.2.6 – Rab27a can be silenced efficiently using two siRNA oligos.  (A) HL-60 cells were 
transfected with 20 µM non-targeting or two different Rab27a siRNA sequences using amaxa 
program T-001 and amaxa kit V. HL-60 were cultured for 72 hours in the presence of 1.3% DMSO and 
analysed by western blot. (B) Quantification of 3 independent knockdown experiments as assessed 
by Image J software.  *** P  ≤ 0.001, Student’s t-test. Error bars s.e.m. Experiment performed during 
supervision of Mr. Wenjia Liao. 
 
 
Figure 4.2.7 – Rab27a promotes HL-60 chemotaxis in vitro. Transwell migration of control treated or 
Rab27a knockdown DMSO differentiated HL-60 cells towards indicated concentration of fMLP after 
60 mins. Data compiled from three independent experiments. P values, two-way ANOVA of all data 
points. Error bars s.e.m. Experiment performed during supervision of Mr. Wenjia Liao. 
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4.2.8 – Rab27b is expressed in primary murine bone marrow derived neutrophils (BMDN) 
Having obtained evidence that Rab27a regulates chemotaxis we tested the role of Rab27b 
as other data suggested a role for this protein in granule secretion (80). The first step in 
determining whether Rab27b plays a role in neutrophil chemotaxis was to confirm that 
Rab27b is expressed in BMDN. Consistent with previous observations from murine blood 
neutrophils (80), Rab27b protein was detected by western blot at lower levels than Rab27a 
(Fig 4.2.8) using rabbit polyclonal (S087) anti-Rab27b antibody.  While the Rab27b antibody 
used appeared more specific for Rab27b than Rab27a in earlier characterisation, cross 
reactivity was observed in some cells and so the other band observed by western blot is 
Rab27a as observed by the absence of the cross reactive band in ashen and Rab27DKO 
BMDN lanes. 
 
Figure 4.2.8 – Expression of Rab27b in purified murine BMDN. Western blot of 50 µg lysates from 
wild-type from ashen strain Rab27a
+/+, 
ashen (Rab27a
ash/ash
) from wild-type from Rab27b KO strain 
Rab27b
+/+
, Rab27b KO (Rab27b
-/-
) and Rab27DKO (Rab27a
ash/ash
, Rab27b
-/-
) bone marrow purified 
neutrophils using rabbit polyclonal anti-Rab27b (S087) antibody. Data representative of 2 
experiments. 
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4.2.9 – Rab27b KO and Rab27DKO neutrophils display impaired transwell neutrophil 
chemotaxis in vitro 
The in vivo impairment of Rab27DKO neutrophil migration (Fig 4.2.1) may have been due to 
loss of Rab27a and/or Rab27b. As the time point for MIP-2 driven migration was 2 hours for 
Rab27DKO mice and 6 hours in the previous experiment for ashen mice, it is not appropriate 
to compare the two. To test whether Rab27b specifically contributes to chemotaxis and 
whether Rab27 isoforms might act synergistically to promote chemotaxis, the migration of 
Rab27b KO and Rab27DKO neutrophils was analysed by transwell migration assays in vitro.  
Wild-type, Rab27b KO and Rab27DKO neutrophil migration numbers increased with 
concentrations of MIP-2 and LTB4, however both Rab27b KO and Rab27DKO neutrophils 
displayed significantly reduced numbers of migrated neutrophils compared to wild-type 
over 30 mins (Fig 4.2.9). Interestingly Rab27DKO BMDN chemotaxis was observed at similar 
efficiency to Rab27b KO BMDN chemotaxis. The comparison between ashen, Rab27b KO 
and Rab27DKO neutrophils (Fig 4.2.10) highlights that loss of one Rab27 isoform is sufficient 
to inhibit chemotaxis and that there is not an additive effect in absence of both isoforms. 
Interestingly absence of Rab27a or Rab27b impair chemotaxis to a similar degree suggesting 
that both isoforms are important in the regulation of chemotaxis and that they may function 
in the same pathway to promote chemotaxis. Rab27a deficiency but not Rab27b or Rab27-
double deficiency also appeared to impair chemokinesis as measured by migration at 0 nM 
MIP-2. The reasons for this are uncertain but may relate to previous findings that detectable 
secretion of primary granule marker myeloperoxidase is observed from Rab27b KO and 
Rab27DKO neutrophils but not from ashen neutrophils.  
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Figure 4.2.9 – Rab27b KO and Rab27DKO BMDN display reduced chemotaxis in vitro. Transwell 
migration of wild-type (C57BL/6), Rab27b KO (Rab27b
-/-
) and Rab27DKO (Rab27a
ash/ash
,Rab27b
-/-
) 
neutrophils after 30 minutes over a range of (a) MIP-2 and (b) LTB4 concentrations after 30 mins. 
Data compiled from three independent experiments. * P ≤ 0.05, *** P ≤ 0.001, two-way ANOVA of 
all data points. Error bars s.e.m. 
 
Figure 4.2.10 – Comparison of ashen, Rab27b KO and Rab27DKO BMDN transwell chemotaxis. 
Data obtained from transwell chemotaxis assays using 30 min chemotaxis and indicated 
concentrations of MIP-2  was collated and expressed as a % of cells migrated vs wild-type (WT) 
BMDN.  
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4.2.10 – CXCR2 surface expression is similar to wild-type on Rab27b KO and Rab27DKO 
neutrophils 
To test whether the chemotaxis defect of Rab27b KO BMDN is due to defective chemokine 
receptor trafficking and/or expression, CXCR2 surface expression was assessed by flow 
cytometry. Rab27b KO and Rab27DKO neutrophils displayed wild-type levels of surface 
CXCR2 expression (Fig 4.2.11). These results suggest that Rab27b does not play a role in 
CXCR2 trafficking and surface expression in neutrophils.  
 
4.2.11 – Slp1 and Munc13-4 are expressed in primary murine bone marrow derived 
neutrophils 
The process of Rab27 mediated secretion of primary granules in neutrophils is known to 
proceed through the effectors Munc13-4 and Slp-1 (24). To further test the hypothesis that 
primary granule secretion represents a mechanism that promotes chemotaxis, the functions 
of Slp1 and Munc13-4 in chemotaxis were tested. The first step to test this was to confirm 
their expression in BMDN. Consistent with data from HL-60 cells and primary purified 
human blood neutrophils (24), Slp1 and Munc13-4 protein could be detected from BMDN 
lysates using rabbit polyclonal anti-Slp1 and goat polyclonal anti-Munc13-4 antibodies and 
their expression levels remain constant in absence of Rab27a and Rab27b (Figure 4.2.12). 
This results suggests that the stability of Slp1 and Munc13-4 in neutrophils does not depend 
on their association with Rab27a and/or Rab27b as is the case for melanophilin in 
melanocytes  where the presence of Rab27a stabilises protein levels of both melanophilin 
and myosin Va (76). 
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Figure 4.2.11 – CXCR2 surface expression is as wild-type on Rab27b KO and Rab27DKO neutrophils. 
Flow cytometry of wild-type (C57BL/6), Rab27b KO and Rab27DKO neutrophils stained with rat anti-
CXCR2 antibody or isotype control.  
 
Figure 4.2.12 – Rab27 effectors Slp1 and Munc13-4 is expressed in murine bone marrow derived 
neutrophils. Western blot of 100 µg lysates from wild-type (Rab27a
+/+
), wild-type (Rab27b
+/+
), ashen 
(Rab27a
ash/ash
) and Rab27b KO (Rab27b
-/-
) bone marrow purified neutrophils immunoblotted with 
rabbit polyclonal anti-Slp1 or goat anti-Munc13-4 antibodies for 1h at room temp. Data 
representative of 2 experiments. 
 
 
121 
 
 
4.2.12 – Slp1 and Munc13-4 promote neutrophil chemotaxis in vitro 
Without access to knockout mouse models of Slp1 and Munc13-4 for the purpose of 
studying neutrophil chemotaxis, another method was required to assess Munc13-4 and Slp1 
function in primary neutrophil chemotaxis. A method of permeabilising neutrophils using 
streptolysin-O (SLO) followed by incubation with a blocking antibody has already been 
described to assess secretion (24) and so this method was modified for use with the 
transwell chemotaxis assay. SLO is a bacterial protein that creates reversible pores in the 
plasma membrane of cells. When cells are briefly treated with SLO, relatively large proteins 
such as antibodies are able to pass through the pores generated and enter the cell 
cytoplasm. Once there, the antibody can bind its target in the cell and block its function. 
This method relies heavily on the specificity of antibodies as non-specific binding can affect 
cell function. The antibodies for Slp1 and Munc13-4 were raised against the Rab binding 
domain so binding of the antibody to this portion of Slp1 would likely block Rab27 binding 
and block its function. The antibodies for Rab27a and Rab27b were raised against the whole 
protein but the crystal structures of Rab27a/Slp2 and Rab27b/Mlph interactions highlighted 
a variety of interactions on the Rab27 surface important for effector binding (31, 95). 
Therefore these antibodies were likely to block effector binding by attaching to different 
places on the Rab27 surface. Acute blockade of Slp1 and Munc13-4 in wild-type neutrophils 
with 5 µg of antibody prior to chemotaxis significantly inhibited neutrophil transwell 
chemotaxis and mimicked blockade of Rab27a and Rab27b with 5 µg of purified rabbit 
antibodies (N689 and S089) (Fig 4.2.13). This result suggests that Rab27a promotion of 
chemotaxis through release of primary granules may also depend on its effectors Slp1 and 
Munc13-4.  
 
4.2.13 – Rab3d is expressed in primary murine bone marrow derived neutrophils 
This study has already suggested the importance of one exocytic Rab GTPase (Rab27) in 
neutrophil chemotaxis, however Rab27DKO BMDN do not show complete inhibition of 
chemotaxis, suggesting multiple partially redundant pathways may promote chemotaxis. 
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The Rab27 subfamily is closely related to the Rab3 subfamily consisting of 4 isoforms (a, b, c 
and d). Rab3d has previously been shown to be expressed in human myeloid cell line HT93A 
and to be upregulated during differentiation to neutrophils (133). To investigate a general 
role for exocytic Rab GTPases in neutrophil migration, Rab3d was analysed. Two bands for 
Rab3d protein (based on its distinct size vs other Rab3 isoforms) (158) were detected in 
neutrophil lysates by western blot using a commercial Rab3 antibody from Synaptic systems 
(Fig 4.2.14). Using the same commercial antibody and others, this double band has been 
observed in a previous study and was suggested to be as a result of unprenylated (lower 
band) and prenylated (upper band) Rab3d protein (158). Another explanation might be that 
the lower band is a Rab3d degradation product and this may be the case as the epitope 
recognised by the antibody is the middle of Rab3 (aa 95-151), therefore a small C-terminal 
of N-terminal cleavage would mean the protein would still be recognised by the antibody. 
Interestingly total expression levels of Rab3d were consistently increased in Rab27DKO 
neutrophils. This result suggested the possibility that Rab3d may compensate for loss of 
Rab27a/b in neutrophils.  
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Figure 4.2.13 – Slp1 and Munc13-4 promote chemotaxis of BMDN in vitro. Transwell migration of 
wild-type neutrophils permeabilised with SLO and incubated with control or antibodies specific for 
Rab27a, Rab27b, Slp1 and Munc13-4 for 10 mins prior to transwell migration towards a range of 
LTB4 concentrations for 30 mins. Error bars  s.e.m. *** P ≤ 0.001 two way ANOVA. Data compiled 
from 2 independent experiments. 
 
Figure 4.2.14 – Rab3d is expressed in murine bone marrow derived neutrophils. Western blot of 50 
µg lysates from wild-type from wild-type (Rab27a
+/+
), wild-type (Rab27b
+/+
), ashen (Rab27a
ash/ash
),  
Rab27b KO (Rab27b
-/-
) and Rab27DKO (Rab27a
ash/ash
, Rab27b
-/-
) bone marrow purified neutrophils 
and blotted with commercial mouse monoclonal anti-Rab3 antibody and calnexin as a loading 
control for 1h at room temp. Data representative of 3 independent experiments. 
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4.2.14 – Rab3d promotes neutrophil chemotaxis in vitro 
To test the function of Rab3d in neutrophil chemotaxis, Rab3d was blocked using the same 
SLO method described previously using neutrophils purified from wild-type and Rab27DKO 
mice to test whether Rab3d is able to promote neutrophil chemotaxis in the presence 
and/or absence of Rab27. Wild-type and Rab27DKO neutrophil transmigration increased 
with increasing concentrations of LTB4, however using wild-type neutrophils pre-treatment 
with anti-Rab3d antibody did not significant impair neutrophil chemotaxis compared to 
wild-type cells pre-treated with control antibody. By contrast Rab27DKO neutrophils pre-
treated with anti-Rab3d antibody did display significant impairment of chemotaxis 
compared to control antibody treated cells (Fig 4.2.15). This results suggests that Rab3d can 
promote secretion in absence of Rab27 and may be a compensatory mechanism to restore 
chemotactic activity in Rab27DKO neutrophils. During the course of blocking experiments, 
sometimes differences were observed in baseline migration at 0 nM chemokine and in these 
experiments, it was more appropriate to use chemotaxis index rather than number of 
migrated cells. However raw data (migrated cells) has been plotted wherever possible.  
 
4.2.15 – Rabphilin is expressed in primary murine bone marrow derived neutrophils 
The effectors that Rab27 and Rab3 interact with are partially overlapping. Rabphilin was 
originally identified as a Rab3a interacting protein (166) however further analyses have 
demonstrated that rabphilin is not required for Rab3 functions (160) and that in C. elegans 
rabphilin functions with Rab27 but not Rab3. However Rabphilin expression is known to be 
stabilised by Rab3 in the brain (159), suggesting it is probably a shared effector. To 
investigate the role of a potential shared effector, rabphilin expression was first confirmed 
in primary bone-marrow derived neutrophils. Rabphilin expression levels were slightly 
elevated in Rab27DKO neutrophils (Fig 4.2.16), and this is consistent with the finding that 
Rab3d expression levels were observed to be elevated in Rab27DKO BMDN.  
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Figure 4.2.15 – Rab3d promotes Rab27DKO but not wild-type neutrophil chemotaxis in vitro. 
Transwell migration of wild-type or Rab27DKO neutrophils permeabilised with SLO and incubated 
with control or antibodies specific for Rab3d for 10 mins prior to transwell migration towards a 
range of LTB4 concentrations for 30 mins. Error bars  s.e.m. *** P ≤ 0.001 two-way ANOVA. Data 
compiled from 2 independent experiments. 
 
Figure 4.2.16 – Rabphilin is expressed in murine bone marrow derived neutrophils. Western blot of 
50 µg lysates from wild-type (Rab27a
+/+
), wild-type (Rab27b
+/+
), ashen (Rab27a
ash/ash
),  Rab27b KO 
(Rab27b
-/-
) and Rab27DKO (Rab27a
ash/ash
, Rab27b
-/-
) bone marrow purified neutrophils and blotted 
with commercial rabbit polyclonal anti-Rabphilin antibody for 1h at room temp. Data representative 
of 2 experiments. 
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4.2.16 – Rabphilin promotes neutrophil chemotaxis in vitro 
To assess rabphilin function in neutrophil chemotaxis, neutrophils were permeabilised and 
pre-incubated with rabphilin antibody prior to chemotaxis assay. Blockade of rabphilin 
inhibited transmigration of wild-type neutrophils over a range of LTB4 concentrations 
compared to species matched anti-V5 control antibody (Fig 4.2.17). No study to date has 
characterised the role of Rabphilin in any leukocyte cell type and this result suggests that 
Rabphilin may play a role in secretion and chemotaxis of neutrophils, possibly through 
interaction with Rab27a/b or Rab3d.  
 
4.2.17 – Gunmetal neutrophils display impaired chemotaxis in vitro 
Gunmetal mice display reduced activity of RabGGTase (roughly 20% compared with wild-
type) due to a splice acceptor site mutation in the gene encoding the alpha subunit of the 
enzyme (47). This would likely affect all Rab GTPases as prenylation is required to allow their 
insertion into endomembranes. Given the findings in this study that Rab27a, Rab27b and 
Rab3d can all promote neutrophil chemotaxis, it was interesting to analyse neutrophil 
chemotaxis from gunmetal mice. Consistent with the observations of this study, gunmetal 
neutrophils display impaired transwell migration compared to wild-type (C57BL/6) 
neutrophils at 5 nM MIP-2 and at 1 and 50 nM LTB4 (Fig 4.2.18). The scale of the defect was 
similar to ashen BMDN chemotaxis. While this result suggests that partially blocking 
function of many Rab GTPases does not inhibit chemotaxis more than single knockout of 
Rab27a, gunmetal BDMN still retain 20% prenylation activity and this may be enough for 
near normal functionality for some Rab GTPases.  
 The use of statins to lower cholesterol levels in the blood are commonly used to 
prevent cardiovascular disease. Statins inhibit HMG-CoA reductase and as a result inhibit 
the production of geranylgeranyl groups necessary for the membrane localisation of many 
classes of GTPases. This has a similar effect as the gunmetal mutation in that GTPases 
remain unprenylated and cannot insert into the membrane to perform their function. 
Recent interest in statins as an anti-inflammatory drug has come from observations that 
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patients treated with statins have reduced neutrophil migration (88) though to be as a result 
of defective prenylation of RhoGTPases (114). As suggested by the defective chemotaxis of 
gunmetal neutrophils, defective prenylation of RabGTPases also causes impaired neutrophil 
chemotaxis. This raises the possibility that statin mediated impairment of neutrophil 
chemotaxis might also be due to defective prenylation of RabGTPases. Further studies 
should aim to clarify this question.  
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Figure 4.2.17 – Rabphilin promotes chemotaxis in vitro. Transwell migration of wild-type 
neutrophils permeabilised with SLO and incubated with control anti-V5 antibody or antibodies 
specific for Rabphilin for 10 mins prior to transwell migration towards a range of LTB4 concentrations 
for 30 mins. Error bars  s.e.m. *** P ≤ 0.001 two-way ANOVA of all data points. Data compiled from 
2 independent experiments. 
 
 
Figure 4.2.18 – Prenylation deficient gunmetal BMDN display reduced chemotaxis in vitro. 
Transwell migration of wild-type (BL/6) or gunmetal (Gm) neutrophils towards buffer alone (0) or a 
range of (a) MIP-2 or (b) LTB4 concentrations for 30 mins. Error bars  s.e.m. * P ≤  0.05, ** ≤  0.01 
student’s t test. Data compiled from 2 independent experiments. 
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4.2.18 – Dilute neutrophils display enhanced chemotaxis in vitro 
While the role of myosin Va has been well established in connection with Rab27a function in 
melanocytes (76), the role of myosin Va does not follow that of Rab27a in cytotoxic T 
lymphocytes (21). This suggests that while myosin Va is expressed in CTLs, it does not 
function together with Rab27a. To investigate whether Rab27a and myosin Va function 
together or independently in neutrophils, BMDN chemotaxis from the dilute mouse 
deficient in myosin Va were analysed. Dilute neutrophils consistently displayed enhanced 
chemotaxis compared to heterozygous control neutrophils (Fig 4.2.19). This result suggests 
that as in CTLs, the role of myosin Va does not follow that of Rab27a and requires further 
characterisation to understand why lack of myosin Va enhances neutrophil chemotaxis. As 
hypothesised in chapter 3, Rab27 binding proteins that also bind actin may stabilise the 
actin cytoskeleton and therefore in absence of myosin Va, a more dynamic actin 
cytoskeleton may exist that allows the shape of the cell to be altered more easily. This 
would have the effect of enhancing neutrophil chemotaxis as the actin cytoskeleton 
becomes more dynamic to initiate cell movement and chemotaxis.  
 
 
Figure 4.2.19 – Dilute BMDN display increased chemotaxis in vitro. Transwell migration of 
heterozygous (plus dil (+/dil)) control or dilute (dil) neutrophils towards buffer alone (0) or a range of 
(a) MIP-2 or (b) LTB4 concentrations for 30 mins. Error bars  s.e.m. . * P ≤  0.05, student’s t test. Data 
compiled from 2 independent experiments. 
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4.3 – Discussion 
The data presented suggests that Rab27a/b promote neutrophil migration in vivo using a 
model of MIP-2 induced neutrophil recruitment to the lungs (Fig 4.2.1, 4.2.3) and in vitro 
using murine BMDN transwell chemotaxis to MIP-2 and LTB4 (Fig 4.2.4, 4.2.9, 4.2.10). They 
also suggest that Rab27a can promote chemotaxis in human cells using siRNA knockdown 
and transwell chemotaxis of HL-60 cells differentiated to mature neutrophils by DMSO 
treatment (Fig 4.2.6, 4.2.7).  The finding that Rab27b is expressed in bone-marrow derived 
neutrophils (Fig 4.2.8) was expected given that its expression was observed previously in 
murine blood derived neutrophils (80). Somewhat surprisingly Rab27DKO neutrophils did 
not display significantly increased impairment in chemotaxis vs Rab27b KO neutrophils or vs 
ashen neutrophils (Fig 4.2.10). Rab27 effectors Slp1, Munc13-4 and Rabphilin were shown to 
be expressed in BMDN (Fig 4.2.12) and inhibition of both effectors impaired BMDN 
chemotaxis and mimicked Rab27a and Rab27b inhibition (Fig 4.2.13). Rab3d expression was 
shown to be upregulated in Rab27DKO BMDN (Fig 4.2.14) and to promote chemotaxis in 
Rab27DKO but not wild-type BMDN (Fig 4.2.15) suggesting that it may compensate for loss 
of Rab27 in neutrophil chemotaxis. The shared Rab27/Rab3 effector Rabphilin was shown to 
be expressed in neutrophils and its stability was not dependent on Rab27a/b expression (Fig 
4.2.16). Inhibition of Rabphilin also inhibited chemotaxis of BMDN (Fig 4.2.17), suggesting 
that Rabphilin may regulate secretion and chemotaxis of BMDN. These results together 
suggest that Rab27/Rab3 and effectors may present a general mechanism of chemotaxis, 
possibly through release of primary granules.  
 
4.3.1 - How might Rab27a/b and effectors promote neutrophil chemotaxis? 
In transwell assays ashen, Rab27b KO and Rab27DKO BMDN consistently displayed 
significantly impaired chemotaxis compared to wild-type BMDN (Fig 4.2.9). This result was 
the same using blocking antibodies against Rab27a and Rab27b (Fig 4.2.13). Using the same 
assay, inhibition of Slp1 and Munc13-4 significantly reduced neutrophil chemotaxis. Rab27a, 
Rab27b, Slp1 and Munc13-4 have all previously been suggested to promote azurophil 
granule secretion from neutrophils by measurement of release of myeloperoxidase 
(azurophil granule marker) from Rab27 deficient murine neutrophils and using blocking 
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antibodies against Slp1 and Munc13-4 on SLO permeabilised human neutrophils (24, 80). A 
recent study suggested that release of azurophil granule contents (neutrophil elastase, 
cathepsin G and proteinase-3) are important for cleavage of CD11b, part of the αMβ2 
integrin complex that is required for neutrophil detachment during chemotaxis (199). This 
occurs mainly at the back of the cells at a place called the uropod. The uropod is the tail of 
the cell where actomyosin contraction occurs to promote rear end retraction. Uropods also 
contain adhesion molecules that bind to extracellular matrix components such as fibrinogen. 
Cycles of adhesion and de-adhesion at the front and back of the cell are important for 
directed neutrophil movement and maintenance of polarity. Therefore azurophil granule 
release may be important for integrin cleavage and uropod detachment during neutrophil 
chemotaxis and may be where Rab27 (and effectors) act to promote chemotaxis. 
Comparison of ashen, Rab27b KO and Rab27DKO BMDN chemotaxis suggests that 
primary granule secretion may be responsible. The finding that ashen, Rab27b KO and 
Rab27DKO display the same level of impaired chemotaxis was surprising (Fig 4.2.10). In a 
study using blood derived neutrophils (80), Rab27a deficient neutrophils did not display 
detectable secretion of primary granules. Rab27b deficient neutrophils exhibited impaired 
secretion and Rab27DKO neutrophils displayed slightly less but still detectable secretion. 
Johnson et al suggested the reason for this being that Rab27a and Rab27b regulate primary 
granule secretion via independent mechanisms and lack of one isoform was sufficient to 
impair primary granule secretion. The fact that Rab27DKO displayed low but detectable 
secretion vs ashen neutrophils that did not display any detectable secretion was 
counterintuitive and Johnson et al suggested this might be due to compensatory 
mechanisms in absence of both Rab27 isoforms. In this study, the expression of Rab3d was 
shown to be upregulated Rab27DKO BMDN and inhibition of Rab3d was shown to impair 
chemotaxis of BDMN independently of Rab27 expression. This may represent a 
compensatory mechanism to preserve primary granule release in Rab27DKO BMDN and 
may explain why Rab27b KO and Rab27DKO BMDN display the same level of impairment in 
chemotaxis (Fig 4.2.10), though Rab3d has not yet been implicated in primary granule 
secretion. This finding also suggests that primary granule secretion plays a critical role in 
neutrophil function. 
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4.3.2 - What Rab27 effectors/Rab27 related proteins might be involved? 
The Rab27 effectors Slp1 and Munc13-4 were identified to be expressed in bone marrow 
derived neutrophils. The function of Slp1 and Munc13-4 in neutrophil chemotaxis was 
studied and acute blockade of Slp1 impaired chemotaxis and closely mimicked blockade of 
Rab27a and Rab27b (Fig 4.2.13). A recent study found that jinx mice deficient in Munc13-4 
did not display defective neutrophil migration in vivo (81). While this result is contradictory 
to findings presented here, the model used was one of systemic inflammation and did not 
recruit neutrophils to a specific place. In the same assay inhibition of Rab27a reduced 
chemotaxis more strongly than inhibition of Rab27b (Fig 4.2.13). If Rab27a and Rab27b 
promote chemotaxis through secretion of primary granules, this correlates with previous 
data suggesting that Rab27a is more important for primary granule secretion than Rab27b 
(80). These data also suggest a general mechanism of chemotaxis regulated by Rab27 and 
effectors and primary granules secretion, possibly at the uropod to promote uropod 
detachment. 
The result that Rabphilin is expressed in bone marrow derived neutrophils is the first 
report of expression of Rabphilin in a leukocyte (Fig 4.2.16). Because of this, the role of 
Rabphilin in granule secretion has not been characterised. The finding that Rabphilin also 
promotes neutrophil chemotaxis (Fig 4.2.17) may suggest that like Slp1 and Munc13-4, 
Rabphilin may regulate primary granule secretion through interaction with Rab27a, Rab27b 
or Rab3d. However more studies need to be performed to determine the source of the 
defect the neutrophil chemotaxis arising from acute blockade of Rabphilin. As the knockout 
mice for both Rab3d and Rabphilin are available (159, 160), this can be performed by future 
studies. 
Rab GTPases require prenylation in order to be inserted into the membrane and 
perform their function. Prenylation deficient gunmetal mice have a mutation in RabGGTase 
α subunit and display ~20% RabGGTase activity. Gunmetal mice therefore show partial 
albinism due to defects in melanosome transport/secretion (130) that may in part be due to 
defective Rab27a function and in this study gunmetal neutrophils displayed impaired 
chemotaxis as did ashen (and Rab27b KO) neutrophils (Fig 4.2.18) . Defective prenylation of 
Rab27a would mean that the majority of Rab27a and Rab27b would be found in the cytosol 
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and that it cannot associate with membranes. Prenylation deficiency would also inhibit 
Rab3d function and mean that it would not compensate for loss of Rab27a or Rab27b. It is 
likely for these reasons that gunmetal BMDN display inhibited chemotaxis. 
Myosin Va has been shown to be expressed in CTLs but it does not seem to work in 
conjunction with Rab27a as it does in melanocytes (21, 76). This would suggest a different 
role for myosin Va in the immune system than Rab27a. In agreement with this, dilute 
neutrophils do not display defects in neutrophil chemotaxis. In contrast to the phenotype of 
ashen neutrophils, dilute neutrophils display enhanced chemotaxis in vitro. Interestingly a 
study found enhanced CTL target cell killing in dilute CTLs versus control, an indication that 
lytic granule secretion is also enhanced in dilute CTLs (69). Myosin Va is able to directly bind 
actin and so its presence may stabilise the actin cytoskeleton and the actin cytoskeleton in 
dilute neutrophils may therefore be more dynamic. Disruption of the actin cytoskeleton is 
known to significantly enhance neutrophil granule secretion and particularly primary 
granule secretion (79).  This is probably because actin presents a physical barrier to 
secretion. The enhanced chemotaxis observed in dilute neutrophils may therefore stem 
from an enhanced capacity for primary granule secretion during chemotaxis. However as 
specific antibodies for myosin Va were not available, protein levels in BMDN could not be 
determined. 
Rab3d was shown to be expressed in bone marrow derived neutrophils (Fig 4.2.14). 
Previous Rab3d had been shown to be upregulated during myeloid differentiation to mature 
neutrophils, much in the same manner as Rab27a (133). Acute blockade of Rab3d impairs 
chemotaxis of Rab27DKO neutrophils. This suggests that Rab3d may promote chemotaxis in 
a Rab27 independent manner. The finding of another RabGTPase that regulates chemotaxis 
strengthens the idea that exocytosis and chemotaxis are intimately linked.  
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Chapter 5 – Role of Rab27a in neutrophil chemotaxis 
5.1 – Introduction 
The data presented in chapter 4 has suggested that Rab27a/b promotes neutrophil 
chemotaxis. The findings from chapter 4 suggest that primary granule secretion may 
represent a general mechanism regulating neutrophil chemotaxis however the mechanism 
by which Rab27 promotes neutrophil chemotaxis remains ill defined. To provide further 
details, Rab27a deficient ashen neutrophils were analysed in more detail to highlight how 
Rab27 is able to promote chemotaxis and at which step it may act. 
 
5.2 –Results 
5.2.1 – CXCR2 surface expression on ashen BMDN is similar to wild-type 
The first critical step in chemotaxis is chemokine and chemokine receptor engagement. As 
the source of chemokine was provided, the ability of Rab27a to alter chemokine receptor 
levels was tested in primary murine neutrophils. Wild-type or ashen BMDN were analysed 
for surface levels of CXC chemokine receptor 2 (CXCR2) which is the receptor for one of the 
chemokines used to assess chemotaxis (MIP-2). By flow cytometry ashen BMDN displayed a 
slight increase in surface levels of CXCR2 compared to wild-type BMDN but this was not 
significant (Fig 5.2.1 A and B). This data suggested that chemotaxis defect does not result 
from defects in chemokine receptor trafficking. Having also tested chemotaxis of ashen 
BMDN using LTB4, it would have been desirable to also analyse the high affinity LTB4 
receptor BLT1 surface expression, however the lack of commercial antibodies towards 
murine BLT1 did not allow this to be performed. Fig 5.2.1 suggests that Rab27a does not 
regulate chemotaxis through chemokine receptor surface expression or function. While it is 
possible that CXCR2 may be misfolded in ashen BMDN and prevents MIP-2 binding, this is 
not likely for several reasons. Firstly the CXCR2 antibody using in Fig 5.2.1 recognises the 
extracellular domain of CXCR2, the same portion that binds MIP-2. Misfolded CXCR2 that 
does not bind MIP-2 would likely also not bind anti-CXCR2 antibody well and this was not 
the case. Secondly misfolded CXCR2 would likely be retained in the endoplasmic reticulum 
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and cause a net decrease in the surface expression of CXCR2 in ashen BMDN. This was also 
not the case so there is no reason to expect misfolded CXCR2 in ashen BMDN. 
 
5.2.2 – Ashen BMDN display increased forward scatter and reduced side scatter by flow 
cytometry 
During flow cytometry measurements of CXCR2 expression, differences in the forward and 
side scatter profile of wild-type and ashen BMDN were observed. Changes in cell 
morphology might underlie the chemotaxis defect observed as increased granularity or size 
might impair their ability to squeeze through cell-cell junctions in vivo or through pores in 
vitro. For this reason cell morphology was measured more systematically. Upon closer 
examination, ashen BMDN displayed a small but significant increase in forward scatter, as 
did Rab27a
+/ash
 BMDN, compared to wild-type (Fig 5.2.2 A). Ashen BMDN also displayed a 
significant reduction in side scatter that was not present in Rab27a
+/ash
 (Fig 5.2.2 B). These 
results suggested that ashen BMDN may be larger and less granular than wild-type BMDN. 
However flow cytometry profile is a relatively crude way to measure differences in cell 
morphology, so electron microscopy was used to assess ashen BMDN morphology. 
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Figure 5.2.1 – CXCR2 expression remains as wild-type in ashen BMDN. (a) Flow cytometry of wild-
type (C57BL/6) and ashen neutrophils stained with rat anti-CXCR2 antibody or isotype control and 
(b) quantification of CXCR2 expression from wild-type (n=3) and ashen
 
(n=3) neutrophils. Error bars 
represent SEM. 
 
Figure 5.2.2 –ashen neutrophils display increased forward scatter and reduced side scatter profile 
by flow cytometry. (a) Forward scatter and (b) side scatter as measured by flow cytometry. Data 
compiled from purified neutrophils from Rab27a
+/+
 (n=6), Rab27a
+/ash 
(n=5) and Rab27a
ash/ash
(n=6) 
mice. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, Student’s t-test. Error bars s.e.m. 
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5.2.3 – Ashen BMDN display normal morphology by electron microscopy 
To analyse neutrophil morphology more thoroughly to assess whether differences in cell 
morphology were likely to explain ashen BMDN defective chemotaxis, wild-type and ashen 
BMDN were subjected to electron microscopy analysis. Ashen BMDN displayed a similar size 
and contained normal azurophilic and specific granules observed in wild-type (Fig 5.2.3). 
Murine neutrophils are known to differ from human neutrophils in that they do not contain 
tertiary granules, and consistent with this we did not observe structures resembling tertiary 
granules (24). From this we concluded that ashen neutrophils display no gross 
morphological defects and therefore altered morphology was unlikely to explain defects in 
chemotaxis in ashen BMDN. This finding is in agreement with a previous study that analysed 
blood purified neutrophils from ashen mice by electron microscopy (80). 
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Figure 5.2.3 – Wild-type and ashen neutrophil morphology by electron microscopy. Wild-type or 
ashen neutrophils were purified from bone marrow and subjected to electron microscopy analysis. 
Mito – Mitochondria, Nuc – Nucleus, Azu – Azurophilic granule, Sp – Specific granule. Scale bars 1 
µm upper panels and 200 nm lower panels. EM performed by Dr. Clare Futter. 
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5.2.4 – Agonist-stimulated actin polymerisation of ashen BMDN is similar to wild-type 
The next important step in chemotaxis of neutrophils is the ability of cells to respond to 
chemokine by polymerisation of actin at the leading edge of the cell to allow membrane to 
be pushed forward during the chemotactic response. While there is little precedent for Rab 
GTPases regulating actin polymerisation, Rab27a is known to interact with the actin 
cytoskeleton through effectors e.g. Myosin Va (76). Knockdown of Rab27 effector Slp5 in the 
SupT1 T cell line had previously been reported to impair chemokine induced actin 
polymerisation (39). Therefore it is possible that defective chemotaxis in ashen BMDN may 
arise from impaired actin polymerisation upon chemokine stimulation. To test this, ashen 
BMDN were analysed for their ability to polymerise actin in response to MIP-2 and LTB4 in 
suspension by staining with fluorescent phalloidin and analysis using flow cytometry. Ashen 
BMDN displayed very similar actin polymerisation responses to wild-type BMDN (Fig 5.2.4 A 
and B). This suggested that Rab27a does not alter chemoattractant stimulated actin-
polymerisation within neutrophils. This result also suggested that the chemoattractant 
signalling was functional in ashen BMDN and directly excludes the previous idea of 
chemokine receptor misfolding in ashen BMDN being a possible cause for their defective 
chemotaxis.  Differences in F-actin may also arise from differences in rear end contraction, 
however as ashen BMDN display normal actin polymerisation responses, defective rear end 
contraction is unlikely to explain ashen chemotaxis defect. 
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Figure 5.2.4 – Actin polymerisation remains as wild-type in ashen BMDN. Quantification of total F-
actin content in wild-type (n=3) or ashen
 
(n=3) neutrophils after incubation with (c) MIP-2 (10 nM) 
and (d) LTB4 (100 nM) for given times followed by immediate fixation in 4% PFA. Neutrophils were 
permeabilised, stained with phalloidin-alexa-647 and analysed by flow cytometry. Error bars s.e.m. 
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5.2.5 – Ashen BMDN display impaired live cell chemotaxis using a Zigmond chamber 
Having excluded a role for Rab27a in several mechanisms important for chemotaxis, and to 
shed further light on the mechanism by which Rab27a might promote neutrophil 
chemotaxis, live cell chemotaxis of neutrophils using a microscopy based assay was 
performed. This was done by utilising the Zigmond chamber, a device with a raised area 
flanked by two wells was performed. BMDN were plated onto coverglass and allowed to 
adhere for 20 min, and subsequently inverted onto the chamber. Medium was placed into 
the left well and chemoattractant into the right well, creating a gradient by diffusion of 
chemokine into the medium across the raised area that may be imaged (Fig 5.2.5 A). A 
gradient was allowed to form for 5 minutes prior to imaging. Stacks of images were 
recorded every 30 seconds for 30 minutes and analysed using ImageJ software with the 
manual tracking plugin to track BMDN cell migration for wild-type and ashen BMDN. 
Comparison of cell tracks using this method confirmed that ashen BMDN displayed impaired 
chemotaxis compared to wild-type (Fig 5.2.5 B). 
 
5.2.6 – Ashen BMDN display reduced migration distance, velocity and directionality in 
vitro 
Using the live cell assay with a Zigmond chamber carried a significant advantage in that it 
allowed direct observation of the chemotactic defect, including cell migration distance, cell 
velocity and efficiency of directional migration. This was done using the chemotaxis and 
migration tool plugin for ImageJ (Ibidi) that used data from tracks generated using the 
manual tracking plugin. Ashen BMDN displayed significantly reduced migration distance, 
velocity and directional migration compared to wild-type BMDN (Fig 5.2.6 A, B and C). 
Directional migration was measured as migration index which was defined as the migration 
efficiency parallel to the x axis which represents directed migration (chemotaxis) or y axis 
representing random migration (chemokinesis). Fig 5.2.6 C showed that while chemotaxis 
was impaired in ashen BMDN chemokinesis was not. 
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Figure 5.2.5 – Live cell analysis of wild-type and ashen BMDN chemotaxis using a Zigmond 
chamber.  (a) Schematic of Zigmond chamber setup. (b) BMDN from wild-type (C57BL/6) mice or 
ashen mice (c) were seeded onto coverglass and inverted into a Zigmond chamber with medium in 
the left well (w1) and 10 nM MIP-2 in the right well (w2). Stacks of images were recorded every 30s 
for 30 mins. Tracks were obtained manually using Image J with the manual tracking plugin.  
 
 
Figure 5.2.6 – Quantification of live cell chemotaxis of wild-type and ashen BMDN.  Tracks of 
migrating cells were taken using Image J software (NIH) using the Chemotaxis and migration tool 
plug in (Ibidi). Average track distance (A), cell velocity (B) and migration efficiency parallel to the x or 
y axes (C) were measured. Data compiled from 4 independent experiments. P values student’s t test. 
Error bars s.e.m.  
 
ashen
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5.2.7 – Ashen BMDN neutrophils display impaired uropod release during chemotaxis in 
vitro 
Observations of live cell images of migrating neutrophils displayed an obvious defect in 
ashen BMDN in the release of the back of the cell (uropod) where the cell was attached (Fig 
5.2.7 B). Measurements were made of uropod lifetime defined as the time taken for a 
uropod to be released as characterised by a change of the cell from an elongated to a 
spherical morphology. Average time of uropod release was significantly increased in 
absence of Rab27a, 65.24 ± 2.32 sec for wild-type BMDNs and 201.74 ± 13.5 sec for ashen 
BMDNs (Fig 5.2.7 C). Delay in uropod release was particularly striking as ashen BMDNs 
seemed for a long time stuck in an elongated position before the uropod was released or 
the cell lost polarity and became arrested. The small error in uropod release time suggests 
that all ashen BMDN display defects in uropod release and that defective uropod release is 
not limited to a subset of ashen BMDN. Delayed uropod release was also reflected in the 
total number of uropods made during 30 minutes, which was significantly less in absence of 
Rab27a, 16.5 ± 1.28 for wild-type and 6.27 ± 0.93 for ashen BMDN (Fig 5.2.7 D). These 
results suggested that Rab27a promotes neutrophil chemotaxis by promoting uropod 
detachment in migrating cells.  
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Figure 5.2.7 – Uropod release is defective in ashen BMDN during chemotaxis. Wild-type (A) or 
ashen (B) neutrophils were observed over a course of 180 s for any abnormalities in cell morphology 
during chemotaxis.  (C) Measurement of lifetime of wild-type neutrophil uropods (n=166) or ashen 
neutrophil uropods (n=69) from migrating neutrophils. (D) Measurement of number of uropods 
created during 30 minutes of migrating wild-type (n = 10) or ashen (n=11) neutrophils. Data 
compiled from 4 independent experiments. P values student’s t test. Error bars s.e.m.  
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5.2.8 – Rab27a positive structures redistribute to the uropod in migrating neutrophils 
A recent study suggested that neutrophil secretion of proteases cathepsin G, neutrophil 
elastase and proteinase-3 aids uropod detachment during chemotaxis by promoting 
cleavage of the CD11b subunit of αMβ2 integrin (199). These proteases are stored in 
azurophilic granules. The secretion of azurophilic granules is known to be regulated by 
Rab27a in neutrophils (24, 127). These studies gave rise to the hypothesis that Rab27 might 
regulate release of proteases at the uropod to aid detachment during chemotaxis. As a first 
step to test this hypothesis, the localisation of Rab27a was investigated in moving 
neutrophils. BMDN from EGFP-Rab27a expressing mice (180) were allowed to adhere to 
coverglass and then placed into a MIP-2 gradient in the Zigmond chamber to allow BMDN to 
start moving prior to fixation. At rest Rab27a positive structures were evenly distributed 
throughout the cytoplasm and some were localised at the plasma membrane (Fig 5.2.8 A). 
Upon movement, a significant proportion of Rab27a positive structures were observed at 
the back of the cell in the uropod in polarised cells (Fig 5.2.8 B) suggesting that Rab27a 
regulates secretion at the uropod during chemotaxis. At a later stage of migration, EGFP-
Rab27a distribution followed the pattern of membrane association at the back of the cell 
(Fig 5.2.8 C) suggesting that Rab27a had already fulfilled its function in secretion at the 
uropod in these cells and granule-plasma membrane fusion resulted in Rab27a being in the 
membrane at the uropod. This result suggested that Rab27a regulates the secretion of 
Rab27a positive structures at the uropod during neutrophil migration.  
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Figure 5.2.8 – Rab27a positive structures redistribute to the uropod in migrating neutrophils. 
EGFP-Rab27a BMDN were plated onto coverslips for 20 mins at 37ºC, and fixed with 4% PFA (a) or 
placed into a MIP-2 chemokine gradient in a Zigmond chamber for 5 mins and then fixed (b,c). Scale 
bars 5 µm. Arrows indicate uropods. Data representative of migrating cells from 3 independent 
experiments. 
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5.2.9 – Inhibition of extracellular proteases severely inhibits neutrophil chemotaxis 
The next question was then what class of organelle do these Rab27a positive structures 
represent and what is the cargo that they are releasing that is critical for uropod 
detachment and efficient chemotaxis. From previous studies, it is thought that a significant 
proportion of Rab27 localises to primary granules in murine and human neutrophil and 
regulates the release of primary granule marker myeloperoxidase (24, 127). Recent 
evidence has suggested that the secretion of serine proteases Cathepsin G, proteinase-3 and 
neutrophil elastase contained in primary granules is important for uropod detachment 
during chemotaxis (199). Neutrophils from the mouse model of Chediak-Higashi syndrome 
(beige) lacking neutrophil elastase and cathepsin G have a detachment phenotype similar to 
that observed in ashen mice observed in this study (199). Therefore to understand if 
defective chemotaxis of ashen BMDNs was the result of defective serine protease secretion 
at the uropod, the functional effect of blocking serine protease function during chemotaxis 
of wild-type and ashen BMDNs was tested. 
Extracellular protease function was blocked during chemotaxis of wild-type and 
ashen BMDN. The simplest way to block extracellular proteases is to use a widely available 
broad spectrum protease inhibitor cocktail. The cocktail contains a mixture of protease 
inhibitors that inhibit serine proteases, cysteine proteases and metalloproteases. Wild-type 
and ashen BMDNs were treated with this protease inhibitor cocktail prior to transwell 
migration. Neutrophil chemotaxis in response to MIP-2 was completely inhibited for both 
wild-type and ashen BMDNs (Fig. 5.2.9). Interestingly chemokinesis (random migration) was 
also significantly inhibited in both wild-type and ashen BMDNs indicating that random 
migration is also dependent on protease function. While this result was interesting and 
highlighted the important role of extracellular protease function during neutrophil 
chemotaxis, it did not reveal differences in wild-type and ashen BMDNs. This is probably 
because the protease inhibitor cocktail targets every class of protease and is not specific. It 
was necessary to find a more specific inhibitor of serine proteases to test our hypothesis 
more specifically.  Serine proteases are so called because the active site of the proteases 
contains a serine that assists cleavage of the target protein. 
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Figure 5.2.9 – Inhibition of extracellular proteases inhibits wild-type and ashen BMDN chemotaxis. 
Transwell migration of wild-type and ashen
 
neutrophils towards 0 or 10 nM MIP-2 over 30 mins 
treated with O or 1x concentration of protease inhibitor cocktail. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001, Student’s t-test. Error bars s.e.m.  
 
 
Figure 5.2.10 – High concentration of serine protease inhibitor AEBSF strongly inhibits wild-type 
and ashen BMDN chemotaxis. Transwell migration of wild-type and ashen
 
neutrophils towards 10 
nM MIP-2 over 30 mins treated with 200 nM extracellular AEBSF. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001, Student’s t-test. Error bars s.e.m. 
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5.2.10 – Inhibition of extracellular serine proteases reduces wild-type neutrophil 
chemotaxis 
To specifically inhibit serine proteases, a broad spectrum inhibitor of this class of proteases 
4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) was employed. AEBSF 
inhibits by reacting covalently and irreversibly with the active site serine of serine proteases 
forming a stable acyl-enzyme bond. At a concentration of 200 µM AEBSF, MIP-2 stimulated 
wild-type and ashen BMDN chemotaxis was significantly inhibited (Fig 5.2.10). This result 
highlighted the key role of serine proteases in neutrophil chemotaxis and suggested that 
migration is dependent of extracellular serine protease function. However to test the 
hypothesis that serine protease secretion underlies the ashen BMDN chemotaxis defect, the 
concentration of AEBSF would need to be titrated to observe the effect of increasing 
concentrations of extracellular AEBSF on wild-type and ashen BMDN chemotaxis.  
To this end, extracellular AEBSF was titrated in to assess the contribution of serine 
proteases in wild-type and ashen BMDN chemotaxis. At 10 µM AEBSF both wild-type and 
ashen BMDN chemotaxis was reduced but at 50 µM AEBSF, wild-type BMDN chemotaxis 
was reduced to ashen chemotaxis levels (Fig 5.2.11). The finding that ashen BMDN 
chemotaxis is inhibited predominantly at 10 µM and wild-type BMDN chemotaxis at 50 µM 
indicates that a lower concentration of AEBSF is required to inhibit chemotaxis of ashen 
BDMN than wild-type BMDN. While there may be a few interpretations to this finding, 
considering the results of previous studies (24, 127) the most likely reason is that ashen 
BMDN secrete less serine proteases than wild-type BMDN during chemotaxis and therefore 
a lower concentration of AEBSF will inhibit chemotaxis. The finding that at 50 µM 
concentration of AEBSF, the difference between wild-type and ashen BMDN chemotaxis is 
negated suggests that serine protease secretion is responsible for ashen defective 
chemotaxis. 
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5.2.11 – Inhibition of extracellular elastase reduces wild-type neutrophil chemotaxis to 
ashen levels 
Interestingly studies of disease models resembling Griscelli syndrome type II and ashen, 
such as the beige mouse model of Chediak-Higashi syndrome and the gray collie canine 
model of Hermansky-Pudlak syndrome type II suggested that defective trafficking of 
neutrophil elastase were responsible for neutrophil dysfunction in those animals (12, 199). 
Neutrophil elastase is an important serine protease contained in azurophilic granules and 
mediates cleavage of CD11b. Elastase upregulation can compensate for absence of MMP-9 
during neutrophil recruitment (94, 199). Elastatinal is a specific inhibitor for elastase as it 
binds specifically to the active site of elastase and the C-terminal aldehyde reacts with the 
active site serine (182). It was therefore added to wild-type and ashen BMDNs prior to 
chemotaxis to specifically inhibit elastase. Elastatinal treatment was able to reduce wild-
type BMDN chemotaxis to ashen levels at 500 µM concentration (Fig 5.2.12) while not 
affecting ashen BMDN chemotaxis. It is known that multiple serine proteases are required 
for normal neutrophil chemotaxis (199). Despite this pharmacological inhibition of elastase 
has previously been shown to significantly inhibit wild-type neutrophil transmigration (198). 
The resistance of ashen BMDN chemotaxis to elastatinal treatment suggests that defects in 
elastase secretion during chemotaxis underlie impaired chemotaxis of ashen BMDNs. As 
well as cleaving CD11b, elastase, and cathepsin G are also known to activate MMP-9 (52, 
187) which in turn can cleave the CD18 subunit of αMβ2 (183). While it is unlikely that 
Rab27a regulates release of elastase but not cathepsin G or proteinase-3 during chemotaxis 
as the proteases are stored in the same compartments, this result suggests that elastase 
secretion during chemotaxis may be an important determinant, possibly reflecting a better 
cleavage efficiency of αMβ2 or a higher total content of elastase versus cathepsin G or 
proteinase-3.   
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Figure 5.2.11 – Inhibition of extracellular serine proteases reduces wild-type neutrophil 
chemotaxis to ashen levels. Transwell migration of wild-type and ashen neutrophils towards 10 nM 
MIP-2 over 30 min treated with indicated concentrations of extracellular AEBSF.  P values Student’s 
t-test. Error bars s.e.m. Data representative of 3 independent experiments. 
 
 
Figure 5.2.12 – Inhibition of extracellular elastase reduces wild-type neutrophil chemotaxis to 
ashen levels. Transwell migration of wild-type and ashen
 
neutrophils towards 10 nM MIP-2 over 30 
mins treated with indicated concentrations of extracellular AEBSF. P values student’s t test. Error 
bars s.e.m. Data representative of 3 independent experiments. 
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5.2.12 – Ashen BMDNs display prolonged surface expression of CD11b after chemokine 
stimulation 
One prediction of the neutrophil elastase hypothesis is that if impaired secretion of elastase 
(or other serine proteases) was to explain impaired chemotaxis of ashen BMDNs, it would 
likely impair cleavage of CD11b as a functional consequence and prolong attachment of the 
rear end and lead to the observed defects in uropod release. To test this hypothesis, wild-
type and ashen BMDNs were stimulated with MIP-2 in suspension and the surface levels of 
CD11b measured over a time course. Interestingly the cleavage/recycling of CD11b was 
delayed in ashen BMDNs supporting our hypothesis (Fig 5.2.13). CD11b in an integrin 
(integrin alpha M) and forms part of the heterodimeric intergrin αMβ2 and so delay in its 
cleavage would likely impair de-adhesion during the chemotaxis process. This data taken 
together suggests that delayed uropod release in ashen BMDN occurs as a consequence of 
delayed integrin cleavage due to impaired serine protease secretion. 
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Figure 5.2.13 – Chemokine stimulation increases surface expression of specific granule marker 
CD11b in wild-type and ashen BMDN. Wild-type and ashen neutrophils were stimulated with 1 nM 
MIP-2 at 37ºC for given times at subsequently placed on ice and stained for Ly6G and CD11b. * P ≤ 
0.05 Student’s t test. Error bars s.e.m. Data compiled from 4 independent experiments. 
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5.3 –Discussion 
Ashen BMDN displayed wild-type chemokine receptor levels (Fig 5.2.1) and functional 
chemokine-induced actin polymerisation (Fig 5.2.4) suggesting that Rab27a does not play a 
role in these processes. By live cell microscopy ashen BMDN exhibited significantly reduced 
migration velocity, distance and directionality (Fig 5.2.6) due to defective uropod release 
(Fig 5.2.7). Rab27a positive structures consistently localised to the uropod in migrating cells 
(Fig 5.2.8) supporting the hypothesis that Rab27a regulated cargo may be released to aid 
uropod detachment. Extracellular treatment of broad spectrum serine protease inhibitor 
AEBSF reduced wild-type BMDN chemotaxis to ashen levels (Fig 5.2.10) suggesting that this 
Rab27a regulated cargo may be serine proteases. Treatment of elastase inhibitor elastatinal 
mimicked this effect (Fig 5.2.12), suggesting that elastase secretion may be deficient in 
ashen BMDN and underlie defects in uropod release and chemotaxis. Finally prolonged 
surface expression of αMβ2 intergrin subunit CD11b was observed in chemokine stimulated 
ashen BMDN versus wild-type BMDN (Fig 5.2.13) suggesting that increased integrin surface 
expression as a result of defective serine protease secretion may cause defective uropod 
release in ashen BMDN. 
 
5.3.1 – How might Rab27a promote chemotaxis? 
In this study Rab27a was suggested to promote migration of murine neutrophils in vivo and 
in vitro using two different chemoattractants. Furthermore Rab27a knockdown was 
suggested to impair HL-60 cell chemotaxis. HL-60 cells lack specific and tertiary granules but 
contain azurophil granules, a clue as to the origin of the chemotactic defect. In live cell 
assays ashen BMDN displayed clear defects in uropod release and in migrating neutrophils 
Rab27a localises to the rear of the cell, suggesting that Rab27a may promote secretion at 
the uropod to promote uropod detachment. These data suggesting Rab27a plays a positive 
role in neutrophil chemotaxis mirror those observed in Rab27a knockdown SupT1 T cell line 
(39). In that study both Rab27a and Rab3a were found to participate in chemotaxis 
suggesting a general role for exocytic Rab GTPases in chemotaxis. However this study did 
not provide details on how such regulation could occur. A comment on this study suggested 
that these results might mean that Rab27a regulates vesicle trafficking at the front of the 
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cell to promote chemotaxis (41). However data presented here suggest that this is not the 
case in neutrophils. Studies from Griscelli syndrome patients found defects in neutrophil 
chemotaxis (93, 97), however these reports focussed on secretory defects. Furthermore 
these studies did not detail which type of Griscelli syndrome patients had so they may have 
been deficient in Rab27a, Melanophilin or Myosin Va, however as Melanophilin and Myosin 
Va have not been linked to immune defects, it is likely that these patients were Rab27a 
deficient.  
An interesting recent study using an LPS model of inflammation found that ashen 
mice had wild-type levels of neutrophils accumulating in the lungs but significantly reduced 
neutrophil accumulation in the liver due to reduced CD44 expression levels (81). While this 
may seem contrary to data presented here, a systemic model of LPS stimulates most of the 
immune system so other cells may produce proteases to compensate for the deficiency of 
neutrophil protease secretion in ashen mice. The reduction of neutrophils accumulating in 
the liver in ashen mice compared to wild-type is consistent with this study. While the role of 
Rab27a in neutrophil migration has not previously been characterised, these previous 
studies support data presented here on a role for Rab27a in chemotaxis.  
  In migrating cells, a significant proportion of EGFP-Rab27a localised to the uropod. 
Interestingly EGFP-Rab27a localisation appeared to be in the cytoplasm and the membrane 
at the rear of the cell (Fig 5.2.8 B and C) suggesting that Rab27a promotes secretion of 
Rab27a positive compartments at the uropod during chemotaxis, possibly to promote de-
adhesion. A significant proportion of Rab27a was previously reported to localise to primary 
granules in neutrophils though it is known that azurophilic granules are not easily mobilised. 
However recent studies have suggested that chemoattractant stimulation of neutrophils 
causes release of azurophilic granules and of serine proteases, suggesting that they are also 
released during chemotaxis (24, 199). While no study to date has specifically shown that 
Rab27a controls protease release in neutrophils, serine proteases are a cargo of primary 
granules.  
This was tested in assays using protease inhibitors AEBSF and elastatinal which 
reduced wild-type chemotaxis to ashen BMDN levels suggesting that the cargo regulated by 
Rab27a might be serine proteases known to be contained in azurophil granules. 
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Furthermore upon chemokine stimulation, ashen BMDN display prolonged surface 
expression of CD11b, an integrin subunit suggested to be cleaved by serine proteases during 
chemotaxis (199). If this were the case, one might expect ashen neutrophils to resemble 
neutrophils from serine protease knockout mouse models. In peritonitis models of 
neutrophil recruitment, neutrophil elastase deficient mice displayed comparable neutrophil 
recruitment numbers to wild-type (197). This is also true of mice deficient in cathepsin-G 
(113). Using a model of subcutenous immune complex-mediated inflammation model, it has 
been demonstrated that combined absence of proteinase-3 and elastase impairs neutrophil 
recruitment whereas absence of elastase alone did not (86). Likewise the beige mouse 
model of Chediak-Higashi syndrome that has a combined deficiency in cathepsin-G and 
elastase displayed significant impairment neutrophil recruitment using a zymosan induced 
peritonitis model (199). These studies suggest that single deficiency of a serine protease 
may be compensated for by others and allow neutrophil chemotaxis to remain intact, 
however a combined deficiency cannot. Rab27a regulates primary granule secretion 
containing neutrophil elastase, proteinase-3 and cathepsin-G. Absence of Rab27a is likely to 
impair secretion of all three proteases and likely acts similarly to a combined deficiency. It is 
probably for this reason that we are able to see in vivo defects in neutrophil recruitment in 
ashen
 
mice. These reports argue against a model where Rab27a regulates secretion of just 
one protease, though data using elastatinal inhibition does resemble that of 
pharmacological inhibition of elastase previously suggested to impair neutrophil 
transmigration (198). 
 
5.3.2 - A model of Rab27a function in neutrophil chemotaxis 
Together these data suggest a model where Rab27a promotes the directed secretion of 
serine proteases from azurophil granules at the uropod of migrating neutrophils (Figure 19). 
This directed secretion of proteases may cleave adhesion molecules such as CD11b that 
mediate cell-substrate adhesion. This de-adhesion then would allow the rear of the cell to 
be retracted and is important for the cell to maintain polarity and to continue to migrate 
towards the source of chemokine. Furthermore as neutrophils share features of chemotaxis 
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with monocytes and NK cells and because Rab27a is widely expressed in the immune system, 
such a function is likely to have implications for other cell types. 
 
Figure 19. Model of Rab27 regulated chemotaxis of neutrophils through secretion of primary 
granules. Upon movement, calcium transients at the rear of the cell stimulate Rab27 to locally 
secrete azurophil granules at the uropod to release serine proteases. These proteases would cleave 
CD11b attachments to fibrinogen to allow uropod detachment and promote neutrophil chemotaxis. 
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Chapter 6 - Discussion 
6.1 - Two different models of Rab27a/b function 
6.1.1 - Role of Rab27a/b in neutrophils 
Lack of Rab27a or Rab27b is sufficient to impair primary granule secretion (80) and is 
sufficient to inhibit chemotaxis (Fig 4.2.4, 4.2.9, 4.2.10) and deficiency of the other isoform 
does not compound inhibition of secretion or chemotaxis. Johnson et al have suggested two 
models of Rab27 mediated primary granule secretion. The first is based on the observation 
that while Rab27a localises convincingly to a low density subset of primary granules, Rab27b 
colocalises poorly to primary granules and mainly localises to peripheral low density vesicles 
rich in VAMP-2. This model suggests that primary granules may undergo a maturation step 
where primary granules fuse with Rab27b positive vesicles and this allows subsequent 
fusion with the plasma membrane. The inadvertent release of primary granules would be 
deleterious to the host and cause unnecessary damage to the surroundings, so this 
maturation step may function as a secretory checkpoint to ensure the cell is activated 
sufficiently prior to primary granule release (Figure 20). This is a similar model to that 
demonstrated in cytotoxic T lymphocytes (121) and would explain the chemotaxis of Rab27a 
and Rab27b KO BMDN (Fig 4.2.4, 4.2.9). 
The second model proposed by Johnson et al was one where Rab27a and Rab27b 
interact with different effectors to promote secretion via independent mechanisms. This is 
because both Slp1 and Munc13-4 were found to colocalise well with primary granules in 
human neutrophils (24) and to follow the pattern of Rab27a localisation. This would suggest 
that both effectors function with Rab27a unless there were a maturation step prior to 
exocytosis as suggested in the first model. However Munc13-4 also localises on small 
vesicles in human neutrophils and blockade of Munc13-4 function inhibits primary granule 
secretion after LPS priming and was previously demonstrated to be involved in lytic granule 
maturation in cytotoxic T lymphocytes prior to secretion (121) so Munc13-4 might be 
involved in the maturation/priming step prior to exocytosis. This was also suggested by a 
recent study in which Munc13-4 was shown to be increase localisation to Rab27a expressing 
granules upon LPS priming and to be responsible for LPS induced priming of Rab27a positive 
granules (82). Slp1 was found to be on primary granules and blockade of Slp1 was found to 
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inhibit fMLP induced exocytosis of primary granules but this defect was rescued by LPS 
priming (24).  This data argues against a role for Slp1 in the priming/maturation step 
involving Rab27b. Blockade of Rab27a was shown to inhibit fMLP induced exocytosis and 
LPS primed fMLP induced exocytosis and a recent study suggested that Rab27a is required 
for LPS induced priming of primary granule exocytosis (82). This suggests that Rab27a (and 
Munc13-4) might also be involved in the priming/maturation step (24). These data together 
suggest a model where Rab27a and Slp1 regulate azurophil granule secretion and Rab27b 
and Munc13-4 regulate a granule maturation step prior to azurophil granule secretion 
(Figure 20).  
 
 
Figure 20 – Proposed model of Rab27a, Rab27b, Slp1 and Munc13-4 regulated chemotaxis of 
neutrophils through secretion of primary granules. 
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6.1.2 - Role of Rab27a/b in mast cells 
The data presented in chapter 3 suggested several alternate models of Rab27a function. 
Evidence such as EM data showing ashen BMMC granules were more dense than wild-type 
suggested a role for Rab27a in granule biogenesis and immunofluorescence data showing 
ashen BMMCs have irregular distribution of cortical F-actin suggested a role for Rab27a in F-
actin stabilisation. This may relate to reduced granule-plasma membrane distance observed 
in ashen and suggests that Rab27a may negatively regulate granule docking through 
stabilisation of F-actin. Beta-hexosaminidase secretion assays also suggested that Rab27a 
may also promote granule docking and secretion through interaction with Munc13-4 though 
this is more obviously observed in absence of Rab27b. The role of Rab27b was seemingly 
more straightforward, to promote granule docking and secretion through Munc13-4. 
Microtubule transport of granules has previously been shown to be important for mast cell 
granule secretion (117), a process which Rab27b is thought to play a role in (124). Rab27b 
mediated microtubule transport and subsequent granule docking and secretion through 
interaction with Munc13-4 may be the main functions of Rab27b. A role for Rab27b in 
destabilising actin also was not ruled out. This data points to a model where Rab27a and 
Rab27b may both promote granule docking and secretion through Munc13-4 but may play 
opposing roles in the regulation of F-actin (Figure 21). It is this function that may explain 
increased secretion observed in ashen BMMCs using IgE crosslinking (Fig 3.2.3). 
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Figure 21. Model of Rab27 function in BMMCs. Presence of Rab27a, Mlph and possibly Myosin Va in 
wild-type BMMCs stabilises F-actin and regulates the distribution appropriately so that granules are 
not held too close to the plasma membrane. In ashen BMMCs, F-actin is not regularly distributed 
such that thin areas of F-actin allow granules to be closer to the plasma membrane. This allows 
granules to be more easily released upon activation. In activated cells, Munc13-4 promotes the 
docking and subsequent release of granules through interaction with Rab27a and Rab27b.    
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6.2 - Comparison of different models of secretion 
There are several striking differences in the models of Rab27a/b regulated secretion in mast 
cells and neutrophils proposed by this study. Rab27a seems to play a more important role in 
neutrophil secretion as ashen mice display no detectable secretion of primary granules (80). 
This finding may relate to impaired chemokinesis and chemotaxis in ashen BMDN observed 
in this study while Rab27b KO and Rab27DKO BMDN displayed normal chemokinesis and 
impaired chemotaxis. This leads us to ask why Rab27a is so important in neutrophils. 
Rab27a is upregulated during differentiation in HL-60 cells and therefore is obviously critical 
for the function of mature neutrophils. Rab27a also appeared to be expressed more 
abundantly than Rab27b in neutrophils. A significant quantity of Rab27a is localised on 
primary granules in neutrophils compared to Rab27b which is on VAMP-2 positive 
peripheral vesicles (80). This may allow Rab27a to more directly modulate the secretory 
activity of primary granules though both are critical for secretion and chemotaxis of 
neutrophils.  
By contrast Rab27b seems to play the more important role in secretion than Rab27a 
in mast cells. Rab27b KO BMMCs display severely reduced secretion compared to wild-type, 
however simultaneous treatment of PMA and ionomycin rescue secretion from 22.98% to 
65.64% of wild-type secretion. This suggests that PKC activation can compensate for some 
of the cause of the defect. Another possibility is that Rab27b itself may indirectly activate 
PKC while Rab27a may require PKC activation to function in secretion. This study has 
suggested that it may be activation of PKC that leads to actin depolymerisation in Rab27b 
KO BMMCs that may aid secretion. In beta-hexosaminidase secretion assays, Rab27b 
appeared to be more important that Rab27a in BMMC secretion but this may be because 
Rab27b KO BMMCs have thicker cortical actin. What is clear from secretion assays is that 
both Rab27 isoforms promote secretion but that Rab27b is more effective than Rab27a.  
The role of F-actin was suggested to play an important part in Rab27 regulated 
secretion of BMMCs whereas this is probably not the case in neutrophils as actin 
polymerisation was found not to be affected by deficiency of Rab27a. Defective secretion 
caused by knockdown of Slp1 in HL-60 cells was shown to still occur after cytochalasin 
treatment, suggesting that Slp1 does not act through the actin cytoskeleton to perturb 
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secretion (24). This was not explicitly tested for Rab27. The actin cortex probably plays such 
an important role in regulation of mast cell secretion because of the extremely potent 
products contained inside mast cells. While neutrophils number in the body are high, mast 
cell numbers are low and are usually at peripheral sites such as in connective tissue or near 
musoca. Therefore any deleterious secretion would lead to inappropriate inflammation and 
leukocyte recruitment/activation. The regulation of neutrophil secretion is also tightly 
controlled, but because of the heterogenous nature of neutrophil granules, it is unlikely that 
such stringent regulation would exist. Upon activation, secretion of secretory vesicles must 
proceed unimpaired if the neutrophil is to upregulate chemokine receptors and adhesion 
molecules at the cell surface and is to respond quickly. Mast cells are thought to have 
relatively homogenous granules and cells “degranulate” upon activation, therefore 
suggesting an all or nothing approach to secretion, compared to the hierarchy of granule 
secretion in neutrophils, therefore regulation via the actin cortex is likely to be very 
important in mast cells.   
 
6.3 - Cell lines vs primary cells 
Data from this study has suggested that a more complex model of function occurs when 
Rab27a and Rab27b are expressed in the same cell type compared to cells that pre-
dominantly express only one isoform such as CTLs or melanocytes that abundantly express 
Rab27a. In preliminary experiments, the HL-60 model of neutrophil function were found not 
to express Rab27b and only Rab27a. In HL-60 cells a relatively simple model of secretion 
exists, Rab27a promotes primary granule release, likely through effectors Slp1 and Munc13-
4 (24). In primary neutrophils Rab27b is also expressed but is localised to a distinct subset of 
vesicles, but still regulates primary granule release. This makes the model more complex 
and must then involve a step prior to secretion where the two organelles come together. It 
also raises the question of whether different effectors are working with Rab27a or Rab27b 
and whether the two isoforms are indeed playing exactly the same role as was previously 
thought. One of the areas of research that remain ill-defined is the relative affinities of 
effectors for Rab27a and Rab27b that may explain their differing functions in cells.  
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 In preliminary experiments, RBL-2H3 cell lines from different sources differ in their 
expression of Rab27 isoforms. In a simple system, Rab27a would likely promote secretion 
through Munc13-4 as has been shown previously in RBL-2H3 cells (51). However knockdown 
of Rab27a in RBL-2H3 cells has also been shown to increase secretion (63) suggesting that 
Rab27b may be expressed and that a model like the one proposed by this study might also 
be true for RBL-2H3 cells expressing both Rab27 isoforms. While this study avoided use of 
RBL cells, given the appropriate expression of Rab27 isoforms they might provide a useful 
model for the study of mast cells to support findings from primary cells. This is because they 
can be genetically manipulated more easily than BMMCs and therefore we would be able to 
address some of the questions that remain unanswered from this study. However as RBL-
2H3 cells are of basophilic lineage any results would need to be confirmed using primary 
cells. 
  
6.4 - Rab27, Griscelli syndrome, mast cell secretion and actin 
A recent study suggested that an acceleration of actin remodelling during phagocytosis was 
responsible for increased phagocytosis of zymosan particles by Rab27a knockdown HL-60 
cells and may contribute to haemophagocytic syndrome seen in Griscelli syndrome patients 
(195). It was suggested that this is because Rab27a delays the collapse of actin after the 
engulfment of particles that is required for internalisation and it was hypothesised that it 
does this by suppression of Coronin 1 accumulation at internalisation sites. It is thought that 
contrary to other effectors, Coronin binds Rab27-GDP (87) therefore activation of Rab27 at 
phagocytic sites would exclude and suppress Coronin activity. In this way Rab27 has 
previously been shown to control actin remodelling and dynamics and therefore may be 
working in a similar way in mast cells. 
 While a previous study had suggested that deficiency of Coronin 1A in mast cells 
does not alter their functionality (4), a more recent study has questioned that finding, 
showing that Coronin 1A (but not Coronin 1B) deficiency enhances beta-hexosaminidase 
release and inhibits cytokine (IL-6 and TNFα) release (54). They also show that Coronin 1A/B 
double deficiency further increases beta hexosaminidase secretion and show reduced 
cytokine secretion. They go on to show that Latrunculin B treatment of wild-type cells to 
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depolymerise actin has the same effect, suggesting that Coronin 1A/B stabilise the actin 
structure in mast cells and that the actin cytoskeleton has a differential effect on pre-
formed mediator and cytokine secretion. In wild-type cells, Coronin 1 localises to the actin 
cortex to stabilise it, however upon mast cell activation, Coronin 1 redistributes to the 
cytosol, presumably to help destabilise the cortex and allow greater access of granules to 
the plasma membrane. This data fits well with the results from ashen BMMC secretion and 
suggest that Rab27a may work with Coronin 1 to stabilise the actin cytoskeleton. Coronin 1A 
and Coronin 1A/B deficient mast cells also display increased F-actin accumulation, 
something which Rab27b KO BMMCs were observed to have in this study, suggesting both 
Rab27a and Rab27b may play a role in actin dynamics, possibly through Coronin 1. 
 
6.5 - Independent roles for Rab27 and Munc13-4? 
Several studies have suggested independent roles for Munc13-4. Among them are the 
recent findings that Rab27a deficiency but not Munc13-4 deficiency inhibits neutrophil 
recruitment to the liver (81), a role for Munc13-4 but not Rab27a in LPS induced exocytosis 
in neutrophils (83) and a role for Munc13-4 but not Rab27a in CTL secretory granule 
maturation (121). The ability of Munc13-4 to act independently of Rab27 seems to be cell-
type specific and while Munc13-4 has been shown to work with and without Rab27 in  
neutrophils (82), in mast cells Munc13-4 deficiency strongly mimics Rab27 deficiency (Fig 
3.2.18, 3.2.19) and the Munc13-4/Rab27 complex has been shown to specifically be 
required for mast cell secretion to occur (51) suggesting that at least in mast cells, Munc13-
4 may function exclusively through Rab27.  
 
6.6 – Conclusions and significance 
Rab27 is commonly thought to merely promote exocytosis of secretory organelles. This 
study has suggested that while this may explain a significant portion of Rab27 function, 
Rab27 can also function in other processes such as regulation of actin distribution in mast 
cells and chemotaxis in neutrophils. While the latter may be linked to its secretory function, 
the formed probably isn’t as BMMCs analysed were unstimulated. Furthermore this study 
has shown that the function of Rab27 in cells expressing both Rab27 isoforms is likely to be 
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more complex than cells expressing one isoform, likely due to the interplay between 
isoforms that may be explained by differing affinities for effectors, different activation 
kinetics and/or different GTPase activites. Further studies aiming to understand the role of 
Rab27 should analyse these differences with the aim of better understanding Rab27 
function in cells expressing both isoforms (including mast cells, platelets and neutrophils).  
 The findings of this study are significant. Regulation of cortical F-actin is known to be 
important for mast cell secretion but this study has shown that this is a process which Rab27 
may influence. This has significance for other cell types as the actin cytoskeleton plays a role 
in many processes including secretion, migration, cell growth and division, adhesion and 
cancer cell invasion. This study has also highlighted the indispensible role for Rab27 and 
Munc13-4 in mast cell secretion and suggests that these proteins would be attractive 
therapeutic targets if inhibition could be directed specifically at mast cells. 
 This study contains the first analysis of Rab27a function in neutrophil chemotaxis 
and has suggested a mechanism by which Rab27a may regulate chemotaxis. It has also 
described the positive role of several other Rab27 related proteins in neutrophil chemotaxis 
and has strengthened the link between secretion and chemotaxis in neutrophils. This carries 
clinical significance as many diseases are characterised by excessive neutrophil infiltration 
including cystic fibrosis and chronic obstructive pulmonary disorder (COPD). These proteins 
may act as therapeutic targets in future for neutrophil related diseases. This study has also 
suggested an additional role for statins in the inhibition of neutrophil chemotaxis through 
defective prenylation of Rab GTPases. Further study may lead to routine use of statins for 
neutrophil related diseases. 
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